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Summary
The increasing focus on treating cancer with personalized medicine is accompanied by the develop-
ment and improvement of targeting strategies. The growing knowledge about the aberrant nature
of tumors and their microenvironment can be exploited to facilitate the delivery of therapeutics to
the tumor and specifically address their binding to tumor cells. Nanocarriers promote the accu-
mulation of medicinal cargo in tumor tissues. Specific attachment to target cells can be achieved
by linking targeting ligands to the delivery systems. These targeting moieties recognize specific
receptors which are exposed on the surface of target cells in high numbers. Experiments in vitro
to assess the specific binding capacity of receptor targeted delivery devices are usually performed
as cell culture assays under static conditions. In these approaches, diffusion and gravitational
sedimentation of the nanocarriers determine the amount of particles arriving on the cells und thus
influence the results.
In this thesis, a microfluidic technique in combination with fluorescence microscopy was developed
for quantification of cellular binding of nanoparticles providing reduced sedimentation and con-
stant particle concentration. With this method, we were able to assess the potential of two peptide
ligands to serve as targeting ligands.
First of all, model nanoparticles were synthesized which mimic the surface characteristics of thera-
peutic delivery systems, simultaneously meeting the requirements for quantitative analysis such as
sufficient colloidal stability, good detectability and reproducibility. Successful surface modification
of latex beads was verified by characterization with several methods including zeta potential mea-
surements and dynamic light scattering. The shielding with polyethylene glycol revealed beads
with reduced surface charge, increased solubility and decrease aggregation tendency. The equip-
ment with short peptide ligands resulted in a positive surface potential. As a second step, a flow
setup was developed and optimized. The experiments were designed such that a continuous flow
of particles was passed over a cell monolayer and adhered particles were detected by fluorescence
microscopy. For quantification, the particles were counted on individual cells. This procedure en-
abled in addition the monitoring of particle aggregation and cell integrity. Third, beads with ligand
were compared with internal control beads. With this method, particle binding was quantified
under the same experimental conditions diminishing heterogeneity of results.
Finally, binding studies were performed to quantify the effect of two short peptide ligands. The
transferrin receptor is expressed at high levels in several malignant cells and brain capillaries, rep-
resenting a suitable target for the delivery of therapeutics to diseased tissues and the brain. The
peptide B6 was found to specifically bind to this receptor and was coupled onto the model parti-
cles. Likewise, the c-Met binding peptide cMBP2 which specifically addresses the c-Met/hepatocyte
growth factor receptor was linked to the particles. This receptor is normally not activated in nor-
mal tissue, but promotes progression and invasive growth in some cancer cell lines. Quantitative
adhesion studies of both types of particles were performed with several adequate internal control
particles acting as electrostatic and specificity controls. The results showed that both peptides, B6
and cMBP2 promote binding to target cells. Furthermore, the findings suggest that the peptide B6
improved cellular adhesion of the beads by nonspecific interactions such as electrostatic interac-
tions whereas the peptide cMBP2 enhanced binding of the beads in a specific manner only when
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its amino acid sequence was in the correct order. Moreover, B6 particles showed high binding
capacities to non-target endothelial cells while cMBP2 particles did not. Consequently, cMBP2 was
assessed as potential targeting ligand while B6 was disqualified due to its presumably unspecific
binding behavior.
The main administration route of nanocarriers is intravenously. Before a targeted delivery sys-
tem can attach to receptors on target cells in vivo, it encounters blood components, cells lining
the vessel walls and the tumor microenvironment. Adhesion of nanocarriers to these nonspecific
binding sites can cause toxic effect. Therefore, it is not only important to assess the specificity of
delivery systems, but also approximate their unspecific adsorption to normal tissues, organs and
biomolecules. By extension of the flow setup to a system with four parallel channels, the binding of
actual therapeutic delivery devices was screened to quantify their specific and nonspecific binding
on four different surfaces. In two flow channels, cell were seeded, e.g. target cells and endothelial
cells (which usually line the vessel walls). The other two flow channels were coated for instance
with artificial extracellular matrix gel or collagen, both parts of the tumor microenvironment, and
with serum which is contained in blood. Preliminary experiments were performed using poly-
plexes, non-viral gene vectors composed of nucleic acids complexed with polycationic carriers.
They revealed for example that linear polyethylene imine (LPEI) as a carrier polymer mediated
binding of the polyplexes to cells and coatings regardless if equipped with the peptide ligand GE11
or not. The number of attached polyplexes varied most on endothelial HMEC-1 cells suggesting a
high sensitivity or heterogeneity of this cell line. Furthermore, when the serum content in the cell
medium was increased towards levels present in humans, polyplex adhesion on all surfaces was
reduced. Polyplexes composed of STP polymer as carrier and modified with the peptide ligand
cRGD showed low binding to matrix gel and collagen at high serum levels which is desirable for in
vivo applications. In conclusion, the flow experiments in combination with fluorescence microscopy
and quantitative analysis represent powerful tools for the selection of appropriate targeting ligands
and suitable actual delivery devices.
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1 Introduction
The slogan of the German Cancer Congress 2016 pronounced "four Ps": prevention, precision,
participation and personalization [1]. Especially, future cancer therapeutics will be more oriented
on the individual patient. With about 500.000 newly diagnosed cancer patients alone in Germany,
estimates of 14 million new cases worldwide and 8.2 million cancer related deaths in 2012 [2],
personalized cancer treatment represents a huge challenge. Moreover, more than one hundred
types of cancer exist and already tumor cells of single populations exhibit heterogeneous pheno-
types including their metastatic potential and survival prognosis of therapy [3]. Diagnostic and
therapeutic approaches are required which assess multiple parameters in high throughput and for
personalization of medicine preferentially single-cell analysis should be performed to detect and
treat specifically the diseased cells. The development of nanocarriers enables the accumulation of
imaging and therapeutic agents in tumor tissue. For specific attachment to target cells, ligands,
such as small molecules, protein, peptides and antibodies, are attached on the delivery systems to
address receptors on target cells which are exposed specifically on diseased cell lines or in very
high numbers. Studying the efficiency of such nanocarriers is conventionally performed first in
cell culture experiments in vitro, followed by in vivo approaches with animal models before the
transfer into the clinic. In recent years, a variety of additional nanotechnological techniques were
invented to model tumors in vitro or adapt important experimental features for the characterization
of nanocarrier efficiency. For example, microfluidics are used to simulate the delivery of nanoth-
erapeutics to tumor vasculature or whole tumor models on a chip [4] were designed to assess the
binding and uptake of them in vitro. Cell culture models experience a new dimension by model-
ing 3D environments as for instance hydrogel-based mimicry of the tumor microenvironment [5].
Thus, the assessment of nanocarrier efficiency can be performed by in various in vitro models and a
combination thereof is required as each model adapts different aspects of the reality and increased
complexity often is accompanied by technological effort and raising costs.
The aims of this thesis include the development of reliable and reproducible experiments for quan-
titative binding studies of receptor targeted nanocarriers to assess the effect of a targeting ligand
and to provide information about the nonspecific binding behavior to relevant surfaces. Therefore
flow experiments were introduced and optimized with which the potential of two peptides on
model nanoparticles, mimicking the surface characteristics of therapeutic delivery devices, was
assessed to serve as a targeting ligand. And second, the flow system was extended to quantify the
adhesion of non-viral gene vectors on four different surfaces in parallel to estimate their specific
and nonspecific binding behavior.
This thesis is divided into eight chapters. The introduction is followed by two chapters describing
the biological and technical background of this work. In chapter 2, nanocarriers for drug and gene
delivery are described concerning their design and function as well as their biodistribution and
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clearance in vivo. The most important part of this chapter is the description of tumor targeting
including the basics of the tumor microenvironment, passive targeting approaches and active tar-
geting with the description of receptors addressed by nanocarriers used in this work. A final section
explains the fundamentals of cellular uptake of nanocarriers and their intracellular distribution. In
chapter 3, the basics of fluorescence and applied microscopy methods to investigate the binding of
nanocarriers are explained.
Four chapters depict the results of this thesis. In chapter 4, the synthesis, characterization and
cellular uptake of model nanoparticles (beads) which mimic the surface characteristics of thera-
peutical particles are illustrated. Most important parts of this chapter include the conception of the
particles (introducing part), the characterization of their zeta potential and measurement of their
hydrodynamic diameter (subsection 4.2.2), and the summary (section 4.4). Chapter 5 documents
the development and optimization of flow experiments with internal control for the assessment of
cellular binding of nanoparticles. Apart from the introduction and illustration of the conceptional
design (section 5.1), the description of the internal control (section 5.3) provide useful information
for an easier understanding of the results presented in the subsequent chapter. In chapter 6, the
binding studies of receptor targeted beads are elucidated. After providing a rationale for trans-
ferrin receptor and c-Met/hepatocyte growth factor receptor targeting, cellular adhesion of beads
equipped with the peptide ligand B6 are described in section 6.1. The binding studies of B6 beads
under flow conditions are depicted in the subsection 6.1.1. Additional information of experiments
investigating the specificity of cellular adhesion of B6 beads under static conditions is described in
the sections below with the exception of subsection 6.1.2.6 which depicts the binding to non-target
endothelial cells under flow conditions. Furthermore, the specific binding capacity of the peptide
cMBP2 attached to model beads was studied under flow conditions and showed promising results
(section 6.2). In the summary of this chapter, detailed conclusions about the binding behavior the
peptides B6 and cMBP2 on model nanoparticles are drawn. In chapter 7, the proof of principle is
shown how flow experiments can be extended to investigate specific and nonspecific interactions
of actual therapeutic delivery systems with multiple surfaces. Most interesting parts of this chapter
include the introductory part and the first three paragraphs of section 7.1 and the description of
experiments screening the binding of polyplexes on four different surfaces under flow conditions
investigating various aspects (section 7.3). Additional information is given in the section above
which describes the selection of suitable polyplexes for flow experiments and quantitative analy-
sis. The conclusion provides a perspective of the screening experiments and motivation for future
directions of the quantitative screening approach.
Chapter 8 contains the information about experimental materials and methods.
2
2 Nanocarriers for drug and gene delivery
Nanocarriers are nano-sized transporters which are designed to detect, image and treat specific
sites in a living system. For imaging, radio-nucleic contrast agents can be encapsulated and
super-paramagnetic nanoparticles can visualize tissues or organs in which they accumulate [6].
Furthermore, diseased cells can be addressed using specific molecules coated on the nanoparti-
cles. The encapsulation of agents is not only used for diagnostics, but also an important strategy
for therapy. Improvements of nanoparticle-based transport of therapeutics compared to directly
administered free drugs include the trans-membrane delivery of molecules which are poorly water-
soluble [7], prolonged blood circulation times in the body [8] and reduction of systemic side-effects
[6]. Furthermore, nanocarriers offer the possibilities of highly localized release of their therapeutic
cargo [9], and the simultaneous observation thereof and of the therapeutic feedback [10].
In this chapter, nanoparticle-based drug and gene delivery systems are introduced. Their interac-
tion with biological materials will be described and the specific attachment to target cells will be
elucidated in more detail. Finally, their cellular fate will be explained.
2.1 Delivery systems
Drug and gene delivery systems are nanocarriers that transport their therapeutic cargo in the hu-
man body to specific tissues and subsequently to the target site in the addressed cells. They reduce
or prevent degeneration of the payload, enhance biodistribution of the medicine and control the
release of cargo [11]. Delivery devices are mainly administered intravenously, but the application
can also be oral, intramuscular, subcutaneous, transmucosal, transdermal and pulmonary [12].
The design options of delivery devices show a huge variety in shape, size and composition (Fig.
2.1). Mostly spherical particles are fabricated, but also rod-like, cylindrical, ellipsoidal and disk-
like particles have been produced [13]. Especially the size has an enormous impact on the half-life,
clearance, accumulation and cellular uptake of the nanocarriers and ranges from few nanometers
up to several hundred nanometers. Delivery systems are composed of a multitude of materials
comprising organic molecules like lipids and polymers, inorganic constituents like metals and
metal oxides, or viruses [14]. For cancer therapy nano-transporters have been developed including
quantum dots [15], gold nanoparticles [16], mesoporous silica nanoparticles [17], hydrogel-based
systems [18], carbon nanotubes [19], dendrimers [20], solid-liquid particles [21], polymeric particles
[22], liposomes [23], drug-conjugates [24] and genetically modified viruses [25]. The composition of
the nanocarriers and their surface groups determine their physical properties, such as the colloidal
stability, surface charge and hydrophobicity. These characteristics can be shielded or modified by
surface coatings to either enhance their blood circulation time or direct them to specific tissues. The
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latter approach can be achieved by attaching targeting ligands to the delivery systems such as small
molecules [26], proteins [27], peptides [28], antibodies [29] or antibody fragments [30], nanobodies
[31] and aptamers [32] (see also section 2.2.3).
Figure 2.1: Nanocarriers. Delivery systems vary in composition, shape and size. Their surface groups can be
modified by shielding with water-soluble polymers or lipid layers and coated with targeting ligands. These
modifications determine their surface properties.
The configuration of nanocarriers has to be chosen carefully considering several challenges they
will face upon administration. First, they have to provide a prolonged half-life and be prevented
from systemic clearance. Second, they should be biocompatible, which means exhibiting low
interaction with non-target tissues, organs and blood components which would result in toxic,
immunogenic, thromogenic and carcinogenic responses [33]. Third, they should accumulate within
the target tissue, bind specifically to target cells and be internalized effectively. Forth, they should
be transported intracellular to the target compartment and last, the cargo should be able to act at
the target site. Depending on the transported cargo, the nanocarriers can be categorized into drug
and gene delivery devices.
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2.1 Delivery systems
2.1.1 Drug delivery devices
Since the first attempts of nanoparticle-base drug delivery sixty years ago, the field greatly ad-
vanced and the first products are on the market [34]. Mostly hydrophobic drugs are encapsulated
in hydrophobic or amphiphilic carriers [35] such as doxorubicin, docetaxel, methotrexate or pa-
clitaxel. Also hydrophilic drugs are transported in nanoparticles, for example transtuzumab or
gemcitabine. One of the main challenges is the accumulation of the drugs in the carrier or, in
other words the loading capacity of the transport vehicles. During transportation in the vascular
system, it is important that the drugs remain within the nanoparticle and that the carrier provides
a sufficient stability. After overcoming the obstacles of specific cellular binding, uptake, escape
into the cytosol and translocation to the target site, the drugs have to be released from the delivery
device. There are two methods for controlled release: either the disposal of the drugs is sustained
for a controllable period of time [36] or it is triggered by a stimulus at the target site [37]. The first
approach involves either the diffusion of the drugs from an insoluble polymer shell or matrix, or
the erosion of the particle. The release can be triggered by varying pH values, enzymatic, ther-
mosensitive or photo-activated reactions.
Transported cytostatic drugs encapsulated in nanocarriers can be classified according to their mode
of action [38]. There are alkylation reagents which transfer alkyl groups to nucleic acids and
proteins. Antimetabolites are inhibitors which compete with the natural substrate for the active
site of essential enzymes or receptors, e.g. folic acid antagonists, pyrimidine or purin analogues.
Cytotoxic antibiotics can affect the function and synthesis of nucleic acids. Spindle poisons include
vinca alkaloids which bind to tubulin, thus inhibiting mitosis and taxoids which act inversely
by promoting the assembly of microtubules, thus compromising disassembly. Topoisomerase in-
hibitors cleave, unwind and rejoin DNA structures, and platinum agents like cisplatin cross-link
DNA strands, thus producing DNA adducts [39].
So far, most approved drug delivery systems are liposomes, but also include also polymeric
nanoparticles and protein conjugates. They are used for the treatment of a variety of cancers
including (metastatic) breast cancer [40, 41], Kaposi’s sarcoma [42], ovarian cancer [41], lung cancer
[43] and leukemia [44]. The number of launched clinical trials of nanoparticles for cancer therapy
tripled in the past decade [14] and next-generation particles with targeting ligands for improved
selectivity and stimuli-responsive characteristics for increased efficiency [45] are in pre-clinical
evaluation.
2.1.2 Gene delivery vectors
In contrast to drug delivery devices, gene delivery systems transport therapeutic nucleic acids,
mainly double-stranded DNA [46], small interfering RNA (siRNA) [47] and micro RNA (miRNA)
[48]. They either correct dysfunction of gene expression, introduce novel desired functions or
disable undesirable functions. Furthermore, they prevent the digestion of naked nucleic acids by
naturally occurring nucleases [49]. Gene delivery devices can be categorized in viral and non-viral
vectors.
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Viral vectors are genetically modified natural viruses. Commonly adeno-associated viral (AAV)
and lentiviral (LV) vectors are used for gene delivery. AAV delivery systems remain episomal, i.e.
the DNA is not integrated in the genome of the transduced cell and hence are used for short-term
gene expression or in terminally differentiated cells [25]. An AAV vector (alipogene tiparvovec,
Glybera) which substitutes a gene encoding for lipoprotein lipase was the first gene therapeutic
product approved by the European commission in 2012 [50]. Several years before, in 2004, an AAV
vector for recombinant AD-p53 gene therapy for head and neck squamous cell carcinoma became
commercially available in China [51]. LV delivery systems are retroviral vectors which integrate
their genetic material stably into the genome of the host cell and thus are used for modification of
stem cells or dividing cells [25]. Viral vectors represent the most efficient delivery systems as they
are optimized by nature to infect host cells and transfer their genetic information. However, they
bear the risk of high immunogenicity. Their cargo capacity is limited and the costs of production
and analytics are high.
Non-viral vectors are suitable alternatives exhibiting lower immunogenicity, reduced toxicity and
a high loading capacity for genetic material despite their low transfection capability [52]. These
artificial delivery systems are formed by condensation of nucleic acids and cationic lipids (e.g.
lipoplexes) [53] and/or polymers (e.g. polyplexes) [54] via electrostatic attraction of the negatively
charged phosphate backbone of the DNA or RNA and the positive charge of the polycationic
carrier. Especially polymers are advantageous offering high versatility, reproducibility and the
possibility of precise production and identification. Polycationic carriers include polyamino acids
like poly-L-lysine (PLL) [55], protein derivatives [56], carbohydrates [57], polyethylene glycol (PEI)
[58], dendrimers [59], copolymers [60], chitosan [61] and cyclodextrin (CD) [62]. In physiological
medium, the non-viral vectors remain usually positively charged which promotes the interaction
with negatively charged cell surfaces. Another benefit of the positive charge is the capability of
escaping from endosomal vesicles after cell internalization (see section 2.3). On the other hand, the
positive charge is disadvantageous because it increases unspecific binding, promotes higher toxic-
ity and faster removal under in vivo conditions. With the development of new building blocks like
succinyl tetraethylene pentamine (Stp) units, polyplexes with less surface charge can be generated
which in addition allow for precise analysis of structure-relationship activity [63].
First reported about twenty years ago [64], PEI is nowadays one of the golden standards of trans-
fection reagents [52] and meanwhile has been investigated in clinical studies for cancer therapy
and anti-HIV vaccination [54]. There are two variants, linear PEI (LPEI) and branched (BPEI). The
linear version is more flexible and facilitates intranuclear delivery in non-dividing cells in contrast
to BPEI which transfects only dividing cells in or before mitosis [65, 66]. For the transfection of
specific cells, targeting ligands can be attached to the polymer chains which promote their binding
to respective receptors on target cells (see section 2.2.3). Depending on the complexed nucleic
acid, polyplexes can have hydrodynamic diameters of a few nanometers (single siRNA-polymer
[67] or single pDNA-polymer [68]) up to hundreds of nanometers (e.g. large nucleic acids with
many polymers [69]). In biological media, polyplexes can be partially or completely dissolved
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by electrolytes, proteins or cellular surfaces [70]. Furthermore, they posses a high tendency to
self-aggregate. The colloidal stability can be increased by advanced packing techniques such as
cross-linking of polymer chains or introduction of hydrophobic moieties, and surface shielding
[54]. On the other hand, the nucleic acids need to intracellularly dissociate from the carrier at the
target site. For pDNA delivery, the plasmid has to enter the nucleus which occurs mainly by active
transport as only nucleic acids below 250 bp can passively cross the nuclear membrane through
the nuclear pore complex. A nuclear localization sequence (NLS) can be integrated into the nucleic
acid delivered by the polyplex, promoting active nuclear import via binding to nuclear proteins [71].
Clinical trials using polyplexes investigate the treatment of patients with melanoma [72], bladder
cancer [73], ovarian cancer [74] and solid tumors [75] amongst some others.
2.1.3 Biodistribution and clearance
In aqueous media, nanoparticles are stabilized by an electrical double layer formed by counter-ions
and co-ions. In biological media, serum components interact with the particle surface via elec-
trostatic, electrodynamic and steric interactions and are adsorbed to form a so called corona [76].
Often, it is referred to as protein corona as the main components are proteins, containing a smaller
number of lipids and sugars [77]. This layer can be categorized into a hard and a soft corona. The
hard corona is the part of biomolecules which is tightly adsorbed on the particle surface whereas
the soft corona is a dynamic layer. The composition may vary upon time and especially in the
human body in different extra- and intracellular compartments.
Upon entering the blood flow, nanoparticles are covered with opsonins which comprise comple-
ment proteins, immunoglobolins (IgG and IgM), albumins, fibronectins, fibrinogens, apolipopro-
teins and laminin [78]. This opsonization results in an increased detection by phagocytes. These
cells posses phagocytic, Fc and complement receptors which usually recognize conserved motifs
of pathogens and opsonins [79]. Consequently, opsonized objects larger than 10 nm including
nanoparticles and viruses are internalized by the phagocytes mainly in a receptor-mediated man-
ner [80]. Within the cells, enzymatic degradation decomposes the pathogens and nanoparticles, or
the nanomaterial is accumulated if it is non-degradable, e.g. heavy metals [81]. Especially, the liver,
the spleen and the bone marrow contain many phagocytic cells like macrophages, e.g. Kupffer cells
and monocytes. Apart form the clearance of nanoparticles by the mononuclear phagocytic system
(MPS), particles larger than 150 nm are removed by physical filtration in the spleen or liver [82],
and particles smaller than 6-8 nm are excreted by glomerular filtration in the kidney [83]. This renal
clearance depends strongly on the size of the nanoparticles, but also the surface charge can have
an impact on this process, because it can promote adsorption of serum proteins which increases
the hydrodynamic diameter of the particle [84]. In principle, charged particles are more prone to
be cleared from the blood flow due to opsonization, especially when containing a positive surface
charge [85].
To prevent rapid clearance in vivo, delivery systems are coated with water-soluble polymers such
as polyethylene glycol (PEG), polyethylene oxide (PEO), dextran, and polyacrylic acid (PAA) [86].
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This prolongs their blood circulation time and improves their biodistribution, which means in par-
ticular their increased accumulation in tumor tissue compared to other organs (see section 2.2.2).
PEG is a well established, flexible and highly water-soluble polymer [87] which is an essential com-
ponent of most delivery devices as it shields the surface to 1) prevent the interaction of intrinsically
toxic materials with the biological environment, 2) diminish unspecific binding with the biological
environment, and 3) reduce opsonization. The PEG sheath however impairs also association of de-
livery systems with tumor or other target cells and can have a negative impact on the escape of the
nanoparticles from cellular internalized vesicles (PEG dilemma). Furthermore, PEGylation does
not completely shield nanocarriers from unspecific interactions, immunological effects can also
be induced like complement activation, adsorption of immunoglobulins or anti-PEG-antibodies
[88]. In addition, the extent of shielding and interaction with biological molecules depends on
the length and density of PEG chains on the particle surface. The amount of PEG in combination
with the particle dimensions determine the conformation, which can be densely arranged as a
brush resulting in high colloidal stability and low protein adsorption or can be loosely coiled in
a "mushroom-like" conformation yielding higher protein adsorption [89]. For each carrier system
the amount of PEGylation has to be adjusted to obtain an optimal balance between shielding and
attraction to target cells.
2.2 Tumor targeting
Tumors are usually removed by surgery or treated with radiation and chemotherapy or a combina-
tion thereof. The latter approach implies the administration of cytostatic drugs, which constrain cell
devision and growth. Cancer cells are the main addressers, but healthy cells can also be affected.
A convenient approach to reduce the undesired unspecific binding and to enhance the concentra-
tion is presented by encapsulation of such drugs or other therapeutic cargo in nanocarriers. To
deliver the transport systems specifically to the diseased tissues and cells, two different approaches
are pursued: passive and active targeting. The first approach is based on the aberrant tumor
microenvironment whereas the second method exploits the abnormal characteristics of the tumor
cells themselves. In this section, first the tumor microenvironment is described leading to a better
understanding of passive tumor targeting. Finally, active targeting will be described primarily
focusing on details useful for a better comprehension of the results of this thesis.
2.2.1 Tumor microenvironment
Tissues, in which cancer cells grow, experience molecular, cellular and physical changes, for ex-
ample in gene expression, cellular proliferation, apoptosis and invasion [90]. This induces the
emergence of a tumor microenvironment in the interstitial space (stroma) surrounding the tumor
bed (parenchyma) and the vasculature (Fig. 2.2). The composition of this abnormal tissue differs
across cancer types. An ubiquitous characteristic is a disorganized and leaky vasculature. The fast
proliferation of tumor cells in a limited area induces mechanical forces in the tumor which lead
to cell compression and to deformation of the vascular system. The blood vessels in tumors vary
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highly in diameter, density and spreading [91]. As the growing tumor mass is poorly vascularized,
new blood vessels are formed in avascular regions by extension of existing vessels (angiogenesis)
[92] to enable the supply with nutrients. By this process, the vessels are perforated which promotes
low blood flow and excessive fluid eﬄux from the vasculature into the interstitium (extravasation)
[93]. Additionally, poor vascularization causes deprived oxygen supply (hypoxia) in some regions
of the tumor [94]. Hypoxia is an additional promoter of angiogenesis and activates growth factors
like vascular endothelial growth factor (VEGF) or platelet-derived growth factor (PDGF) [95]. An-
other consequence is a more acidic extracellular environment around hypoxic cancer cells arising
from an enhanced rate of glycolysis [96].
Figure 2.2: Healthy tissue and tumor microenvironment. In normal tissue, the integrity is promoted by
stromal cells which provide growth factors and structural support. Fibroblasts remodel the extracellular
matrix permanently to overcome mechanical stress within the connective tissue. Blood endothelial cells and
pericytes maintain the integrity of blood vessels and enable the supply of nutrients to the tissue. The lymphatic
system drains interstitial fluid. In tumor tissue, the blood vessels are leaky with many perforations. New
angiogenic vessels are formed. The extracellular matrix is denser and contains more collagen fibers and
macrophages, cancer-associated fibroblasts (CAFs) are activated and circulating mesenchymal stem cells are
recruited. In the tumor microenvironment the interstitial fluid pressure (IFP) is increased due to dysfunctional
lymphatic vessels. Furthermore, chemokines and cytokines attract activated T cells. The figure is inspired by
Turley et al. [97].
Additionally, the tumor microenvironment is composed of stromal cell types like blood endothelial
cells, lymphatic endothelial cells, mesenchymal stem cells (MSCs), cancer-associated fibroblasts
(CAFs) and pericytes. Stromal cells, especially MSCs and CAFs support the survival of cancer cells
by secretion of essential growth factors like hepatocyte growth factor (HGF) and fibroblast growth
factor (FGF) [98]. T cells which are activated by chemokine gradients and adhesion molecules
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infiltrate the tumor microenvironment [97]. However, inhibitory cells and molecules compromise
their survival and hinder the propagation of their activation and effect.
Tumor growth increases the stromal cell-related production of extracellular matrix (ECM) com-
ponents and influences their organization [90]. Usually, the matrix is formed by collagens, gly-
coproteins, proteoglycans, elastin and hyaluronan which are important for the regulation of cell
proliferation, differentiation, survival and homeostasis in collaboration with enzymes and growth
factors [99]. The basement membrane matrix is dense and comprises less porous structures like
collagen type IV, fibronectin and laminins whereas the matrix of the interstitium provides the elas-
tic strength of tissues [100]. In tumors, the modified ECM is connected to stromal cells such as
fibroblasts, pericytes, endothelial and immune cells [101] and can be disordered throughout large,
aggressive tumors [102]. The mechanical stress exerted by a denser ECM and hyperperfusion
through leaky blood vessels in combination with a dysfunctional lymphatic system produce an
increased interstitial fluid pressure (IFP) in the tumor interstitium [103]. The pressure gradients are
not adequately maintained across the walls of tumor vessels resulting in diminished extravasation
of drug molecules and their influx into the tumor bed [104]. In addition, also the ECM and stromal
cells hinder the entrance of chemotherapeutics by creating a physical barrier [105].
With the increasing knowledge about the tumor microenvironment, therapeutic strategies emerge
exploiting the discrepancies of normal and tumor tissue. This approach is pursued for instance
by passive tumor targeting. By active targeting of tumor vasculature and angiogenesis [106], the
nutrient supply of solid tumors is cut off, hence providing an additional promising approach for
cancer treatment. In the recent years, researchers have focused more and more on addressing
the tumor microenvironment itself to prevent tumor progression and treatment of drug resistance
[91, 107].
2.2.2 Passive targeting
Nanoparticles in the blood circulation cannot enter the blood vessels through tight junctions be-
tween endothelial cells due to their size. Only nanoparticles with a size below 6-12 nm are able
to penetrate normal tissue [108]. Usually, they are either repelled from the vessel walls or bind
to endothelial cells, which form the inner part of the vessels, in an unspecific manner before they
are cleared from the body (see section 2.1.3). The situation is different in tumor tissue. Through
leaky tumor vasculature, nanoparticles can escape into the interstitial space surrounding the tumor
bed. Normally, the nanoparticles would traverse the epithelial tissue and would be drained by
the lymphatic system. However, in the tumor the lymph system is dysfunctional, preventing the
outflow of nanoparticles through this pathway and enabling the retention of nanoparticles in the
tumor region [109]. This concept is termed the enhanced permeability and retention (EPR) effect
[35, 110].
Extensive angiogenesis and hypervascularization promote the EPR effect by increasing the amount
of nanoparticles in the tumor vasculature. Furthermore, the size of the fenestrations (holes in the
vessel walls) determines the entry of nanoparticles. Typically, these openings in the tumor vessels
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have maximal diameters between 100-800 nm [111], but also larger perforations in the range of
1200-2000 nm have been observed [112]. Subsequently, nanoparticles with a hydrodynamic diam-
eter up to 800 nm are able to penetrate the tumor vasculature, but also smaller cut-off sizes have
been reported, for example 400 nm for the extravasation of liposomes of different sizes [113]. The
efficiency of the EPR effect consequently depends on the tumor type.
The movement of nanoparticles into and within the tumor interstitium is mainly mediated by
diffusion and inversely correlated with their size. Very small nanoparticles diffuse faster and their
retention is lower. The optimal size range for nanoparticles to be accumulated by the EPR effect
is between 30-200 nm [114]. Apart from the size, the shape of the nanoparticles influences their
passive targeting efficiency. Spherical particles mainly exhibit a laminar flow profile, thus only
particles close to the surface exit through the gaps in the vessel walls [115]. On the contrary, rod-
and bar-like particles tumble more during flow providing further possibilities for passive targeting
[116, 117]. In addition, the surface characteristics of a particle influence if it is cleared from the body
or accumulated within a targeted or non-targeted tissue.
To date, nanocarriers approved for clinical use rely on passive targeting [34] which enhances
their enrichment and the concentration of therapeutics in the tumor region. Furthermore, the
biodistribution and biocompatibility are improved and the blood circulation time is prolonged.
Further promising delivery systems are under clinical development [34]. However, no specific cells
are addressed. The selective binding to target cells is pursued by active targeting.
2.2.3 Active targeting
Reaching the close proximity to cells, nanocarriers can interact with molecules on the cell surface
and depending on their nature bind to them. The plasma membrane forming the cell border con-
sists of lipids (phospholipids, glycolipids and sterols) and proteins (integrated in the membrane
like ion channels, proton pumps and receptors, anchored by lipids or peripheral). Additionally,
membrane-bound glycolipids and proteoglycans form a carbohydrate layer, the glycocalyx. Ar-
riving nanoparticles consequently are confronted with a heterogeneous negatively charged surface
with many potential interaction sites. The composition of surface molecules on cancerous cells
is different to the one on normal cells. For example, the glycosylation pattern is changed [118]
and many specific surface receptors are overexpressed [119]. This differences can be exploited to
chose molecular markers or targets for diagnostics and therapy. By attaching targeting ligands on
nanocarriers, complementary overexpressed receptors can be addressed. With this approach two
aims are pursued: to deliver the transport particles to specific cells while sparing normal cells.
Once bound to a receptor, the nanocarriers are internalized predominately by receptor-mediated
uptake.
Overexpressed receptors which are targeted in preclinical cancer models include G-protein cou-
pled receptors (GPCRs) like bombesin [120] (present on a variety of cancer types including lung,
prostate, breast, ovarian and many more), or endothelin receptors [121] (in melanoma tissues),
integrins [122] (on activated endothelial and tumor cells), folate receptors [123] (in most tissues),
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transferrin receptors [27] (present on breast, ovarian and brain cancers), epidermal growth factor
receptors [124] (on lung, breast, bladder and ovarian cells), fibroblast growth factor receptors [125]
(in breast, prostate, bladder and gastric cancer), sigma receptors [126] (in non-small lung carcinoma,
prostate cancer, melanoma and breast cancer) and others [119] (Fig. 2.3). The angiogenic tumor
vasculature can be addressed by targeting [127] of vascular endothelial growth factor (VEGF) re-
ceptor, platelet derived growth factor (PDGF) receptor or integrins [128].
Targeting moieties can be natural and artificial ligands. They include small molecules like vita-
mins (e.g. folic acid or biotin) or bisphosphonates, proteins like transferrin or lactoferrin, growth
factors, antibodies, antibody fragments, nanobodies, peptides, saccharides or polysaccharides and
aptamers composed of single-stranded DNA or RNA [129]. The efficiency of delivery systems
equipped with ligands depends on many factors, for example the affinity, density, accessibility and
multivalency of the targeting ligands on the carrier, the concentration of competing endogenous
natural ligands in the medium and the size of the particles [54].
There are ongoing discussions about the active targeting approach. For instance, the nanopar-
ticles equipped with ligand may be deposited on tumor cells next to leaky blood vessels, thus
compromising their diffusion, penetration and equal distribution in the tumor tissue [130]. The
improvement of the accumulation efficiency of delivery devices in tumors by active targeting strate-
gies is still under debate [131] and is believed to be caused by variations in surface characteristics
of particles, non-uniformity of tumor models and different targeting ligands [132]. In this thesis
we describe experiments which provide an improved comparability by introduction of an internal
control or parallelization of potential binding sites, and quantitative assessment. In addition, we
investigated control particles with similar surface characteristics to provide appropriate conditions
for reliable comparisons. There are some remaining challenges of active targeting approaches and
personalized nanomedicine like heterogeneous cell populations arising from genetic, epigenetic or
microenvironmental influences [133].
Four different peptide ligands and vitamin B9 were used in this thesis for adhesion studies of recep-
tor targeted nanocarriers. The complementary receptors will be shortly described in the following.
Transferrin receptor targeting
The transferrin receptor (TfR, CD71) is a homodimeric transmembrane receptor with a molecular
weight of 190 kDa [134] (Fig. 2.3). Two identical glycosylated subunits of ca. 95 kDa are connected
via two disulfide bonds to form the dimer [135]. The monomers contain a large globular extra-
cellular C-terminal domain with the transferrin (Tf) binding site, a hydrophobic transmembrane
connection and a short N-terminal cytoplasmic domain [136]. The extracellular domain can be
divided in a helical, an apical and a protease-like domain. Two types of transferrin receptors have
been discovered so far. While TfR1 is ubiquitously expressed in most proliferating cells, TfR2
is mostly present in tissues where iron metabolism is regulated such as liver and small intestine
[137, 138]. The TfR2 subtype has a lower affinity for transferrin and its expression is not correlated
with iron levels in contrast to the expression of TfR1 which is inversely correlated with the iron
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Figure 2.3: Receptors activated by their natural ligands. The transferrin receptor homodimer interacts with
diferric transferrin, the c-Met/hepatocyte growth factor receptor (HGFR) homodimer is activated by HGF
binding, the asymmetrical epidermal growth factor receptor (EGFR) homodimer is phosphorylated by EGF
binding, the integrin α/β heterodimer is illustrated in its active form binding an extracellular matrix (ECM)
ligand and the folate receptor (FR) with its natural ligand folic acid are depicted. Abbreviations: HGF,
hepatocyte growth factor/scatter factor; PSI, plexin, semaphorin and integrin (domain); IPT, Ig-like, plexins,
transcription factors; EGF, epidermal growth factor; sema, sempahorin; ECM, extracellular matrix.
concentration. Both receptor subtypes show 45-66 % similarity in the extracellular domain [139].
The physiological function of the TfR involves the controlled import of transferrin-bound iron
which is required for several cellular processes such as DNA synthesis, metabolism and prolif-
eration [140]. Transferrin is a glycoprotein of 78 kDa which reversibly binds iron with very high
affinity (Kd = 10−22 M at pH 7.4) at the binding sites in the N-lobe and the C-lobe [141]. Only ferric
iron (Fe3+) has a high affinity to transferrin and binds to the apo-transferrin present in its open con-
formation [142]. This induces a conformational change and results in the closed conformation of
the holo-transferrin upon binding of a second ferric iron. Ferric iron is almost insoluble in aqueous
neutral media and thus is chelated or complexed to proteins or macromolecules [143].
The transferrin receptor homodimer can bind two transferrins which implies the transportation
of up to four iron molecules. Transferrin binds to the TfR fast via interaction of the C-lobe with
the helical domain of the receptor, or slow by the interaction of the N-lobe with the protease-like
domain. The latter process occurs with high affinity in the nanomolar range [144]. Upon binding
of Tf to the TfR, the ligand-bound receptor is internalized in a temperature and energy-dependent
manner via clathrin-mediated endocytosis [134]. The trafficking of endosomes containing the
Tf/TfR proceeds via two pathways: either fast recycling back to the surface or transportation to the
endocytic recycling compartment (ERC) [144]. These processes can take place either via static or
dynamic endosomes which differ in their maturation kinetics. Most TfR are recycled back to the
membrane (85-95 %) [145]. The entire recycling process requires only 10 min on average, but also
faster recycling in the range of 4-5 min has been reported [146, 147]. The import of protons pumped
by a V-ATPase into the endosome acidifies the vesicle [134]. At a pH of approximately 5.3, two
lysine residues of Tf are protonated triggering the release of ferric iron from the Tf/TfR complex
[148]. A divalent cation transporter transfers the iron into the cytosol accompanied by reduction of
ferric to ferrous iron (Fe2+) via an oxidoreductase.
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TfR is expressed in non-proliferating cells at a low level including vascular endothelial cells of
brain capillaries, hepatocytes, kupffer cells of the liver, pancreatic cells, breast and kidney cells
[149]. Higher levels of the receptor are found on cells with higher proliferation including the basal
layer of skin, the endothelium of brain capillaries and crypts of the intestinal villi. In cancer, the
TfR is expressed in metastatic and drug-resistant tumors of organs including pancreas, colon, lung
and bladder. Correlations of TfR expression with malignancy, aggressiveness and growth are doc-
umented as well as high turnover rates of the TfR in tumors was reported [149–151] .
TfR targeting of tumor cells or for delivery to the brain is broadly investigated using the natural
ligand Tf, synthetic peptides, antibodies and antibody fragments [27, 152, 153].
Hepatocyte growth factor receptor/c-Met targeting
The c-Met/hepatocyte growth factor receptor (HGFR) is a transmembrane α/β-heterodimer with
a molecular mass of 190 kDa [154] (Fig. 2.3). The extracellular part comprises three domains: a
semaphorin (sema) domain which contains the whole α-subunit and part of the β-subunit, a PSI
(found in plexins, semaphorins and integrins) and a immunoglobulin-plexin-transcription (IPT)
domain consisting of four sub-domains [155]. A transmembrane helix connects the extracellular
part to an intracellular catalytic tyrosine kinase domain flanked by distinctive juxtamembrane and
C-terminal sequences functioning as multi-functional docking sites.
The natural ligand of c-Met, the hepatocyte growth factor (HGF)/scatter factor (SF) is a serine pro-
tease secreted by mesenchymal cells in an inactive state [156]. Extracellular proteases cleave the
single chain to mature HGF into its active form containing an α- and a β-chain connected by a disul-
fide bond. HGF/SF is a pleiotropic factor (one gene influences more phenotypic traits) and cytokine
(regulates growth and differentiation of cells) which promotes cell proliferation, survival, motility,
scattering, differentiation and morphogenesis [157]. In multiple diseases, HGF acts protective, for
example in liver cirrhosis or lung fibrosis [158, 159]. The ligand can bind at the two binding sites
of c-Met/HGFR [157]. First, the IPT3 and IPT4 domains bind the N-domain of HGF/SF with high
affinity, independent of the maturation state of the ligand. Second, the sema domain binds the
HGF/SF with low affinity, only when the ligand is fully matured. Upon binding to c-Met, homod-
imerization and phosphorylation of two tyrosines in the catalytic part of the kinase domain occur.
This activation triggers the phosphorylation of two other C-terminal tyrosines and the recruitment
of effectors. Signaling cascades activate several processes including proliferation, cell motility, cell
cycle progression, transformation, invasion, cell migration and non-adhesive growth, positive and
negative feedback on c-Met [155].
The internalization of c-Met is mainly clathrin-and dynamin-dependent [160]. Often, the E3 ubiq-
uitin ligase c-Cbl is involved in the uptake process. Trafficking of c-Met from early endosoms to
perinuclear regions can occur along microtubules and protein kinase C promotion and non-receptor
tyrosine phosphatase PTP1B [161]. For degradation, direct binding of c-Cbl to Met is required.
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Physiologically, c-Met regulates many essential processes in cell development and function and
wound healing. It is expressed in epithelial cells of organs including liver, pancreas, prostate,
kidney, muscle and bone marrow, during both embryogenesis and adulthood [162]. Aberrant regu-
lation of the proto-oncogene c-Met and its protein product results in development and progression
of several types of cancer [163]. The decisive and continuous activation of c-Met can occur by sev-
eral mechanisms including genetic alterations, transcriptional overexpression and ligand-depended
mechanisms. The up-regulation is caused by activation of oncogenes, inactivation of suppressor
genes, down-regulation of mRNAs or by hypoxia (oxygen depletion) [164]. Cancer therapies
which target HGF/c-Met are mainly kinase inhibitors and antibodies. Only few nanoparticle-based
strategies deliver therapeutics into c-Met expressing cells or tissue. The targeting moieties include
antibodies and peptides [165, 166].
Epidermal growth factor receptor targeting
The epidermal growth factor receptor (EGFR) is a heavily N-glycosylated protein of 170 kDa [167]
(Fig. 2.3). Approximately 20 % of its molecular weight are carbohydrates. The glycosylation is
important for the receptor-ligand interactions. The EGFR contains an extracellular region which
is divided into four domains: domain I, II, III and IV. The domains I and III exhibit a leucin-rich
repeat, thus are called L1 and L2 and both contribute to ligand binding [168] with an affinity of ca.
400 nM [169]. The domains II and IV are similar to those in laminin with several disulfide bonds
and are termed cysteine-rich domains (CR1 and CR2) [170]. Monomeric EGFR is autoinhibited in a
tethered, closed conformation and extends to an untethered open conformation upon dimerization
which is fully receptor-mediated [171]. Ligand binding stabilizes the open state. Apart form the
extracellular part, the EGFR contains a hydrophobic transmembrane region and an intracellular
catalytic tyrosine kinase domain and multiple tyrosine moieties.
The EGFR family consists of four receptors: EGFR (erbB-1/Her1), erbB-2 (Her2), erbB-3 (Her3) and
erbB-4 (Her4). Pairing of specific monomers results in different functionality. While ligand binding
is obligatory for Her3 and Her4, there is no activating ligand for Her2 [172]. In general, there are
several ligands for the EGFR including epidermal growth factor (EGF), transforming growth factor
alpha (TGFα), heparin-binding EGF-like growth factor, amphiregulin, epiregulin, β-cellulin, epigen
and neuregulin 2β [173, 174]. The ligands are integral membrane proteins which are cleaved by
metalloproteinases to yield mature ligands.
The activation of EGFR does not depend on the phosphorylation of the activation loop [175]. The
receptor is rather activated by the formation of an asymmetric dimer where the C-terminal lobes of
two kinase domains interact with each other. Ligand binding recruits two monomers resulting in
dimerization and subsequent activation of the kinase domains. Several ligands induce dimerization
and heterodimerization with related receptors which results in receptor autophosphorylation of ap-
proximately 10 tyrosine residues [176]. The phyosphorylated tyrosins are binding sites for several
cytosolic proteins with Src homology 2 (SH2) domains or phosphotyrosine binding motifs. The
recruitment of multiple downstream effectors results in the activation of signaling cascades which
for example stimulate proliferation and cell survival [177]. Phosphorylation of Tyr974 induces
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endocytosis and activation of Tyr1045 triggers EGFR ubiquitination and proteosomal degradation
[178, 179]. EGF binding promotes internalization to lysosomes while signaling is sustained until
the receptor is degraded. In contrast, TGFα dissociates from the receptor in the endocytic recycling
compartment. The main route of EGFR internalization is clathrin-mediated endocytosis, followed
by fusion with early endosomes and sorting compartments from where the receptor is recycled
back to the surface or to multivesicular bodies (MVB) from where it can follow the pathway to
lysosomal degradation [180]. EGFR is constitutively endocytosed and recycled back to the surface
with a half-life of 30 min in the absence of ligand. The receptors remain on the cell surface most of
the time (80-90 %) [181].
EGFR normally regulates cell proliferation, survival and differentiation. In cancers, receptors are
overexpressed and continuous signaling is activated for instance caused by mutations or hypoxic
tumor microenvironment which can promote increased EGFR mRNA translation. In many types
of cancer, EGFR is overexpressed including head and neck, breast, renal, non small cell lung, colon,
ovarina, glioma, pancreatic and bladder cancer [182]. The malignant states influence cell motility,
proliferation, angiogenesis and reduced apoptosis. Cancer therapies target the function of the
kinase domain with tyrosine kinase inhibitors like erlotinib (Tarceva) or monoclonal antibodies,
e.g. cetuximab (Erbitux) [183]. Furthermore, EGFR targeting is performed using antisense oligonu-
cleotides, antibody based immunoconjugates, peptides, affibodies and nanobodies are used apart
from small molecule kinase inhibitors and monoclonal antibodies [124].
Integrin targeting
Integrins are integral membrane proteins which link the extracellular matrix (ECM) to the cy-
toskeleton [184] or bind other adhesion receptors on neighboring cells (see Fig. 2.3). They are
heterodimers of an α- and a β-subunit [185]. At least 24 heterodimers exist which are combinations
of 18 α- and 8 β-subunits. The subunits usually consist of 750-1000 amino acids and their domains
are connected by flexible linkers. They are integrated into the membrane via a single helix and
posses a short unstructured cytoplasmic tail. The α-subunit consists of four or five extracellular do-
mains including a seven-bladed β-propeller, a thigh and two calf domains (and half of the subunits
contain a α-I domain). Within the β-propeller are at least three or four Ca2+-binding sites which
influence ligand adhesion upon Ca2+ binding. The β-subunit has seven domains: a βI-domain, a
hybrid domain, a plexin-semaphorin-integrin (PSI) domain, four cysteine-rich epidermal growth
factor (EGF) modules and a β-tail domain. In an inactivated state, the integrin heterodimers are
in a bent conformation with low ligand affinity which is also present in a primed, extended con-
formation with closed head-piece. In the active state, the conformation is extended presenting an
open head-piece and high ligand affinity [186].
The combination of the heterodimeric integrins implicates the binding of one or more ligands. The
integrin αvβ3 binds for instance vitronectin, fibronectin, von Willebrand factor (vWF), tenascin,
osteopontin, fibrillin, fibrinogen and thrombospondin [119].
The αv and αvβn integrins are highly expressed in activated endothelial cells and tumor cells while
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they are not present in resting endothelial cells or most adult epithelia. The expression of integrins
αvβ3, αvβ5, α5β1, α6β4, α4β1 and αvβ6 is correlated with disease progression in numerous tumor
types and thus investigated most in cancer studies [187]. The expression and exposure of various
integrins at the cell surface determines to which ligand or cells they bind and thus the survival in
a particular microenvironment. Their functions involve physiological processes like development,
maintenance and repair of tissues as well as pathological processes including proliferation, differ-
entiation, the sprouting ability of endothelial cells during angiogenesis, invasiveness of tumor cells
and cell migration [188, 189]. The regulation of their functions is achieved by ligand engagement,
binding of intracellular proteins and endocytic uptake and trafficking [190]. The internalization of
integrins occurs via various endocytic pathways including clathrin- or caveolin-mediated mecha-
nisms and is highly dependent on the combination of the heterodimer, cell type, stimuli and matrix
[191]. Usually, integrins have a long half-life, are mainly recycled back to the plasma membrane
and barely degraded [190].
The targeting of integrins involves both the tumor cells and the supporting vasculature [192].
Mainly αvβ3 integrins are addressed by various ligands including peptides, peptidomimetics and
non-peptide ligands which simulate the RGD (arginine-glycine-aspartic acid) sequence of several
ECM proteins [122].
Folate receptor targeting
The folate receptor (FR) is a cysteine-rich glycosyl phosphatidylinositol (GPI) anchored gylcopro-
tein which binds folate with high affinity (Kd ≈ 0.1 nM) [193] (see Fig. 2.3). Folate receptor α has
a globular structure which is stabilized by eight disulfid bonds and incorporates a deep binding
pocket for folate with conserved residues in all receptor subtypes (α,β,γ,δ) [194].
The natural ligand, folate (vitamine B9) occurs either in its oxidized state as folic acid or in its phys-
iologcially active reduced state as tetrahydrofolate (THF) [195]. Reduced folates have biosynthetic
functions including the synthesis of DNA and RNA, metabolism of amino acids, and methyla-
tion reactions. Subsequently they are involved in the differentiation, proliferation and survival of
cells [196]. Folate can be internalized by cells via three different routes: 1) proton-coupled folate
transporters (PCFT) import the vitamin in acidic environments of the upper small intestine [197].
Hereditary folate malabsorption has severe consequences which occur within few month after birth,
for example anemia, recurrent or chronic diarrhea and hypogammaglobulinemia [198]. 2) Reduced
folate carriers (RFC) which are ubiquitously expressed are usually the main route for folate inter-
nalization at physiological pH [196]. This anion exchanger absorbs reduced folates and organic
phosphates, but has very low affinity for folic acid [199]. 3) Folate receptor endocytosis internalizes
folates and 5-methyl-THF, the major circulating form of folate, both exhibiting high affinities to the
receptor in the range of 0.1-1 nM [200]. Folate receptor endocytosis includes a variety of uptake
pathways [201]. Mainly clathrin-independent pathways are suggested for FR uptake. Only after
cross-linking of the receptors, selective localization to caveolae has been reported which is followed
by caveolae-mediated uptake [202]. The majority of FRα (50-75 % is located in endosomal compart-
ments and the recycling back to the surface via the endocytic recycling compartment is slow [203].
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Whereas FRα is expressed in low levels in normal cells and tissues, it is upregulated in many hu-
man cancer cells of organs including the ovary, brain, kidney, breast, colon, myeloid cells and lung
[119], but mostly not elevated in sarcomas, lymphomas and cancers of pancreas, testicles, bladder,
prostate and liver [200]. FRα is required to increase the concentration of folate in fast dividing
cancer cells [204]. There is evidence that FR expression is correlated with advanced stages of dis-
ease [205] and overexpression is accompanied by poor prognosis for breast, colorectal, ovarian and
endometrial cancers [206]. Folic acid is widely used for tumor targeting as this vitamin is small,
cheap and easy to attach to nanocarriers.In addition, it is non-toxic and non-immunogenic [207, 208].
2.3 Cellular uptake, trafficking and endosomal escape
Cellular uptake
The internalization of nanocarriers into cells can occur via natural processes or can be induced
by physical methods. The latter include several procedures: 1) the direct introduction of delivery
systems or therapeutic cargo via microinjection [209] into the cytosol or nucleus of the cells, 2) the
application of an electrical field to increase the permeability of the cell membrane (electroporation)
[210], and 3) the destabilization of the plasma membrane by treatment with ultrasound (sonopora-
tion) [211]. However, these strategies have limitations in their practical use as they require detailed
knowledge of localization or compromise the cell integrity.
Small molecules which are essential for cell survival, such as sugars, ions and amino acids, cross the
cell membrane through integrated pumps or ion channels. Nanocarriers and macromolecules can-
not traverse this double-layered lipid barrier and are internalized by encapsulation into membrane
vesicles (endocytosis). The highly regulated endocytotic pathways mediate complex physiological
processes, for example signal transduction via hormones, antigen-presentation, immune control
and cellular homeostasis [212]. The uptake of large particles is called "cell-eating" or phagocytosis
and the upatke of fluid and solutes is termed "cell-drinking" or pinocytosis.
Phagocytosis is typically restricted to specialized mammalian cells such as macrophages, neu-
trophils and monocytes. These cells decompose pathogens like bacteria, or cell debris and other
remnants [79] which attach to receptors presented on the cell surface, e.g. Fc receptors, complement
receptors and phosphatidylserine receptors that are recognized by dead cells. The binding induces
a signal transduction and the recruitment of actin. By extension of the membrane, the pathogens
are enclosed and degraded by free oxygen radicals and acidic hydrolysis in the phagosomes.
Pinocytosis pathways are categorized into at least four types: 1) macropinocytosis, 2) clathrin-
mediated endocytosis (CME), 3) caveolin-dependent endocytosis and 4) clathrin- and caveolin-
independent endocytosis (Fig. 2.4). Macropinocytosis is stimulated by activation of tyrosine kinases
upon growth factor binding or other stimuli [214]. Driven by changes of the actin structure, mem-
brane ruﬄes are formed which protrude from the cell and collapse onto the plasma membrane
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Figure 2.4: Cellular uptake and internal transport of nanoparticles. Nanoparticles internalized by various
uptake pathways into endosomal vesicles are transported within the cell along cytoskeletal structures medi-
ated by motor proteins. The nanoparticles in early endosomes can be transferred to sorting endosomes, or
excreted from the cell by fusion with the plasma membrane. An alternative pathway involves the maturation
into lysosomes accompanied by acidification and recruitment of degradative enzymes. The nanoparticles
must escape from the endosomal vesicles to reach cytoplasmic or nuclear targets after translocation in the
respective compartment and diffusion through the crowded cytoplasm. Abbreviations: ERC, endocytic recy-
cling compartment; ER, endoplasmic reticulum; MTOC, microtubule-organizing center; MVB, multivesicular
bodies. The figure is inspired by Chou et al. [213] and modified according to Sun et al. [34].
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to form macropinosomes (0.5-10µm). By these uptake pathways small and larger particles are
internalized non-specifically. Clathirin-mediated endocytosis involves the more selective uptake of
essential nutrients like cholesterol bound to low density lipoprotein (LDL)-receptor, or transferrin
(Tf) bound to the Tf receptor (TfR). Furthermore, CME supports cell and serum homeostasis and
controls the levels of ligand-bound surface signaling receptors by concentration and internalization
thereof [215]. Coated pits are formed by polymerization of the cytosolic protein clathrin in com-
bination with assembly proteins. These vesicles (ca. 120 nm) are pinched off by the small GTPase
dynamin [216]. After disassembling of the clathrin coat, vesicles merge with early endosomes
[217]. Caveolin-mediated endocytosis involves the enrichment and internalization of multiple signal-
ing molecules and membrane transporters in flask-shaped lipid microdomains of cholesterol and
sphingolipid-rich plasma membrane (caveolae) [218]. The hairpin-like membrane protein caveolin
is integrated in these structures which binds and promotes sorting of several molecules including
lipids, fatty acids and membrane proteins [219]. In combination with other proteins like cavin,
which induces surface curvature, and dynamin, which promotes budding, endosomal vesicles (ca.
60 nm) are formed [220]. They merge with caveosomes or multivesicular bodies (MVBs) at neutral
pH and can circumvent fusing with liposomes [221]. This uptake mechanism is in general slower
than CME. Clathrin- and caveolin-independent endocytosis can be categorized into Arf6-dependent,
fotillin-dependent, Cdc42-dependent and RhoA-dependent pathways according to their effectors
[215]. Cholesterol-dependent membrane parts with specific compositions are involved in these
uptake routes.
Apart from endocytotic pathways, nanocarriers can enter cells via other mechanisms including
membrane fusion [222], transient induction of holes in the membrane [223, 224] or via cell-
penetrating peptides [225]. These processes do not compromise the integrity of the cell membrane.
The uptake pathway by which a nanocarrier is internalized depends on its structure and physico-
chemical properties (size, shape, charge, hydrophobicity) and is governed by the surface modifica-
tion and adsorption of biological molecules [220]. These characteristics can alter the uptake route
and efficiency. Many positively charged nanoparticles are predominantly internalized by CME. An
exception are for instance PEI-based polyplexes, which take several uptake pathways including
caveolae-mediated endocytosis [226]. In cell culture assays, the excess of free polymer could have an
impact on internalization. Negatively charged nanoparticles preferentially use caveolae-dependent
endocytosis [227]. The impact of the particle size is discussed in literature, but there are no clear
tendencies and it is suggested that chemical composition has a much higher influence [220]. Uptake
capability and efficiency is further affected by the shape of the particles and their orientation [228].
Moreover, the cell line into which the delivery systems are transferred are crucial as they may be
able or may not be able to internalize particles via specific uptake routes. Furthermore, other cell
line-related factors may contribute to preferential uptake pathways.
Trafficking
Internalized nanoparticles encapsulated in membrane vesicles are transported within the cells along
cytoskeletal structures (trafficking) or are secreted from the cell back into the extracellular space
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(exocytosis)(Fig. 2.4). Usually, the cargo in the vesicles first arrives in early endosomes. In this
organelle, the nanomaterial is sorted and can be transported via several pathways including routes
to late endosomes and lysosomes for degradation, to the trans-Golgi network, or to the endocytic
recycling compartment (ERC) from where receptors and other payload is returned to the plasma
membrane [229]. The transport involves motor proteins carrying the vesicles along the cytoskele-
ton e.g. on microtubules [213]. The pH varies in different endosomal compartments, for example
acidification occurs during maturation of early endosomes via late endosomes into lysosomes.
Endosomal escape
There are several strategies for nanocarriers to escape from endosomes to release their cargo at the
target site where it can execute its therapeutic effect. These mechanisms include 1) pore formation
in the endosomal membrane, 2) swelling and rupture due to a pH buffering effect, 3) fusion in the
endosomal membrane and 4) photochemical disruption of the endosomal membrane [230].
Peptides with high affinity to lipids can insert into the lipid bilayer of the endosome and cause
tension [230]. When they cluster into barrel-like or toroid-shaped structures, the tension can be
reduced and pores are formed. Thus, small cargo can diffuse out of the vesicles. Pore formation is
also one of the processes bacteria use for endosomal escape [231].
Another escape mechanism is the so termed "proton sponge hypothesis" which exploits the buffer-
ing capacity of certain cationic polymers or other agents which usually contain secondary and/or
tertiary protonatable amine groups with pKa values in the range of the endosomal/lysosomal pH
[232]. During maturation of the endosome, membrane integrated V-ATPases pump protons into the
endosomal compartment which is accompanied by the influx of chloride ions and water. Succes-
sive protonation results in continuous import of protons and increased osmotic pressure. Different
theories exist to explain the release of the endosomal content [54]. One explanation is that the en-
hanced pressure leads to swelling of the vesicles and finally rupture of the endosome. Furthermore,
the protonatable agent is believed to interact with the phospholipid membrane which causes in
addition tension and permeabilization of the membrane. This processes might contribute to cargo
release from the endosome.
The sheath of enveloped viruses can fuse with the lipid bilayer via single integral membrane
peptides (fusogenic peptides). These molecules can undergo a conformational change via certain
triggers such as pH changes, which initiates fusion in the membrane [233]. By insertion of fusogenic
peptides on nanocarriers, the payload can exit the endosome by membrane fusion.
Photochemical internalization (PCI), the photochemically induced endosomal release strategy, is
achieved by using photosensitizer which localize mainly in membranes of endosomes and lyso-
somes [234]. Upon excitation with light, reactive oxygen species (ROS), predominantly singlet
oxygen is generated which destroys the membrane integrity. The cargo of the vesicles can escape
without damage.
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Several natural products derived from viruses, bacteria, plants, animals and humans as well as
synthetic peptides and chemical agents are used to promote endosomal escape of nanocarriers
which is one of the main hurdles of gene and drug delivery [230].
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In past decades, a huge variety of nano-sized materials have been developed involving the demand
for imaging techniques of their interactions with biological systems in a non-invasive manner. In
this respect, fluorescence microscopy represents a powerful tool. Many fluorescent dyes such as
organic molecules, nanocrystals or fluorescent proteins have been evolved covering a large spectral
range of visible light and part of the infra red (IR) and ultra violett (UV) regions. With elaborate
labeling techniques it is possible to mark specific molecules in order to visualize certain cellular or
extracellular regions. Using multiple colors, different parts of a specimen overlapping or intersect-
ing each other can be imaged. So, also distinct biological processes can be observed surrounded
by many others occurring simultaneously in the immediate environment [235]. With the improve-
ment of bio-orthogonal fluorophores concerning their solubility, quantum yield and photochemical
stability, an enormous variety of biological systems is imaged nowadays ranging from whole living
animals, huge samples like tissues over cells and subcellular regimes down to the interaction of
single large molecules in the nanoscale range. By live-cell imaging, dynamic processes were visu-
alized in real-time, for example, studying the internalization dynamics of receptor targeted gene
delivery systems [236] with single particle tracking. Applying quantitative analysis, uptake [237]
and uptake kinetics [238] of nanoparticles into cells were investigated. Furthermore, mechanistic
insights into the uptake pathway of receptor targeted nano therapeutics [239] or the controlled
endosomal escape of delivery devices via photosensitizer activation [240] have been gained.
Widefield microscopy provides sufficient temporal resolution to measure processes in real-time,
but the spatial resolution is restricted to few hundred nanometers. Besides this conventional flu-
orescence microscopy technique, advanced methods have emerged in the past decades [241]. An
approach with improved axial resolution, thus enabling resolution in all three spatial dimensions
is confocal microscopy. As the focus volume is reduced and out-of-plane fluorescence is not mea-
sured, the background is highly reduced. Though, to obtain the whole image, the sample has to
be scanned which extends the acquisition time. Fortunately, fast scanning systems and advanced
approaches like spinning disks for simultaneous illumination and detection of multiple points have
been developed. Another approach to increase the axial resolution of a large field of view without
scanning [242] can be achieved by total internal reflection microscopy (TIRFM) [243]. Various other
fluorescence techniques can be combined with microscopy, including quantitative approaches like
fluorescence recovery after photobleaching (FRAP) [244], Förster resonance energy transfer (FRET)
[245] and co-localization. Thus, diffusion coefficients of cargo released by nanocarriers [246], re-
ceptor trafficking dynamics [247] or the fate of biodegradable drug delivery systems [248] can be
studied.
Spatial resolution can be improved by multiple techniques including structured illumination mi-
croscopy (SIM) [249], near-field optical microscopy (NSOM) [250], 4Pi microscopy [251], I5M mi-
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croscopy [252] or light sheet microscopy (LSM) [253] can be applied. In addition, resolution down
to few nanometers (ca.20 nm) can be achieved by super-resolution microscopy, whose development
was awarded with the Nobel prize in chemistry 2014 [254]. These methods include the raster scan-
ning microscopy approach with stimulated emission depletion (STED) and the localization-based
techniques like photoactivated localization microscopy (PALM) [255], fluorescence photoactivation
localization microscopy [256] or stochastic optical reconstruction microscopy (STORM) [257]. These
methods require high labeling densities, photoswichable or phototunable dyes, often high laser
powers and are restricted in acquisition time. These requirements can induce non-physiological
behavior and phototoxicity.
Depending on the research question and subsequent the addressed problem, the most adequate flu-
orescence methods and evaluation tools should be chosen. In this work, widefield microscopy was
used to study the cellular adhesion of nanoparticles and spinning disk microscopy was employed
for characterization of nanoparticles as well as to explore their specific attachment to receptors. In
this chapter, these microscopy methods will be introduced, with respect to their spatial resolution
after description of the principles of fluorescence and characteristics of fluorophores.
3.1 Principles of fluorescence
A molecule can be excited from its electronic ground state (S0) into its first (S1) or higher excited
states (S1+x) by the absorption of light if its energy is at least the difference of the two states. The
excitation energy E is inversely proportional to the wavelength λ of the excitation light:
E =
h · c
λ
= h · ν (3.1.1)
where h is the Plank’s constant, c the speed of light in vacuum and ν is the excitation frequency.
Excitation and emission processes are depicted in a Jablonski diagram in Fig. 3.1 [258]. A fluo-
rophore in its ground state can absorb one or more photons within femtoseconds (blue arrows). The
probability of absorbing a photon is given by its molar extinction coefficient ε. It is excited more
likely when the electric field of the excitation laser light is polarized parallel to the molecule’s dipole
moment [259]. During excitation with an energy of at least the difference between the first excited
and ground state (S1-S0), usually vibrational changes occur as well according to the Franck-Condon
principle. The molecule does not stay long in its excited state and returns to its ground state by
radiative and non-radiative transitions. First, energy is transferred to surrounding molecules by
direct interactions during vibrational relaxation (purple arrows). Within the same time range, inter-
nal conversions occur by isoenergetic transition from vibrational modes of an excited state to high
vibrational levels of a lower excited electronic state (gray arrow). Then, from the vibrational ground
state of an excited singlet state (S1), fluorescence is emitted when the molecule relaxes back to the
electronic ground state (S0) by radiating a photon (green arrow). This process takes place in the
range of nanoseconds. The cycle is repeated until the molecule photobleaches. Good fluorophores
have a high quantum yield which represents the ratio of emitted to absorbed light. A maximum
value of 1 is obtained when all absorbed photons are emitted. Another pathway for an excited
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fluorophore to return to the ground state is to undergo a spin-forbidden transition to the triplet
state (T1), the so-called intersystem crossing (red dotted arrow). As another forbidden transition
is required to return to the ground state (S0), it can remain in the triplet state for microseconds.
Returning back to the ground state by emitting a photon is called phosphorescence (orange arrow).
Long-lived triplet states are disadvantageous for good fluorophores as they prevent the molecule
to cycle through absorption and fluorescence emission. In addition, the lifetime of the fluorophore
is extended which represents the time it spends in the excited state before emitting a photon.
Figure 3.1: Jablonski diagram. The energy states of a molecule are shown. By light absorption, the molecule
is excited from its electronic ground state, S0, to an excited singlet state, S1, S2,etc. within fs (blue). By non-
radiative transitions, the molecule relaxes to electronic states of lower energy within ps, including vibrational
relaxations (purple arrows) to the vibrational ground state, V0, internal conversion (gray arrow) to higher
vibrational states of a lower electronic excited state and intersystem crossing red arrow), the isoenergetic
forbidden transition to a triplet state, T1, by spin conversion. Radiative transitions back to the ground state
occur as fluorescence (green arrow) within ns or as phosphorescence (orange arrow) within µs. Schematic
adapted from Lichtman et al. [258].
In Fig. 3.2, the absorption and emission spectra of ATTO 488 are shown. The absorption spectrum
(blue line) illustrates the wavelengths at which the dye can be excited. Photons are absorbed more
likely at the absorption maximum. The fluorescence emission spectrum (green line) usually has
a mirror symmetry. The emission maximum is offset to longer wavelengths with respect to the
absorption spectrum, the so termed "Stokes shift". This displacement occurs due to energy losses
during non-radiative de-excitation processes such as vibrational relaxation and internal conversion.
3.2 Fluorophores
Typical fluorescent molecules usually have conjugated double bonds or aromatic systems delo-
calized electrons. The more rigid and the more extended a pi-electron system is, the lower is the
distance between energetic levels. This means, light with less energy, i.e. longer wavelength, is
25
3 Fluorescence microscopy
Figure 3.2: Absorption and fluorescence emission spectra of ATTO 488. The absorption spectrum (blue) and
the emission spectrum (green) have mirror symmetry and are separated by the Stokes shift. Values taken from
[260].
required to excite the molecule. Moreover, a high photostability is advantageous meaning the
resistance against irreversible damage caused by light exposure. Apart from bleaching, the fluores-
cence can be diminished by quenching processes, like excited state reactions, the transfer of energy
to a close-by molecule, the formation of a complex with another molecule, or the collision with
molecules which promote non-radiative de-excitation [261], such as oxygen or iodide.
To link a fluorophore to biological samples, a variety of methods is available including covalent
coupling chemistry, adsorption processes, intercalation of molecules, gene expression of fluorescent
proteins tags and immunostaining. In Fig. 3.3, the chemical structures of the fluorophores used in
this work are depicted as way of example. To visualize the nuclei of cells the DNA can be stained by
4’,6-diamidino-2-phenylindole (DAPI) which intercalates into A-T rich regions of double-stranded
DNA. The fluorescence emission maximum of DAPI is around 461 nm. This dye also interacts with
RNA, but the fluorescence signal is much lower. The xanthene dyes ATTO 488, Alexa Fluor 488 and
FITC, and the indocarbocyanine dyes Cy5 and Alexa Fluor 647 are typical organic dyes. They are
usually coupled covalently to functional groups of biological probes or nanoparticles via reactive
groups. Fluorophores are linked to amino groups for example with reactive esters, carboxylates,
isothiocyanates and sulfonyl halogenides. Thioles can be labeled via maleimide or iodocaetamide
chemistry. Biocompatible and specific attachment of fluorophores to alkynes or azides is achieved
by click chemistry. Differently, the green fluorescent protein (GFP) discovered in the jellyfish
Aequorea Victoria can be tagged on many proteins via genetically engineering [262]. The fusion
protein is preferentially attached at the C- or N- terminus of a protein where it does not influence
its function. In the center of the β-barrel structure of GFP, the amino acids serine65, tyrosin66 and
glycine67 are post-transcriptionally modified to yield the chromophore of the fluorescent protein
[263]. The absorption maxima of GFP are at 395 nm and 475 nm.
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Figure 3.3: Fluorophores. Chemical structures of the fluorophores used in this work are depicted. The dye 4’,6-
diamidino-2-phenylindole (DAPI) was excited with a 405 nm laser, the xanthene dyes ATTO 488-NHS, Alexa
Fluor 488-NHS and fluorescein isothiocyanate (FITC), as well as the chromophore of the green fluorescent
protein (GFP) consisting of post-translational modified Ser65Tyr66Gly67 can be excited with a 488 nm laser
and the indocarbocyanines Cy5-NHS and Alexa Fluor 647-carboxy with a 633 or 639 nm laser.
3.3 Widefield and spinning disk microscopy
The fundamentals of modern light microscopy are based on the diffraction of light by the specimen
and the objective lens which limit the resolution of an image [264]. The image of a point emitter is
described by its point spread function (PSF). In the lateral plane, this diffraction image consists of
concentric bright and dark circles alternating with gradually weaker intensity. Two emitters can be
resolved when the central bright disk, the so termed Airy disk, of the one spot is located at least in
the first minimum of the second spot or further apart (Rayleigh criterion). The lateral resolution, i.e.
the radius of the Airy disk r is defined by the wavelength λ of the emitted light and the numerical
aperture (NA) of the objective:
r = 0.61 · λ
NA
= 0.61 · λ
n · sinα (3.3.1)
where n is the refractive index of the medium between objective and cover slip and α the half angle
of the aperture. This resolution applies to conventional widefield microscopy in the lateral plane.
In axial direction however, the sample should be imaged in the focus plane, otherwise it will appear
blurred. Depending on the type of the objective, air, water or oil are between the lens and the cover
glass.
In Fig. 3.4 A, a typical light pathway of an epi-fluorescent widefield microscope is depicted. From a
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light source, a beam is focused on the back focal plane of a condenser illuminating the sample on a
cover slip. A convenient light source is a laser as it provides intense, coherent and monochromatic
light. If several laser lines are used in a microscope, an accusto optical tunable filter (AOTF) can
be integrated in the light pathway to enable selection of the desired wavelength. When a radio
frequency is applied to such a piezo crystal, a diffraction grating is created and diffracts light of
only a narrow band of frequencies. By varying the amplitude of the sound wave, not only the range
of selected wavelengths can be tuned, but also the intensities. In an epi-fluorescent microscope, the
condenser is also the objective lens which magnifies the sample and collects the emitted fluorescent
light. Thus, only the small amount of reflected excitation light has to be separated from the emis-
sion light. A dichroic mirror separates the emission from the excitation light by reflecting a certain
range of wavelengths while transmitting others. Implementing bandpass filters in the emission
pathway narrows down the range of wavelengths arriving at the camera. The fluorescence is typ-
ically detected by charged coupled devices (CCD) cameras. Improvement of sensitivity and thus
the number of images recorded before a probe photobleches is achieved by electron multiplying
CCD (EMCCD) cameras using impact ionization for increased EM gain.
Figure 3.4: Principles of widefield and spinning disk microscopy. In a widefield microscope the excitation
light is focused on the back focal plane of the objective and illuminates the sample after passing the objective
with a wide beam. In an epi-fluorescent mode, the fluorescence emission is collected by the objective, separated
from the excitation light by a dichroic mirror and directed onto a CCD camera after passing an emission filter. In
a confocal spinning disk microscope, the laser light is directed through a spinning disk unit. Using Yokogawa
technology, mikrolenses on a first rotating disk focus the excitation light onto pinholes on a second disk. Thus,
only a small confocal volume of the sample is excited with light after passing the objective. The fluorescence
is collected by the objective and again passed though the rotating pinhole disk, separated from the excitation
light by a dichroic mirror and recorded by a camera after passing a pinhole and emission filter. With this
method the sample can be resolved with increased axial resolution.
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Resolving a fluorescent probe in the axial direction is enabled by confocal microscopy. This tech-
nique uses the implementation of a pinhole into the light pathway restricting the excitation and/or
emission volume of the sample. This means that only the focal plane is illuminated and/or the flu-
orescence of the focal plane detected while out-of-focus signal does not pass through the pinhole.
The signal-to-noise ratio is improved and hence the contrast is increased. However, only small
regions of the sample are probed and raster scanning has to be applied to obtain the whole image.
This procedure takes time and restricts the temporal resolution.
The scanning speed can be drastically reduced by insertion of a Nipkow disk into the conjugated im-
age plane [265]. This spinning disk with multiple perforations allows for parallel point-illumination
and detection of the specimen. Though, a high percentage of the illumination light does not reach
the sample and is reflected which can cause background signal. An advanced system represents
the Yokogawa spinning disk unit (see Fig. 3.4 B). A second disk with 20 000 microlenses is used to
focus the illumination beam on the pinhole disk mounted on the same axis. Hence, the excitation
light arriving at the probe is one order of magnitude increased. Emitted light is passed through
the pinhole disk and reflected by a dichroic mirror between the two disks. The axial resolution of
a spinning disk microscope with a pinhole disk depends on the refractive index n of the medium
between objective and cover glass, the wavelength λ and the numerical aperture NA:
r = 0.67 · λ
n − √n2 −NA2
= 0.67 · λ
n(1 − √1 − sin2α)
(3.3.2)
where α is the acceptance angle of the objective. The fluorescence recorded in the axial direction
should be detected at a distance of not more than half of the axial resolution [266] to avoid under-
sampling (Nyquist criterion). Otherwise signals with artifacts might be obtained.
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4 Model nanoparticles for receptor
targeting studies
With the increasing interest in nanoparticle based strategies for diagnostics[267] and therapy[14,
268], precise and reliable investigation strategies are required to be able to develop biocompatible
and efficient nanosystems. To gain insights into the efficiency of nanoparticles to detect, image,
target or treat diseased cells and tissue [269, 270], standard procedures include as a first step cell
culture based assays, followed by experiments in animals until finally clinical trials are performed.
After administration into the test system, the nanoparticles can interact with the surrounding com-
ponents like proteins, ions and cells whereby a corona around the nanoparticles can be formed
usually determining their fate [271]. Especially for diagnostic and therapeutic purposes, it is of
great importance that the nanoparticles interact specifically with the diseased tissue and cells.
Therefore, targeting ligands are coated on the nanoparticles to enhance the specific interaction
with targeted receptors on the cell surface and particle uptake [272]. In our studies, we aimed to
quantify the effect of such targeting ligands. To pursue this goal, model nanoparticles were devel-
oped, experiments under flow conditions with an internal control were designed and optimized
(see chapter 5) and the potential of two short peptides to serve as targeting ligands was assessed
(see chapter 6). In this chapter which is partially adapted from our publication in the Journal of
Controlled Release [273], the synthesis and characterization of model nanoparticles as well as the
uptake into cancer cells will be described. The synthesis was developed in collaboration with Dr. Ul-
rich Lächelt and the peptide conjugates were synthesized by Dr. Ulrich Lächelt and Stephan Morys.
Model nanoparticles were established to serve two purposes: First, to investigate the effect of
targeting ligands, comparable and easy-to-synthesize nanoparticles were required which mimic
the surface characteristics of common drug and gene delivery devices. Second, the model deliv-
ery system should meet the requirements for quantitative analysis. Desired characteristics of the
nanoparticles are low aggregation behavior, good detectability, reproducibility and stability over
several months. These goals were accomplished by synthesizing labeled, PEGylated latex beads to
which ligands or control molecules were coupled.
In Fig. 4.1 a model nanoparticle is illustrated. The core is a commercially available latex (polystyrene)
bead with surface amino groups which are positively charged under physiological pH value. Two
different bead sizes were tested, one with 110 nm diameter and another one with 200 nm diameter.
A small amount of the amino groups (5 − 10 %) was labeled with fluorescent dyes (Cy5 or ATTO
488) for detection with fluorescence microscopy. The surface was shielded with polyethylene gly-
col (PEG) to reduce the surface charge and the capability of the dye to interact with the cell or
surrounding molecules. This method is common for many nanocarriers as PEG hinders protein
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Figure 4.1: Model nanoparticle. Schematic drawing of a model bead composed of a latex core and surface
amino groups labeled with a fluorescent dye. The surface charge is shielded by a PEG linker to which a ligand
or control molecule is coupled.
binding, thus preventing unspecific absorption, increases hydrophilicity and enhances biocompat-
ibility of the nanoparticles [274]. Two different sizes of PEG linkers were tested, 2 kDa and 5 kDa,
for optimal shielding. Ligands were linked at the end of the PEG chains to improve specific inter-
action with target cells. Two short peptide ligands, B6 for transferrin receptor (TfR) targeting and
cMBP2 for hepatocyte growth factor receptor (HGFR)/c-Met targeting were coupled to the beads
as well as folic acid for folate receptor targeting. In addition, transferrin, the natural ligand for
the TfR was coupled to the beads for comparison. In order to provide suitable control beads, also
different other molecules were linked to the beads including scrambled or modified peptides, or
β-mercaptoehanol. These will be described in more detail in the following chapter.
4.1 Synthesis
The synthesis of the model beads included three steps: Labeling, PEGylation and ligand attach-
ment (see Fig.4.2). Commercially available polystyrene beads (110 nm or 200 nm diameter) with
surface amino groups were labeled with fluorescent dyes (5 % Cy5 or 8 % ATTO 488 of the amino
groups) via N-hydroxysuccinimide (NHS) ester chemistry. To confirm successful labeling, the
beads were coated on a coverglass by spin coating and the fluorescence of the dyes was observed
by widefield microscopy. Again using NHS ester chemistry, remaining surface amino groups were
linked to NHS-PEG2/5-OPSS which contained 2 or 5 kDa PEG for surface shielding and ortho-
pyridyldisulfide (OPSS) for conjugation with thiols. The amount of coupled NHS-PEG2/5-OPSS
was estimated by the following assay. Dithiothreitol (DTT) was mixed with a small quantity of
beads, 2-thiopyridone (2-TP) was cleaved from the OPSS residue on the beads and its absorption
was measured at 343 nm. The assays yielded that 5-10 % of the NH2 groups on the beads were
coupled to the PEG linker. As a last step of the synthesis, ligand-cysteine, control peptide-cysteine
or β-mercaptoethanol, respectively, was added to the PEGylated beads, the 2-TP leaving group was
cleaved and the corresponding disulfide bridge was formed. Measurements of the zeta potentials
of the differently modified beads suggested successful attachment of the ligands.
Short peptide ligands and a small molecule were used to specifically address overexpressed recep-
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Figure 4.2: Synthesis strategy of model beads. 1. Labeling of polystyrene beads with ATTO 488- or Cy5-NHS
esters, respectively. 2. PEGylation via succinate ester chemistry and 3. Ligand attachment via disulfide
bridges using cysteine modified peptides or β-mercaptoethanol and cleavage of 2-thiopyridone (2-TP).
tors on the surface of target cells. For c-Met (hepatocyte growth factor receptor) targeting cMBP2
was chosen, to address the TfR, the peptide B6 was used (amino acid sequences: see Table 4.1) and
for folate receptor targeting folic acid. In addition, transferrin (Tf), the natural ligand of the TfR was
coupled to the beads. The synthesis was performed in two different ways. In the first procedure
which is similar to the standard synthesis, Tf-iminothiolane [Tf(it)] was coupled to the PEGylated
beads instead of a cysteine derivate. The second method involved a pretreatment of the PEGylated
beads with DTT to reduce the OPSS group and provide a free thiol group for coupling with Tf-
pyridyldithiol propionate [Tf(pdp)]. Control beads were provided by coupling β-mercaptoethanol
to PEGylated beads yielding hydroxyl-terminated (OH) PEGylated beads. As these control beads
exhibit a lower surface charge, additional control beads with similar electrostatic characteristics
were synthesized to investigate the binding specificity of the peptides according to the correct
amino acid sequence. Therefore, scrambled peptide versions (B6scr1, B6scr2 and cMBP2scr) were
provided consisting of the same amino acids, but in different orders. Additionally, to exclude
influences of electrostatic interactions, a modified peptide (B6mod) was used where all highly basic
amino acids such as lysine and arginine were replaced by glycine.
The beads are named according to the following nomenclature: Ax-PEGy-ligand/control, where A
stands for the amino groups on the surface of the beads, x is the original diameter of the bead in
nm, y is the size of the PEG linker in kDa or as subscript the number of ethylene glycol units and
the name of the ligand or control molecule, e.g. B6. As an example, a bead with a diameter of
200 nm, 5 kDa PEG spacer and the peptide ligand B6 is named A200-PEG5-B6.
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4.2 Characterization
To study the efficiency or toxicity of nanoparticles, it is necessary to characterize well these nano
systems as size, shape, surface properties and concentration influence their cellular binding and
uptake [275]. Various methods were applied to characterize the synthesized beads. Fluorescence
microscopy was performed to qualitatively analyze the labeling and aggregation of the beads in the
different synthesis and preparation conditions and to quantitatively obtain the labeling distribution
on single beads. Dynamic light scattering was applied to determine the hydrodynamic diameter
of the beads. The zeta potential was measured and disclosed differences in surface modification
as well as surface charge of the beads. With the determination of the light absorption of the beads
at 225-231 nm, the concentration of the bead suspensions after synthesis could be approximated.
Finally, the uptake of the beads into target cells was investigated under static conditions to get
insights into the functionality of the ligands on the beads.
4.2.1 Fluorescence characteristics
The fluorescence of the beads depends on several factors: First, the intrinsic properties of the dye
including excitation and emission maxima, quantum yield and lifetime, second the labeling degree
and third the microscope adjustment like laser intensity at the objective, excitation and emission
filters, exposure time and sensitivity of the detection device. While it is very important to keep
all these factors constant for quantitative analysis, qualitative assessments can be done even under
changing conditions. In this sub chapter, the variation of synthesis and preparation parameters of
the beads will be described step by step in relation to the qualitative effect on the fluorescence im-
ages. Furthermore, the labeling distribution on single beads obtained by quantitative fluorescence
measurements will be discussed.
In Fig. 4.3 A, synthesis and preparation which influence the fluorescence of the model beads are
illustrated. Changing these parameters results in more or less aggregated beads which hence ap-
pear as smaller or larger fluorescent spots. Fig. 4.3 B shows beads prepared with different synthesis
parameters on coverglass. Comparing beads with a diameter of 110 nm and 200 nm, the fluores-
cence of the larger beads seems to be more uniform whereas the smaller beads tend to be more
aggregated. Regarding differently labeled beads (Cy5 and ATTO 488), the fluorescence appearance
depends on the photo-physical properties of the dyes. Better surface shielding decreases the aggre-
gation behavior of the beads. While lower shielding with a PEG spacer of 2 kDa resulted in larger
fluorescent spots of beads with a diameter of 110 nm (A110), and thus higher aggregation, smaller
fluorescent spots could be observed with 5 kDa PEG. The beads are less prone to aggregation with
a larger PEG linker. Another important factor is the surface functionality which affects the steric
configuration on the outer part of the bead, the surface charge and the hydrophilic or hydrophobic
properties. Comparing hydroxylated beads (A200-PEG5-OH) with B6 beads (A200-PEG5-B6), the
beads with peptide seem to have a slightly higher tendency to aggregate. This is caused by the
more hydrophobic structure of the peptide containing highly basic amino acids.
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Figure 4.3: The influence of synthesis and preparation parameters on the fluorescence images of model
beads. (A) Scheme of synthesis and preparation parameters which have been considered and optimized for
the model beads. (B) The fluorescence of spherical model beads on coverglass (excited with 488 nm or 633 nm,
300 ms) is depicted. Several parameters were varied: size (A110 - diameter: 110 nm and A200 - diameter:
200 nm), fluorescent dyes (Cy5 and ATTO 488), surface shielding (2 kDa PEG and 5 kDa PEG linker) and
surface functionalization (short peptide B6 and hydroxylated surface). (C) The fluorescence of Cy5 labeled
A200-PEG2 model beads with folic acid or hydroxylated surface functionalization on coverglass (excited
with 633 nm, 300 ms) is shown. The preparation parameters which were varied are the following: dilution
(1 : 10 and 1 : 100 ) and sonication (no ultrasound, 5 min and 15 min sonication). Scale bar = 5µm.
Apart from synthesis parameters, also the preparation of the beads influences their aggregation
behavior. Fig. 4.3 C illustrates the fluorescence of A200-PEG2 beads on coverglass prepared with
different dilutions and sonication times. The solvent is a main factor influencing the colloidal
stability of nanoparticles. Changing the polarity, the pH value or the ionic strength can contribute
to aggregation of the particles. Studying therapeutic nanocarriers, it is important to remain under
physiological conditions, i.e. to use appropriate buffers or cell medium. With the addition of serum,
e.g. fetal bovine serum (FBS) a protein corona can be formed around the nanoparticles and also
influence the aggregation tendency (in both ways). The model beads were prepared in phosphate
buffered saline (PBS), pH 7.4. During washing steps, where the beads were centrifugated at high
spin (13.400 rpm) aggregates formed which were disrupted by sonication (see Fig. 4.3 C). Addi-
tionally, sufficient dilution of the beads was important as the beads aggregated strongly in highly
concentrated suspensions. For cellular adhesion experiments, the bead suspensions were added to
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Figure 4.4: Integrated fluorescence density (IntDens) of single beads labeled with ATTO 488. The fluo-
rescence of single beads (A200-PEG5) was measured by confocal spinning disk microscopy. The integrated
fluorescence density was analyzed by Particle_in_Cell_3D (routine 4) [276] and the volume of counted objects
(in number of voxels, i.e. volumetric pixels) was confined to 450-800 voxels. The histograms of the fluorescence
of single beads show a Gaussian distribution.
cell medium supplemented with 10 % FBS. Generally, this further dilution was sufficient to obtain a
low degree of aggregation. Experiments where large aggregates could be observed were discarded.
To obtain the labeling distribution on single beads, the integrated fluorescence density (IntDens)
of the beads (A200-PEG5) was analyzed. Therefore, beads labeled with ATTO 488 were diluted
(1:100) in PBS buffer, sonicated and added to cell medium supplemented with 10 % FBS. Stacks of
the fluorescence of the beads sedimented on the bottom of the slides were recorded by excitation
with a 488 nm laser. The image stacks were evaluated according to Torrano et al. [276] To obtain
the fluorescence intensity of single beads, the volume of analyzed objects which correspond to
single fluorescent spots was confined to 450-800 voxels. Fig. 4.4 shows the histograms of the
fluorescence IntDens of single particles of different bead types fitted with a Gaussian distribution.
Similar intensity value distributions were obtained for all bead types. In case of non-uniform
labeling, a tailoring would have been expected. Furthermore, in case of non-resolved dimers,
objects with a doubled IntDens would have been counted. This was only the case for very few
objects. Thus, the preparation and detection of single beads was successful. Aggregation during
synthesis, preparation, storage and experiments could not be excluded completely, however mainly
single beads could be provided.
4.2.2 Zeta potential and hydrodynamic diameter
Electrophoretic and dynamic light scattering measurements were performed to characterize the
zeta potential, the "electrokinetic charge" [277] and the hydrodynamic diameter, the particle diam-
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eter including the solvating shell of the beads. The results are shown in Table 4.1 including the
polydispersity index (PDI) and the peptide sequence of the ligands and control molecules. In the
first part (I) of the table A200 beads used for binding studies in chapter 6 are listed, in the second
part (II) additional A200 beads for control experiments and for testing of the folate ligand are shown
and in the third section (III) parameters of A110 beads are depicted.
Zeta potential
Measurements of the zeta potential at physiological pH value showed a very high positive value
for unmodified amino beads, which was drastically reduced after PEGylation (A200-PEG5-OPSS)
demonstrating effective surface shielding. After addition of 2-mercaptoethanol, the resulting hy-
droxylated (OH) control beads exhibited a zeta potential of 9 mV. The B6 beads and the scrambled
versions (B6scr1 and B6scr2) yielded enhanced positive surface charges with similar zeta poten-
tials in the range of 24-30 mV which can be explained by the presence of four highly basic amino
acids (lysines and arginine) within the amino acid sequence of the peptides. The electrostatically
modified B6mod beads revealed a slightly negative zeta potential with reduced surface charge as
expected. For the beads equipped with the cMBP2 peptide and the scrambled version (cMBP2scr)
a zeta potential of 18-21 mV was measured which is less positive than that of B6 beads as only one
arginine and one lysine with free ε-amino residue are present in the amino acid chain.
Changing the pH value from pH 7.4 to 6.8, a reduced zeta potential of the unmodified beads from
51 mV to 32 mV was measured which can be explained by more neutralized amino groups on the
surface of the beads at more acidic pH. The PEGylated beads (A200-PEG-OPSS) still exhibited a low
absolute value for the zeta potential, however it was positive instead of negative suggesting that
the isoelectric point, i.e. the pH value where the particles are completely uncharged, is within the
range of pH 6.8 and 7.4. The zeta potential of the beads with B6 ligand remained almost constant
whereas beads with one tenth of the peptide B6 used during the synthesis [A200-PEG-B6(1:10)]
had a zeta potential diminished by one third compared to the beads with the original amount of
B6 peptide. As this zeta potential is in the same range as the one for PEGylated beads, this leads to
the assumption that only very few peptides were coupled to the beads or that they were not freely
accessible on the surface. For the beads with the natural ligand transferrin (A200-PEG5-Tf), a nega-
tive zeta potential was measured, as expected since the diferric Tf possesses a negative net charge.
The modification of A200-PEG5 with folate coupled via three different cysteine-(PEG)-derivatives
resulted in zeta potenitals of 7-10 mV suggesting low amounts of folate on the surface.
Finally, regarding the smaller latex beads with a diameter of 110 nm, the unmodified particles had
a similarly high surface charge as the larger ones. Equipped with the ligand B6, the A110-PEG5
beads had a zeta potential of 13 mV which is much lower as for larger beads due to either lower
surface area and/or lower amount of coupled ligands. Without ligand the surface charge was neu-
tral and with folate on the surface it was −13 mV. Interestingly, these beads had a more negative
zeta potential when a much smaller PEG spacer was used (A110-PEG2). A reasonable explanation
could be a high aggregation propensity of the beads.
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Table 4.1: Zeta potential, hydrodynamic diameter and PDI of differently modified aliphatic amine latex
beads and amino acid sequence of peptide ligands. Parameters were obtained for beads with (I,II) 200 nm
diameter used for receptor targeting studies; (I) adapted from [273], and (III) 110 nm diameter. Unmodified
beads (A200/110) were PEGylated with 2 or 5 kDa PEG (A200/110-PEG2/5-OPSS) and functionalized with TfR/c-
Met-targeted peptide or natural ligands (A200/110-PEG2/5-B6/cMBP2/Tf/FA), non-targeting peptide controls
(A200-PEG5-B6scr1/B6scr2/B6mod/cMBP2scr) or a hydroxylated control (A200/110-PEG5-OH). Measurements
were performed as triplicates. Peptide sequences are displayed in the amino acid single letter code.
Name Zeta potential
[mV]
Hydrodynamic
diameter [nm]
PDI Sequence
(I) A200 beads in water, 1 mM NaCl, pH 7.4
A200-NH2 51±7 241±95 0.155 -
A200-PEG5-OPSS -11±7 314±161 0.262 -
A200-PEG5-B6 30±5 313±144 0.212 (C)GHKAKGPRK
A200-PEG5-B6scr1 29±6 234±68 0.084 (C)AGKHGKRPK
A200-PEG5-B6scr2 24±14 260±102 0.153 (C)RPKAHKGKG
A200-PEG5-B6mod -7.9±10.3 324±170 0.277 (C)GHGAGGPGG
A200-PEG5-cMBP2 21±10 236±67 0.082 KSLSRHDHIHHHK(C)
A200-PEG5-cMBP2scr 18±8 286±144 0.255 HHSIHRLHHKSDK(C)
A200-PEG5-OH 9.1±11.0 291±146 0.252 -
(II) A200 beads in water, 1 mM NaCl, pH 6.8
A200-NH2 32±4 651±275 0.355 -
A200-PEG5-OPSS 7.0±6.4 223±57 0.091 -
A200-PEG5-B6 28±6 232±59 0.040 (C)GHKAKGPRK
A200-PEG5-B6(1:10) 10±6 255±91 0.150 (C)GHKAKGPRK
A200-PEG5-Tf(it) -13±4 339±112 0.228 679 amino acids
A200-PEG5-Tf(pdp) -13±5 250±80 0.125 679 amino acids
A200-PEG5-FA 7.1±7.6 250±79 0.085 -
A200-PEG5-PEG2-FA 8.3±5.5 239±59 0.018 -
A200-PEG5-PEG24-FA 10±5 251±84 0.092 -
(III) A110 beads in water, 1 mM NaCl
A110-NH2 47±5 295±226 0.241 -
A110-PEG5-B6 13±4 321±204 0.383 (C)GHKAKGPRK
A110-PEG5-OH 0.68±4.2 232±117 0.308 -
A110-PEG5-FA -13±3 534 0.581 -
A110-PEG2-FA -26±6 2179 0.742 -
38
4.2 Characterization
Hydrodynamic diameter
Dynamic light scattering (DLS) measurements disclosed that the hydrodynamic diameter of the
originally 200 nm polystyrene beads in water at pH 6.8-7.4 is within the range of 230-340 nm when
the beads are functionalized (see Table 4.1). The polydispersity index (PDI) values which correspond
to the size distribution of the nanoparticles are between 0.16-0.26 at physiological pH and 0.36 at pH
6.8 for precursor beads whereas the PDI range drops to 0.02-0.28 after modification. This implies
that the precursor beads aggregated during DLS measurements especially at lower pH values as
the surface charge is low which results in low stabilization while modified beads were not or only
slightly aggregated. Regarding the hydrodynamic diameter of the originally 110 nm polystyrene
beads in water at neutral pH value, the range is within 230-320 nm, thus similar to the A200 beads
and even much larger when equipped with folate. These beads aggregated strongly which is also
indicated by PDI values of 0.24-0.38 for unmodified, hydroxylated and beads equipped with B6
and 0.6-0.7 for beads with folate.
4.2.3 Light absorption
An important factor for cellular adhesion or uptake studies is the dosage of the nanoparticles. By
measuring the light absorption of the different bead suspensions in bulk, we were able to estimate
the concentration of the beads and amino groups on the bead surfaces.
Table 4.2: Light absorption. Mean absorption of aliphatic amine latex beads (200 nm diameter), the corre-
sponding concentration of amino groups on the bead surface and the concentration of the beads in PBS buffer
after modification; n = 5.
Name Absorption at
230 nm
Concentration of
NH2 groups [µM]
Concentration of beads
[number of beads/mL]
A200-PEG5-OPSS 0.46 1.0 3.1·1012
A200-PEG5-B6 0.47 1.0 3.1·1012
A200-PEG5-B6scr1 0.44 0.9 2.9·1012
A200-PEG5-B6scr2 0.43 0.9 2.8·1012
A200-PEG5-B6mod 0.42 0.9 2.8·1012
A200-PEG5-cMBP2 0.47 1.0 3.1·1012
A200-PEG5-cMBP2scr 0.48 1.0 3.2·1012
A200-PEG5-OH 0.52 1.1 3.5·1012
The absorption of the different synthesized beads used for binding studies was measured at 230 nm.
Before, a calibration curve was generated using unmodified beads (see Appendix Fig.1) and the
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attenuation coefficient ε* (947400 M−1cm−1) was calculated using the Lambert-Beer law.The con-
centration of amino groups c(NH2) was calculated according to following equation:
c(NH2) =
A
ε∗ · l · 10
6 · 200[µM] (4.2.1)
where A is the absorption of the diluted beads and l the pathlength. Furthermore, the concentra-
tion of beads per mL c(beads) was derived by the subsequent equation using the manufacturer’s
specifications:
c(beads) =
c(NH2) · 4.978 · 1012
c0(NH2)
[
beads
mL
]
(4.2.2)
where c0(NH2) = 1.58µmol/mL is the concentration of amino groups at the beginning of the synthe-
sis. The results are shown in Table 4.2. The concentration of amino groups was approximately 1µM
for all bead types resulting in about three billion beads per milliliter. As very similar concentrations
were obtained no further adjustment was done for experiments under flow conditions.
4.3 Cellular uptake of model nanoparticles
A major goal of therapeutic nanoparticles is their uptake into specific cells where their cargo can be
released or the genetic material can be modified after translocation. By equipping the nanoparticles
with targeting ligands, cells are addressed which overexpress the target receptor on the surface.
Testing the uptake of such nano systems on target cells gives information about the effectiveness
of the ligand to enhance cellular internalization. Herein, the uptake of model beads into HuH7
cells was tested which were used for binding studies (see chapter 6). The HuH7 cells possessed
both target receptors, TfR and c-Met on their surface which was tested by immunostaining (see
Appendix 6 Fig. 5 and Fig. 4 ).
Labeled beads were incubated on HuH7 cells for 2 h under static conditions, the membrane was
stained and the fluorescence was measured by spinning disk microscopy. The evaluation was
performed with the macro Particle_in_Cell-3D [276]. In Fig. 4.5 A, representative 3D images of
single cells containing internalized beads (magenta) or beads in the apical (yellow) or basal (orange)
membrane are shown. The mean values of internalized fluorescence (IntDens) per cell and bead
type are depicted in Fig. 4.5 B. Beads with the targeting ligand B6 were internalized most effectively.
Cells incubated with beads coated with the scrambled versions contained three-quarters of the flu-
orescence of the B6 beads, whereas only very few neutral control beads showed cellular uptake.
In experiments with cMBP2 or scrambled peptide, only approximately one forth of the amount of
beads compared to B6 were taken up. The uptake efficiency, i. e. the percentage of internalized
fluorescence in relation to the total fluorescence of the beads on the cells was calculated and is illus-
trated in Fig. 4.5 C. Approximately 80 % of B6, B6scr1 and cMBP2 beads were internalized within
2 hours whereas the scrambled versions B6scr2 and cMBP2scr comprised only 55-60 % within the
cytosol. The neutral beads uptake was 30-40 %.
These results suggest that effective internalization depended on the charge of the beads. The
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Figure 4.5: Cellular uptake of different model beads. Cy5-labeled beads were incubated on HuH7 cells for
2 h in 8 well chambers, the fluorescence was measured with spinning disk microscopy and evaluated with the
macro Particle_in_Cell-3D [276] (routine 3). (A) View in 3D of single cells with different internalized beads
(magenta) or with beads within the apical (yellow) or basal (orange) membrane region. (B) Mean fluorescence
integrated density (IntDens) of intracellular beads within single cells. n = 12-15. (C) Mean uptake efficiency
(percentage of intracellular fluorescence) of the different beads in single cells. n = 12-15.
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likelihood of cellular uptake was increased for positively charged beads compared to neutral ones.
Furthermore, the similar percentage of uptake for B6 and B6scr1 beads into HuH7 cells suggests
similar uptake processes.
4.4 Summary and conclusion
In summary, a successful synthesis of model nanoparticles for quantification by fluorescence mi-
croscopy mimicking the surface characteristics of therapeutic nano delivery systems was devel-
oped. Using the versatile coupling strategy via disulfide bridge formation, provides the option to
link various cysteine-modified targeting ligands to the model beads. Thus, there is a large range
of applications. Three different ligands, the peptide B6 for TfR targeting, the peptide cMBP2 for
HGFR/c-Met targeting and folate for folic acid receptor targeting were attached to the beads while in
addition several control beads were provided. The hydrodynamic diameter of the originally 200 nm
large beads was between 230-340 nm after modification. This size range is still small enough for
nanoparticles to penetrate into tumor tissue through leaky tumor vasculature having a pore cut-off
size of >200 nm [278]. An even more advantageous size would be in the range of 100 nm or smaller
as cellular uptake processes are facilitated [275] and clearance via spleen or liver are avoided [279].
However, beads of 110 nm showed much higher aggregation propensity, especially when equipped
with folate as targeting moiety. Much better stabilization was obtained for the larger beads (A200).
Since we aimed to quantify the adhesion of the beads, low aggregation behavior was of greater
importance than an optimal size for nanoparticle uptake.
The original surface charge of the amino beads at physiological pH value was very high and the zeta
potential around +50 mV. An effective shielding was obtained by coating the beads with PEG. This
is a common proceduce as many nanocarriers are equipped with PEG to enhance the biocompati-
bility and blood circulation time [280]. Optimization of PEGylation, i.e. the amount and density of
PEG on the surface of the beads was achieved by using a 5 kDa PEG spacer and resulted in reduced
surface charge, increased solubility and decreased aggregation tendency of the beads. Furthermore,
using PEG spacers with a molecular mass of 5 kDa is shown to maximize circulation half-life and
prevent opsonization, i.e. clearing from the blood system [281, 282]. The amount of PEG linkers
on the bead surfaces was estimated by a small assay. 5-10 % of all amino groups were covered
which corresponds to 0.08-0.15 PEG molecules per nm2 or a distance of 4.6 nm - 9.1 nm between
two PEG molecules. This means that the PEG chains were in a "mushroom"-like conformation for
a low PEGylation degree (5 % PEG), in a "brush"-like conformation for a higher PEG density (10 %
PEG) [283], or most likely in a conformation between these two states (calculations see Appendix 2).
To provide stable model nanoparticles with low aggregation tendency, it was important to addi-
tionally optimize the preparation procedure of the beads. First, dilution of the beads increased the
colloidal stability. Second, the time of sonication during and after synthesis was adjusted such that
single beads could be observed under the microscope and did not show disruption. Relatively low
PDI values of 0.02-0.28 nm were measured and thus beads without or only little aggregation were
used.
42
4.4 Summary and conclusion
The measurements of the zeta potential revealed that beads with the ligand B6 and the scrambled
peptide versions B6scr1 and B6scr2 exhibited high positive surface charges caused by several basic
amino acids. These beads showed the best cellular uptake by HuH7 cells after 2 h. Beads equipped
with the second peptide ligand, cMBP2 and the scrambled version were less positively charged due
to less basic amino acids. Lower amounts of those beads were internalized by the cells. Control
beads with hydroxylated surfaces or with a peptide where all basic amino acids were replaced
by the neutral amino acid glycine had a lower, more neutralized zeta potential. Almost none of
those beads were internalized by the HuH7 cells. This can be explained by the fact that in general,
positively charged nanoparticles exhibit a high affinity to cell surfaces as they can interact with
negatively charged membrane glycans. [55] Thus, they bind more likely to the surface of cells than
neutral particles. Hence, a combination of adhesion and uptake was measured while in chapter 5
an experimental setup was developed to study only adhesion.
Regarding the uptake efficiency of the beads with ligand, 80 % of the cMBP2 and B6 beads were
internalized, but also beads carrying the negative control peptide B6scr1. All other control beads
showed less uptake in the range of 30-55 %. These results indicate that the two peptide ligands
enhanced the cellular uptake and a similar affinity of B6 and B6scr1 beads to HuH7 cells can be
assumed. However, staining the cell membrane of HuH7 cells for these uptake experiments proved
to be difficult with several membrane dyes as the plasma membrane line could not be distinguished
continuously compared to other cell lines. Best results in our experiments were obtained with wheat
germ agglutenin conjugated dyes (WGA-Alexa488).
By measuring the absorption of the latex beads at 230 nm, their concentration could be estimated.
Suspensions of beads which were used for binding studies (see chapter 6) contained approximately
three billion beads per milliliter for all bead types. As the beads were highly diluted for flow
experiments (1:4800), concentrations of all types were in the same range for all nanoparticles and
thus were not adjusted.
In conclusion, a successful, optimized and reproducible synthesis and comprehensive characteriza-
tion of functional model nanoparticles for quantitative adhesion studies was described. In the next
chapter, the development of flow experiments will be specified which were designed to perform
cellular binding studies using the model nanoparticles.
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cellular targeting studies
Functional targeting groups on nanoparticles are designed to improve specific recognition of and
attachment to receptors which are upregulated and exposed on the surface of target cells [269, 284].
In the case of cancer therapy, therapeutic nanoparticles can address circulating tumor cells directly
within the blood flow as well as tumor endothelial cells at the vessel walls. On the other hand,
primary tumors are reached after extravasation of leaky blood vessels [92]. Whether the nanopar-
ticles bind to target cells depends on the following steps: 1) the nanoparticles have to reach the
proximity of the cell surface, 2) avoiding nonspecific interactions with extracellular components
and non-target cells and 3) recognizing of and attaching to receptors on target cells.
As our goal was to investigate the effect of a targeting ligand on cellular binding, we needed an
experimental setup to perform reliable and reproducible in vitro studies. Traditionally, cell culture-
based assays are performed under static conditions, where nanoparticles approach the cell surface
by diffusion and gravitational sedimentation, but also can agglomerate during this process [285].
To avoid this and to mimic better the physiological conditions, a microfluidic setup was used. In
previous studies, the amount of cellular associated nanoparticles is either appraised qualitatively
by visualization or quantified by various methods including light and electron microscopy, radioac-
tive labeling and fluorescence spectroscopy [286]. A commonly used fluorescence technique is flow
cytometry which allows for measuring large numbers of cells within a short time range resulting
in good statistics [287, 288]. Nonetheless, particle localization cannot be determined. Furthermore,
the obtained particle numbers are rather relative instead of absolute values without additional
elaborate calibration [286]. In general, quantification techniques which are based on fluorescence
intensity require many optimized conditions e.g. concerning the illumination, autofluorescence,
crosstalk and potential controls [289]. Additionally, such techniques face problems like photo-
bleaching, blinking [290] and quenching effects. Alternatively, cell-associated nanoparticles can be
counted by selecting the intensity maxima of fluorescent spots. This method requires labeling and
sufficient resolution of single particles in close proximity. Since we could provide single, stable,
low or non-aggregating labeled model nanoparticles, this evaluation procedure was chosen and
validated by a quantitative assessment based on fluorescence intensity. The model nanoparticles
are PEGylated polystyrene beads (diameter: 200 nm) decorated with ligands or control molecules
and described in chapter 4.
In this chapter we present the development of an experimental flow setup in combination with
fluorescence microscopy. It is partially adapted from our publication in the Journal of Controlled
Release [273]. We discuss the application of flow conditions on cell culture experiments. In addition,
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Figure 5.1: Comparison of cellular adhesion of nanoparticles under static and flow conditions. Particles
diffuse in the medium and sediment to the bottom of the well where they can attach to the cell monolayer
when static experiments are performed. Under flow conditions, particles pass over the cell monolayer and
only particles with a certain affinity attach to the cells. Particles with low affinity are flushed away.
we describe the optimization of various experimental parameters and the choice of an appropriate
quantification method. Furthermore, external and internal controls will be debated as experiments
with biological samples like cells show heterogeneous results.
5.1 Cellular adhesion experiments under flow conditions
Intravenously administrated nanoparticles are transported by the blood flow from which they can
extravasculate trough fenestrations of vascular tumor tissues. First, the distribution of the particles
within the tumor region depends on the flow velocity of the fluid and the interstitial fluid pressure
which is increased in solid tumors [291]. The diffusion of the particles within the tumor surround-
ing area is affected by their charge, size and shape [283]. Second, functional groups on the particle
surface contribute to nonspecific interactions such as electrostatic and van der Waals interactions
with extracellular matrix components. Cell culture monolayer models are not able to reconstruct
the complex and heterogeneous tumor microenvironment. Nonetheless, they are a first easy model
system in which cells are cultivated under controlled conditions producing consistent and repro-
ducible results [292]. They represent with appropriate in vivo studies a promising approach for the
pre-clinical assessment of the efficacy of novel cancer treatments in humans [293].
In Fig.5.1 the application of nanoparticles under a) conventional static cell culture conditions is
compared to b) flow conditions. Three facts are important here. First, whether nanoparticles
reach the proximity of the cell surface is determined by gravitational sedimentation and diffusion.
Especially heavy and large particles may sediment and influence the results of cellular uptake
studies [294]. Gravitational sedimentation can be avoided by using a microfluidic system which
additionally contributes to a homogeneous distribution of nanoparticles in the medium [295]. Sec-
ond, the charge of nanoparticles and their hydrophobicity influence their binding behavior to cells.
Generally, the adhesion of positively charged nanoparticles to the negatively charged cell surface
is favored [296] whereas negatively charged particles are repelled. All kinds of particles can bind
to the cell surfaces under static conditions. In contrast, loosely attached particles are flushed away
when shear flow is applied. Third, ligands on receptor-targeted nanoparticles can specifically at-
tach to the corresponding receptors on the cell surfaces enhancing their binding to the cells.
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Figure 5.2: Flow system and conception of experiments with internal control. (A) Schematic drawing of
the flow setup: model nanoparticles suspended in cell medium in a reservoir (left) are passed through a
flow channel (middle) by the force of a syringe pump (right). The fluorescence of bound particles on a cell
monolayer within the flow channel is measured by widefield microscopy. Enlargement: Competitive flow
experiment is performed by streaming differently labeled beads with ligand and control particles through the
flow channel. Particles attached on single cells are imaged by alternating excitation with 488 nm and 633 nm
lasers. (B) Scheme of experimental parameters, read-out methods and heterogeneity factors of single cell flow
experiments.
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To investigate the effect of a targeting ligand on cellular binding, we decided to perform experi-
ments under flow conditions as they offer the above mentioned advantages over static experiments.
Furthermore they provide a hydrodynamic microenvirmonment for the cells which can be closer
to in vivo conditions. For instance, tumor cells can be exposed to elevated interstitial fluid pressure
[291, 297, 298]. This could be mimicked by shear flow. Another example would be to target the
vascular endothelium [299] for the treatment of infectious or cardiovascular diseases.
In Fig. 5.2 A the concept of the flow system is shown. Nanoparticles were suspended homoge-
neously in a heated reservoir (T = 37 °C) and passed through a flow channel on a incubation stage
(T = 37 °C). The syringe pump generates a laminar shear flow which is tunable. In the flow channel,
model beads equipped with ligands were simultaneously perfused with differently labeled control
beads over a cell monolayer. Their cellular association was observed on single cells by measuring
the fluorescence of the beads. The cell membrane was discriminated by recording transmitted light
images using a differential interference contrast (DIC) filter.
A number of experimental parameters influence the adhesion and uptake mechanisms of nanopar-
ticles on and into cells such as particle size [300, 301], shape [302] and functionalization [303–305],
as well as cell type [238] and shear rate [303, 304, 306]. In Fig. 5.2 B, a set of such parameters is illus-
trated and followed by the choice of the evaluation method(s) and factors causing heterogeneous
results. By keeping all other experimental parameters constant, one by one can be investigated
systematically. The measurement of adhesion or uptake of nanoparticles by sensitive fluorescence
microscopy techniques has the advantage that detailed insights can be gained at the cellular level.
Single nanoparticles can be localized and counted on and within cells, the total amount on single
cells can be quantified and binding or uptake kinetics can be determined to give information about
uptake efficiency. However, there are many factors causing heterogeneity of the results, including
cell density, cell shape, receptor expression level, and particle aggregation and degradation. The
choice of suitable parameters and evaluation methods will be described in detail in the following
chapter. Consecutively, the processing of the heterogeneous results will be explained as well.
5.2 Optimization of flow experiments
The optimization of individual experimental settings is focused on the choice of ligands to be exam-
ined, the evaluation method, the flow rate and perfusion time. As all these factors influence each
other, adjustment of multiple of them was done at a time, but they will be described individually.
Two differently labeled bead types were directly compared in our flow experiments. Thus, we
analyzed if the dye combination has an impact on the results.
Choice of the ligand
Two short peptide ligands, the transferrin receptor (TfR)-targeted peptide B6 and the c-Met bind-
ing peptide (cMBP2) were tested for their potential to serve as a targeting molecule. Short peptide
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Figure 5.3: Model beads equipped with the targeting ligand folic acid (FA) bind mainly next to target cells.
Cy5-labeled model beads (A200-PEG5-ligand) with three different folate ligands: I) folate (FA), II) 2 kDa PEG
and folate (PEG2-FA) and III) 24 units of ethylene glycol and folate (PEG24-FA) were incubated with KB cells
for 45 min in folate-free medium under static conditions and fixed afterwards. The fluorescence of the beads
(magenta) and of the cell membrane stained with WGA-Alexa488 (green) were measured by spinning disk
microscopy. Representative z-projections of the KB cells, the beads and merged images are shown. Scale bar
= 10µm.
ligands possess several advantages such as small size, easy and cheap synthesis, good biocom-
patibility and low immunogenicity [307, 308] compared to large protein ligands and monoclonal
antibodies. The B6 peptide (9 amino acids) was chosen by Xia et al. from a phage display assay to
bind the human TfR [309], which is overexpressed in various human cancer cell lines and enhances
their metastatic potential [310]. So far, this peptide ligand has been applied for delivery of PEG-PLA
nanoparticles to the brain [311] and dual targeting approaches with polyplexes [312]. The tyrosine
kinase c-Met (receptor for the hepatocyte growth factor) has gained increasing attention recently
due to its role in sustaining tumor progression [164]. The epitope-mimicking cMBP2 (12 amino
acids) has been selected by Kim et al. from a combinatorial peptide library [313] to bind c-Met and
was recently tested for non-viral gene delivery applications as a potent targeting ligand [166].
Both targeting peptides were tested on HuH7 cells which overexpress the TfR and possess HGFR/c-
Met on their surface. This was confirmed by immunostaining experiments analyzed by flow cy-
tometry (see Appendix 5) and by fluorescence microscopy (see Appendix 4). Furthermore, model
nanoparticles equipped with the peptide B6 or the peptide cMBP2 were efficiently internalized by
HuH7 cells (within 2 h to 80 %; see chapter 4.3).
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Moreover, the small molecule folic acid (vitamin B9) was coated on model beads for folic acid
receptor (FR) targeting. This vitamin was used by Leamon et al. to deliver macromolecules into
living cells by receptor-mediated endocytosis [314]. The surface receptors for folic acid are overex-
pressed in many human cancer cells [315, 316]. FR targeting is performed using multiple strategies,
including antifolates [317], FA-conjugated drugs and nanocarriers [318], folate-based imaging [319]
and immunotherapy agents [320].
To assess the functionality of the folate-equipped beads, their uptake was investigated on KB cells
which overexpress the FR [321]. Since in literature the ratio of folic acid/PEG polymer was found
to be crucial for the uptake of folate conjugates [322], three different folic acid conjugates with
distinct amounts of PEG were tested. In detail, beads without additional PEG (A200-PEG5-FA),
with a 2 kDa PEG spacer (A200-PEG5-PEG2-FA) and with an extra PEG linker of 24 ethylene gylcol
units (A200-PEG5-PEG24-FA) were incubated with KB cells for 45 min. In Fig. 5.3, z-projections of
Cy5-labeled FA beads on KB cells are illustrated: in the first row the cell membranes of KB cells
stained with WGA-Alexa 488 are shown, followed by Cy5-labeled FA beads and in the last row a
merged image of both fluorescence channels is depicted. Interestingly, all three conjugates bound
mainly next to the cells and not on the cells indicated by the fluorescence-free spaces in the particle
images. This means that the affinity of the FA beads to the bottom of the well chamber was higher
than to the target cells. Coating the well bottoms with poly-L-lysine, collagen or fibronectin before
seeding the KB cells did not change the low attachment of the FA beads on the cells. Thus, these
FA model beads rather decrease than increase the binding to target cells which was not expected.
Consequently, they were not suitable for the cellular binding studies. To explain these findings,
several aspects were considered: First, the zeta potential measurements of the FA beads showed
surface charge values similar to PEGylated beads (see Table 4.1), indicating that only few ligands
were accessible on the surface. On the other hand, a higher amount of ligand induced aggrega-
tion. Interactions of the aromatic system of FA with other molecules among each other or with the
surface of the polystyrene beads, despite PEGylation, cannot be excluded. As in literature many
divers PEGylated carrier systems were successfully used for FR targeting such as mesoporous sil-
ica nanoparticles [323], siRNA conjugates [324] or nanodiamonds [325], these nano carriers were
presumably optimized for folic acid. Instead, the polystyrene PEG beads were incompatible with
this ligand.
Evaluation method
Sensitive fluorescence microscopy was chosen to study cellular adhesion. So, the model nanopar-
ticles could be localized on single cells and their aggregation status could be controlled. Two kinds
of experiments were possible: measuring adhesion kinetics and quantifying the number of bound
particles at a defined time point. The latter was applied as more statistics could be obtained.
Furthermore, two recording modes were possible: on the one hand measuring the integral fluores-
cence intensity of the nanoparticles by confocal microscopy and on the other hand recording the
fluorescence by widefield microscopy followed by counting the intensity maxima of fluorescent
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spots. The approach based on the integrated fluorescence intensity requires identical experimental
conditions and settings including additional controls. Thus, to perform comparable experiments,
calibration measurements of a standard sample is necessary accounting for the power and the
performance of the cameras. Therefore, we chose to count the intensity maxima of fluorescent
spots which correspond to single labeled beads or small aggregates. To validate the accuracy of the
results, both procedures were compared.
Figure 5.4: Particle analysis by counting intensity maxima of fluorescent spots and fluorescence integrated
density (IntDens) based evaluation. (A) Z-projection of the fluorescence of labeled A200-PEG5-B6 beads in
CO2-independent medium and 10 % FBS measured by spinning disk microscopy. (B) Selection of intensity
maxima (yellow crosses) corresponding to the counted number of beads. Scale bar = 5µm. (C) IntDens of
objects corresponding to one (first peak) or more B6 beads shown in A) analyzed by Particle_in_Cell-3D. [276]
(D) Number of particles per object analyzed as in C).
Beads labeled with ATTO 488 in PBS buffer were diluted, sonicated and dispersed in CO2 indepen-
dent medium supplemented with 10 % FBS. These suspensions were then added to ibiTreat µ-slide
wells. The beads sedimented on the bottom of the wells. Confocal fluorescence stack images were
recorded exciting with the 488 nm laser. In Fig. 5.4 A, an exemplary z-projection of B6 beads is
illustrated. By analyzing the intensity maxima with ImageJ software, 600 particles were counted
(Fig. 5.4 B). Separately, the fluorescence integrated density (IntDens) of the particles was deter-
mined using the fluorescence intensity calibration routine of the macro Particle_in_Cell-3D [276].
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Table 5.1: Comparison of two evaluation methods: Particle counting and procedure based on the fluo-
rescence integrated density. Z-stacks of different types and numbers of model beads were recorded with
spinning disk microscopy. Intensity maxima were counted on z-projections and are listed in the 1st col-
umn. The integrated density (IntDens) of the beads of the same image stack was determined by the macro
Particle_in_Cell-3D [276] and divided by the mean IntDens of the respective bead type (see Fig.4.4), resulting
in the number of particles displayed in the 2nd column. The last column shows the difference in particle
numbers obtained by both methods.
Name Counted maxima Calculated number of
particles (IntDens based)
Difference
A200-PEG5-cMBP 11 10 1 (10%)
A200-PEG5-OH 65 89 24 (27%)
A200-PEG5-B6scr 167 184 17 (9%)
A200-PEG5-cMBPscr 370 436 66 (15%)
A200-PEG5-B6 600 746 146 (20%)
A200-PEG5-B6mod 654 796 142 (22%)
In Fig. 5.4 C, the IntDens distribution of the fluorescent objects is plotted. Single particles (first
peak), dimers (second peak) and more particles per fluorescent spot (object) could be determined.
In total 405 objects were detected by this routine. By dividing the IntDens of the objects by the mean
value of the IntDens of a single bead (see chapter 4.2.1), the number of particles per object could
be calculated (Fig. 5.4 D). Using this method 746 particles were determined. In total, 20 % more
beads were calculated by using the integrated density based method. This suggests that some parti-
cles were either aggregated or in such close proximity that they could not be resolved as single spots.
The comparison was performed for several bead types (see Appendix 2). In Table 5.1, the ascend-
ing number of counted intensity maxima and the calculated number of particles by the IntDens
approach are compared. In the last column, the difference of the particle numbers determined by
both methods is shown. The divergence ranges between 10-27 %. While just a few beads per field
of view could be determined accurately by both methods, more beads per field of view involved
higher discrepancy. On the other hand, a reasonable number of beads per field of view was required
for significant results. The best agreement in the number of particles obtained by both methods was
in the range of 167-436 beads per field of view. Hence, the number of particles can be determined
most accurately within this range. The concentration of the particles and the perfusion time were
adjusted such that this criterion was met.
Flow rate
The flow rate affects the exerted shear force on the cells. Shear forces influence, for example, the
cytoskeletal arrangement of endothelial cells [299, 326] and can activate them. While these cells
are exposed to blood flow, epithelial tumor cells of solid carcinomas are embedded in a different
microenvironment. They are surrounded by extracellular matrix and a dysfunctional lymphatic
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Figure 5.5: Adhesion kinetics of model beads on HuH7 cells. The adhesion of beads (diameter: 110 nm)
with the peptide ligand B6 (A110-PEG5-B6, black solid squares), labeled with ATTO 488 and control beads
(A110-PEG5-OH, grey open circles), labeled with Cy5 on HuH7 cells was monitored for 80 min of very low
shear flow (0.13 dyn/cm2) by widefield fluorescence microscopy. After a lag time of 12 min, beads start to
bind to the cells. TfR-targeted B6 beads showed increasing attachment with time while only few control beads
bound during the whole experiment.
system which causes an increased interstitial fluid pressure [279]. Thus, we did not intend to
simulate blood flow conditions for cellular binding studies, but rather a shear force in the range of
the hydrodynamic tumor microenvironment. In general, the main goal of applying shear flow was
to provide constant concentration of particles and reduce sedimentation. Therefore, the cells were
perfused only for a short time range in which they did not adapt to the flow conditions and the
surface receptor status of TfR and c-Met remained constant (see Appendix 6).
The applied shear forces of 0.26 dyn/cm2 (0.026 Pa) were relatively low, but in the range of in-
creased interstitial fluid pressure [298]. The influence of shear flow on particle adhesion was tested
by increasing the shear force by one order of magnitude (2.63 dyn/cm2, 0.26 Pa). Attention was
payed that particles were transported in a continuous laminar manner in both investigated shear
conditions. Furthermore, the volume of the cell medium was kept constant for both flow rates to
provide the same particle numbers. To account for that, it was necessary to direct the flow back
and forth several times at the higher flow rate.
Perfusion time
The following three aspects were taken into consideration to find an eligible perfusion time, i. e.
the time range where shear forces are exerted on the cell monolayer in the flow channel. First,
the particles should not be internalized as they can aggregate in endosoms. This would affect the
number of fluorescent spots on the cells in such a way that less particles would be counted. The
uptake of the model nanoparticle started in the range of 60-80 min of incubation on HuH7 cells.
Consequently, a shorter time range was considered as appropriate. Second, the final number of
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beads per cell had to be considered in order to reasonably evaluate the experiment. As mentioned
before, a sufficient number of particles had to be attached to single cells to yield good statistics. In
addition, the fluorescence of single particles should still be resolvable and saturation of the cells
should be avoided. The number of adhered beads per cell does not only depend on the perfusion
time, but also on the flow rate, the particle concentration and the affinity of the particles. These
factors had to be taken into account accordingly. Third, as aforementioned, the surface receptor
levels should remain the same during the time of the flow experiment which means that the cells
should not adapt to flow conditions during that time.
Adhesion kinetics were measured to find an appropriate time point. TfR-targeted model beads
with a diameter of 110 nm (A110-PEG5-B) and hydroxylated control beads (A110-PEG5-OH) were
passed over HuH7 cells for 80 min at a very low shear flow ( 0.13 dyn/cm2). The fluorescence of
the beads was measured by live cell imaging widefield microscopy. The number of counted beads
is depicted in Fig.5.5. While only a low number of both bead types bound during the first 40 min,
increasing amounts of B6 beads attached in the time range between 40 and 80 min. Thus, for this
shear rate an appropriate time point would be in the range of 40-60 min, avoiding uptake and
providing a sufficient number of particles for the statistics. In summary, after 40 min, the number
of bound particles per cell for all used shear rates was high enough to result in sufficient statistics,
but still low enough to count single particles.
Influence of the dyes
When two different particle types are directly compared, it is important to ensure that their different
labeling dyes have no influence on the results. To test if the dye combination has an impact on the
actual outcome, flow experiments were performed with exchanged dye combinations (Fig. 5.6).
Figure 5.6: Flow experiments with exchanged dye combinations. TfR-targeted beads with peptide ligand
B6 and hydroxylated control beads were incubated for 40 min on HuH7 cells under low shear conditions
(0.26 dyn/cm2). Two experiments were performed with exchanged dye combinations. (A) Representative
images of B6 beads with Cy5 labeling (magenta) compared to hydroxylated control beads (ATTO 488, green)
on a HuH7 cell (Experiment 1) and of B6 beads with ATTO 488 labeling (green) compared to hydroxylated
beads marked with Cy5 (magenta) (Experiment 2). The plasma membrane and the nuclei are depicted by
white lines. Scale bar = 10µm. (B) Mean numbers of intensity maxima counted on single cells for Experiment
1 (solid columns) and Experiment 2 (striped columns) with exchanged dye combination. n = 19-20.
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TfR-targeted B6 beads were labeled with Cy5 (magenta) and mixed in equal amounts with hydrox-
ylated control beads (OH beads) labeled with ATTO 488 (green). The mixture was passed over a
HuH7 cell monolayer at a low flow rate (0.26 dyn/cm2) for 40 min, the cells were fixed afterwards
and the fluorescence of the beads was measured by widefield microscopy adjusting the focus over
single cells. The experiment was repeated with beads labeled with an exchanged dye combination,
i.e. B6 beads marked with ATTO 488 and OH beads bearing Cy5. In Fig. 5.6 A, the fluorescence of
the beads on representative single cells for both experiments are shown. The cell membrane and
the nuclei are illustrated by white lines. The mean values of counted intensity maxima on single
cell images are depicted in Fig. 5.6 B. While in Experiment 1 around 22 B6 beads (magenta) bound
compared to 1.2 control beads (green) on average, 96 B6 beads (green) compared to 12 control beads
(magenta) were counted in Experiment 2. Clearly, more TfR-targeted B6 beads bound to the target
cells than control beads in both experiments. Nevertheless, the ratio of beads with ligand compared
to control beads was different in the second experiment and the total number of bound particles
was more than four times higher. In summary, the two different dyes on both particle types could
be detected properly and the dye combination did not influence the major outcome. Nonetheless,
the magnitude of the results was different in both experiments as well as the total amount of cellular
bound particles. This finding suggests that the total number of adhered particles has an impact
on the results. Therefore, additional controls or selection criteria should be introduced. In the
following chapter, considerations of an external or internal control for the flow experiment will be
discussed.
5.3 Internal control
Differences in the number of cellular associated nanoparticles was found in pre-experiments un-
der flow conditions. In addition, factors were detected which cause these heterogeneous results.
These parameters comprise the cell density, shape, receptor expression level as well as particle
aggregation and degradation. Exemplary images of single cells are illustrated in Fig. 5.7 where
different numbers of beads (upper and lower image) due to one of these factors. The fact that less
particles bound to the cells at high cell density or when particles were aggregated was found as a
common result. Different numbers of adhered particles were observed on cells with varying shape,
i.e. height and spreading or with different target receptor expression level.
The question arises, how to account best for the impact of these factors. By comparing the adhesion
of receptor-targeted to control particles on single cells, we provide an internal control. Additionally,
two external controls were tested. In a first external control experiment, the beads presented in
Fig. 5.6 were coated on coverglass and their fluorescence was measured. In Table 5.2 the number
of beads per field of view (63.7x63.7µm2) is shown in the diagonal. The ratio of the number of two
bead types is given by dividing the number of beads of the first row by the one of the first column.
In all instances, the ratio was between 0.72-1.39 suggesting similar amounts of targeted and control
particles. In a second external control experiment, the beads mixture used for flow experiments
was pipetted into collagen coated image spacer chambers of 7.6µL between two coverglasses. As
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Figure 5.7: Influencing factors of single cell experiments causing heterogeneous results. Z-projections of
single cells illustrating heterogenous results caused by different factors: I) cell density: at high confluence, the
total number of adhered beads is lower than at low confluence; II) cell shape/geometry: in total less beads adhere
to smaller cells than on bigger cells, even when the ratio of receptor-targeted to control beads is the same; III)
receptor expression level: more receptor-targeted beads (green) bind to cells with higher receptor expression.
IV) particle aggregation: beads can aggregate which causes reduced numbers of fluorescent spots on the cells.
Scale bar = 10µm.
before, the beads were imaged by widefield fluorescence microscopy and the number of particles
was counted. Ratios were obtained in the range of 0.87-1.7 for B6 beads compared to different
control beads (see Appendix 1). This shows that a factor of at most 1.7 would influence the results
of the flow experiments. Beyond that, the number of beads with ligand B6 were 20-22 per field of
view in the first external control experiment whereas only 16 control beads were counted in two
independent samples with different dyes. This finding lead to the assumption that both particle
types have different affinities to the coverglass. Consequently, the results of flow experiments could
be falsified by including the factors from the external control(s). Hence, we decided to use only an
internal control.
Table 5.2: External control I. Beads with ligand (A200-PEG5-B6) and control beads (A200-PEG5-OH) used for
the flow experiment in Fig. 5.6, labeled with different dyes (Cy5 and ATTO 488) were coated on coverglass
at 3000 rpm. The mean numbers of counted intensity maxima per field of view (63.7x63.7µm2) are displayed
highlighted in the diagonal from the upper left to the lower right. n = 21-25. The ratio of different bead types
was obtained by dividing the number of beads from the first row by the number of beads from the first column.
B6 (Cy5) B6 (ATTO 488) OH (Cy5) OH (ATTO 488)
B6 (Cy5) 22.0±2.9 0,92 0,72 0,72
B6 (ATTO 488) 1,1 20.1±4,0 0,78 0,79
OH (Cy5) 1,39 1,28 15.8±2.8 1,0
OH (ATTO 488) 1,38 1,26 0,99 15.9±1.7
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Summing up, the same experimental conditions could be provided by simultaneously incubating
the receptor-targeted model nanoparticles with control particles. Thus, the same particle concen-
tration of both bead types was used and they were exposed to the same shear conditions, surface
receptor levels and cell density. Instead of averaging over the heterogeneous number of bound
beads, we decided to illustrate the heterogeneity of the results. This was achieved by the following
procedure. For each cell, the number of beads with ligand was divided by the number of control
beads resulting in a factor (see Fig. 5.8 A). The obtained factors were plotted in a histogram.
From this distribution, the subsequent conclusions could be drawn: Factors below or equal to 1
are assigned to the fact that the ligand did not enhance particle binding, whereas factors above 1
(especially above 2) indicated an positive effect of the ligand on cellular particle binding. In Fig.
5.8 B, two factor distributions are shown. In the upper histogram, the factors of Experiment 1 are
shown (Fig. 5.6). Here, Cy5-labeled B6 beads were compared to ATTO 488-labeled hydroxylated
control beads. In the lower histogram, the factors of the number of ATTO 488-labeled B6 beads
divided by the number of Cy5-labeled OH beads are depicted. In both cases, the factors were above
2, suggesting that the peptide B6 improved the binding of the model nanoparticles on every single
cell. These experiments show the "proof of principle" of our method. The effect of a ligand on
cellular binding can be approximated not only by an average value, but also the distribution on
single cells can be displayed. In chapter 6, we present binding studies of TfR and c-Met-targeted
model beadsusing the herein described optimized procedure.
Figure 5.8: Internal control: calculation of factors and factor distribution. (A) The fluorescence of labeled
beads bound onto single cells was imaged by widefield microscopy and the intensity maxima were counted.
The factor of the number of beads with ligand divided by the number of control beads is calculated for each
cell. Plotted in a histogram the factor distribution shows the effect of the ligand. Factors above 1 indicate
enhancement of binding, factors equal or below 1 indicate no effect of the ligand. (B) The factor distributions
of B6 beads compared to hydroxylated control beads on HuH7 cells after low shear flow (0.26 dyn/cm2) are
depicted for two different dye combinations: the upper histogram shows A200-PEG5-B6 (Cy5) compared to
A200-PEG5-OH (ATTO 488) and the lower histogram shows A200-PEG5-B6 (ATTO 488) compared to A200-
PEG5-OH (Cy5).
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5.4 Summary and conclusion
In summary, we developed and optimized an experimental flow setup with internal control for
quantitative adhesion studies on a single cell level. Briefly, a particle suspension is passed through
a flow channel by the force of a syringe pump. A broad range of shear forces can be generated
and thus, a variety of experiments can be performed with this setup. For instance, studies can be
conducted to target the vascular endothelium [299, 327–329], or components of or within the blood
flow such as metastatic cancer cells [303]. Also, other objectives can be pursued with the use of
microfluidics. We intended to provide constant particle concentrations and to reduced sedimen-
tation of larger particles or aggregates [300, 330]. In addition, a hydrodynamic microenvironment
was introduced which can also be present around tumors [331]. Cancer cells are surrounded by
disordered extracellular matrix and interstitial fluid. Due to the leakiness of the tumore tissue, the
interstitial fluid pressure is elevated. This facilitates the transvascular transport of nanocarriers.
Within the tumor diffusion is the predominating transport mechanism in combination with steric,
hydrodynamic and electrostatic interactions between the particles and components of the extracel-
lular matrix [279]. With our flow experiments we provide a first step in the direction of modeling
the in vivo situation. We applied shear forces which are exerted on tumor cell surfaces exposed to
elevated interstitial fluid pressure [332, 333]. Furthermore, the shear flow was increased by one
order of magnitude to investigate the influence of it on cellular particle binding. Next steps towards
the in vivo condition would be sophisticated 3D models [334–336] and animal studies [293, 337]
which can mimic the complexity more realistically.
In our experiments, model nanoparticles (see chapter 4) with targeting ligand and differently la-
beled control beads were simultaneously passed over a cell monolayer within the flow channel.
There is not a standardized norm for pre-clinical studies [270]. Indeed, the choice of experimental
parameters as well as controls influence their results. We decided to perform experiments with
an internal control to provide the same experimental conditions for both, receptor-targeted and
control particles. So, the particles were exposed to the same cell density, the same cell environment
and surface receptor levels. Thus, experimental influences on the heterogeneity of the results could
be minimized. Furthermore, the internal control enabled the calculation of factors, the number of
beads with ligand divided by the number of control beads. By plotting the factor distribution, the
varying ratio of both particle types (with ligand and control) on single cells could be illustrated.
Additionally, external control experiments were performed comparing the number of beads on
cover glass or in collagen coated chambers under static conditions. As a maximum variance of
factor 1.7 was observed, every factor above 2 was considered as positive targeting.
Applying sensitive fluorescence microscopy, the localization of single particles on, within or next
to the cells could be determined. Furthermore, we monitored the aggregation status of the particles
and the integrity of the cells. These qualitative examinations were combined with a quantitative
approach in order determine the efficiency of targeting ligands.
Quantitative assessment of cellular attachment was carried out by counting the fluorescence inten-
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sity maxima of labeled nanoparticles on single cells. This fast method was validated by comparison
with a well established evaluation procedure based on the integrated fluorescence intensity of
labeled nanoparticles (Particle_in_Cell-3D by Torrano et. al. [276]). The following factors were
determined to influence the number of bound particles per cell: cell density and cell geometry,
expression level of target receptors, particle aggregation and degradation. The number of beads
per cell was optimized for reasonable evaluation. Furthermore, the time of shear flow was adjusted
such that the particles were not internalized within that period and the target receptor levels did
not change. Moreover, we tested if the dye combination (Cy5, λmax = 649 nm and ATTO 488, λmax =
501 nm) had an impact on the results when two different types of particles were compared. As the
fluorescent molecules were covalently attached on the particle surface and surrounded by a PEG
layer, no interaction of the dyes with the cells was expected. This was confirmed. Interestingly,
the total number of particles per cell varied strongly in different experiments. Such heterogeneity
of the results is known for biological experiments [338]. This diversity can originate from varying
gene expression of individual cells of the same genetic clone [339]. Hence, we chose to select
only experiments with a reasonable number of particles per cell for evaluation. With this criteria
sufficient statistics could be achieved and misinterpretation of the results could be avoided.
In conclusion, we presented a suitable method to quantify the effect of targeting ligands on cellular
adhesion of nanoparticles. It includes an optimized flow experiment, a suitable measurement
technique and a reliable evaluation procedure.
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6 Binding studies of receptor targeted
beads
Sophisticated nano therapeutics are designed to be transported to diseased tissue, to specifically
attach and be internalized into the target cells, and to be active only at the target site. There are
many strategies to pursue each of these goals. While "passive targeting" enhances the accumula-
tion of nanoparticles of a certain size range within the tumor region, "active targeting" is applied
to specifically address the target. Therefore, targeting ligands are attached at the surface of the
delivery devices. These ligands bind specifically to overexpressed receptors on the surface of target
cells. Targeting moieties include small molecules, peptides, proteins, aptamers and antibodies
or antibody fragments. Short peptide ligands are advantageous because of their low costs, long
term stability, low immunogenicity, high modifiability and low influence on the physicochemical
properties of the nanocarriers [340].
Here, we assessed the potential of two short peptide ligands to serve as a successful targeting
ligand. First, peptide B6 which binds to the transferrin receptor (TfR) was studied. The TfR is a
type II transmembrane receptor. Two identical monomers form a homodimer which is linked by
two disulfide bonds. It consists of a short cytoplasmic part, a single transmembrane pass and a
large extracellular domain [341, 342]. TfR mediates the uptake of transferrin-bound iron in clathrin-
coated endosomal compartments. Furhter functionality involves the regulation of cell growth [343].
TfR is omnipresent on the cell surface of most normal human tissues and expressed at higher levels
in malignant cells [153] as well as in brain capillaries [137]. With these properties, the TfR represents
an attractive target for tumor therapy or delivery to the brain.
A second peptide, the c-Met binding peptide (cMBP2) which adheres to the hepatocyte growth
factor receptor (HGFR)/c-Met was analyzed. The c-Met is a transmembrane receptor tyrosine ki-
nase [344]. An extracellular α-domain and a transmembrane β-domain with an intracellular kinase
part form a heterodimer linked by a disulfid bond [345]. HGFR/c-Met signaling is involved in
invasive growth during embryogenesis and postnatal organ regeneration. It is highly regulated
and usually not activated in adults except during wound healing and tissue regeneration. In cancer
cells, the signaling pathway can be reactivated promoting tumor progression, invasive growth and
metastasis [156]. Moreover, HGFR/c-Met is overexpressed in multiple epithelial and mesenchymal
cancer cells [346]. Hence, c-Met is another reasonable candidate for cancer therapy.
In this chapter which is partially adapted from our publication in the Journal of Controlled Release
[273], the effect of the peptides B6 and cMBP2 on cellular adhesion of nanoparticles is described. To
quantify the impact of nanoparticle binding, flow experiments with internal control were performed
(see chapter 5). Model nanoparticles (beads) that mimick the surface characteristics of therapeutic
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nanocarriers (see chapter 4) were used. By comparing the number of receptor targeted beads to
control beads, the effect of the ligand was approximated. We describe experiments using different
beads as electrostatic and specificity controls. In the first part of this chapter, we focus on binding
studies of B6 equipped beads under shear conditions. As we did not obtain the expected results
with the specificity control, additional experiments were performed to gain more insights into the
cellular binding behavior of model beads with the B6 ligand. In the second part of this chapter, c-Met
targeting experiments under flow conditions are described. In a final summary and conclusion, we
evaluated the capability of both peptides (B6 and cMBP2) to be used as effective targeting moieties.
6.1 Cellular adhesion of TfR targeted B6 beads
The peptide B6 (GHKAKGPRK) which was found to tether the TfR [309] was investigated as a
potential ligand for receptor targeting. PEGylated model nanoparticles (polystyrene beads) were
equipped with a ligand or control molecule. The number of B6 beads on single cells was directly
compared to differently labeled hydroxylated beads (OH). As the latter beads have a reduced sur-
face charge, these control beads were considered as an electrostatic control. In addition, B6 beads
were compared to beads with a scrambled peptide (B6scr, AGKHGKRPK and RPKAHKGKG) con-
sisting of the same amino acids, but in a different order. Apart from this specificity control, beads
with a modified peptide (GHGAGGPGG) were used as a third internal control. The modification
comprised the replacement of all basic amino acids by glycine to yield a neutral peptide and hence
B6mod beads with a similar reduced surface charge as the OH beads.
The binding studies were performed on HuH7 cells which have high TfR expression levels shown
by western blot analysis by Lu et al. [347]. We confirmed the results with immunostaining of TfR
followed by flow cytometry analysis or fluorescence imaging (see Appendix 5 and 4).
6.1.1 Indication of the incapacity of B6 to bind as a specific targeting ligand
To assess the adhesion behavior of TfR targeted B6 beads we performed competitive binding exper-
iments under shear conditons. The method is described in detail in chapter 5. Briefly, the binding of
beads with ligand was compared to the binding of control beads on target cells. Therefore, labeled
B6 beads were mixed with differently labeled control beads in equal amounts within a reservoir
containing cell medium. Then, the bead suspension was passed over a cell monolayer in a flow
channel for 40 min by the force of a syringe pump. Two different flow rates were used. Experi-
ments were performed at low shear flow of 26 s−1, corresponding to shear forces of 0.26 dyn/cm2
and moderate shear flow of 263 s−1, corresponding to shear forces of 2.63 dyn/cm2. The cells were
fixed afterwards and imaged by widefield microscopy.
In Fig. 6.1 A, representative images of the beads with ligand (green) and control beads (magenta)
on single cells are illustrated for each type of experiment. The adjacent bars in Fig. 6.1 B show that
the mean number of beads with B6 ligand bound around 5 times more than non-charged hydroxy-
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Figure 6.1: Effect of the peptide B6 on cellular binding. Adhesion of beads with ligand (B6, dye 1) and
control beads (dye 2) on HuH7 cells after 40 min under low (26 s−1) and moderate (263 s−1) shear conditions.
(A) Representative images of receptor targeted beads (with ligand: B6; green) and control beads (hydroxylated,
with scrambled or modified peptide; magenta) on single cells after low shear flow. The plasma membrane and
the nucleus are depicted by white lines. Scale bar = 10µm. (B) The mean numbers of TfR targeted B6 beads
(black column) and hydroxylated control beads (white column) on single cells after low (left) and moderate
(right) shear flow are shown. ***p<0.0001, n =112-125. (C) The factor distributions of B6 beads compared to
hydroxylated control beads after low (black) and moderate (white) shear flow are depicted. (D) The mean
numbers of TfR targeted B6 beads (black column) and control beads with scrambled peptide B6scr (light grey
column) on single cells after low (left) and moderate (right) shear flow are shown. ***p<0.0001, **p≤0.001; n
=122-140. (E) The factor distributions of B6 beads compared to control beads with scrambled peptide B6scr
after low (black) and moderate (grey) shear flow are depicted. (F) The mean numbers of TfR targeted B6 beads
(black column) and control beads with modified peptide B6mod (dark grey column) on single cells after low
(left) and moderate (right) shear flow are shown. ***p<0.0001; n =123-124. (G) The factor distributions of B6
beads compared to control beads with modified peptide B6mod after low (black) and moderate (grey) shear
flow are depicted.
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lated (OH) beads on average (electrostatic control). The number of bound beads, with and without
ligand decreased by 40-50 % at 10fold higher shear forces. As expected, the number of control
beads dropped even more than the number of B6 beads. This suggests that the attachment forces of
the B6 peptide on the cell surface are stronger than the interactions of the hydroxylated polystyrene
beads. To examine the heterogeneity of particle binding on single cells, the factor distribution of the
number of B6 beads divided by the number of control beads is displayed in Fig. 6.1 C. The obtained
factors ranged from 1.1 to 27 with an average value of around 4 at low shear flow and from 2.1 to 35
with an average value of 6 at moderate shear flow. By comparing the adhesion of B6 beads to the
adhesion of beads with scrambled ligand (B6scr1) (specificity control), similar attachment of both
bead types was detected at both shear rates (Fig. 6.1 D). The peak of the factor distributions were
close to 1 in both cases, indicating similar affinity of both peptides to the HuH7 cell surface (see Fig.
6.1 E). The sequence of the B6 peptide seems not to be crucial for receptor binding, but other inter-
actions like electrostatic attraction might play a role in the adhesion process of B6 equipped beads
to HuH7 cells. Interestingly, the total mean number of beads per cell was in the range of 200-400 for
all experiments and the number of bound B6 beads was reduced in the presence of B6scr1 beads.
This implies that B6 and B6scr1 beads might compete for cell surface binding and that saturation of
cell binding is reached. Theoretically, there should be many more transferrin binding sites (210.000
per HuH7 cell according to Tinder et al. [348]) and also unspecific binding sites like negatively
charged surface molecules on the cell surface. These facts suggest that there could be a charge effect
of already bound, positively charged beads partially repulsing newly arriving positively charged
beads. As we found that the binding of B6 beads seems to be independent of the peptide’s amino
acid sequence, we provided supplementary control beads. Therefore, the B6 peptide was modified
in such a way that all basic amino acids were replaced by glycine, a neutral amino acid. These
B6mod control beads exhibited a lower surface charge than the B6 beads. They showed a similar
binding pattern as the hydroxylated control beads (Fig. 6.1 F). On average, 5 times more B6 beads
bound per HuH7 cell compared to B6mod beads at low shear flow. The ratio of the mean values
was increased to approximately 9 when elevated shear flow was applied. This is comparable to
the results obtained by comparison with hydroxylated control beads. The factor distribution of the
number of B6 beads divided by the number of B6mod beads, displayed in Fig. 6.1 G, was similar as
the factor distribution resulting from experiments with hydroxylated control beads. This indicates
that the basic amino acids are involved in the binding process. Furthermore, our findings point to
the fact that the binding of B6 beads to HuH7 cells seems to be dominated by different interactions
such as electrostatic interactions of the positively charged beads with the negatively charged cell
surface instead of specific receptor-ligand interaction.
In order to confirm the findings, we tested the adhesion of B6 beads on a second target cell line.
Overexpression of TfR on DU145 cells was shown by Nie et al. [349] using flow cytometry. As
before, flow experiments with internal control were performed. The binding of B6 beads was
compared to the binding of hydroxylated beads and of beads with scrambled peptide (B6scr1) at
low shear flow. In Fig. 6.2 A, the mean values of B6 beads (black) and control beads (hydroxylated:
whiten, B6scr1: gray) are displayed. Around 5 times more B6 bound compared to hydroxylated
beads. The number of attached B6scr1 beads was even more than the number of B6 beads. These
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Figure 6.2: Effect of the peptide B6 on binding to TfR targeted DU145 cells. Adhsion of beads with ligand
(B6, dye 1) and control beads (dye 2) on DU145 cells after 40 min under low (26 s−1) shear conditions. (A) The
mean numbers of TfR targeted B6 beads (black column) and hydroxylated (white column) control beads or
with scrambled peptide B6scr1 (grey column) on single cells are shown. n = 40. (B) The factor distribution
of B6 beads compared to hydroxylated control beads are depicted. (C) The factor distribution of B6 beads
compared to control beads with scrambled peptide (B6scr1) are represented.
results were similar as observed on HuH7 cells, but the total number of adhered beads was clearly
lower on DU145 cells. The factor distribution of B6 beads compared to hydroxylated beads ranged
from 1 to 29 (see Fig. 6.2 B), suggesting again an positive effect of the peptide on particle binding.
The factors of the comparison with scrambled peptide are depicted in Fig. 6.2 C. Both bead types
bound with equal ratio to the DU145 cells. These results support the hypothesis that the binding of
the B6 beads does not involve the specific interaction of the peptide with the TfR. So, do the B6 beads
bind specifically to the TfR on the cells or is unspecific attraction the main binding interaction?
6.1.2 Transferrin receptor specificity and unspecific binding
The peptide B6 was found by phage display to improve the gene transfer of adenovirus to several
cell lines expressing the human TfR [309]. This specificity was attributed to a certain motif of
the peptide’s amino acid sequence. However, our experiments could not confirm these findings.
Furthermore, the binding site at the TfR was not identified. Hence, we performed additional exper-
iments to get more insights into the binding behavior of model beads equipped with the peptide
ligand B6.
6.1.2.1 Second scrambled peptide
In previous flow experiments, similar numbers of TfR targeted B6 and control beads with scram-
bled peptide (B6scr1) were counted on single cells. This suggests that both peptides have a similar
affinity to the target cells. To test if the scrambled peptide is by chance another ligand of the
TfR, a second scrambled peptide (B6scr2) was coupled onto the model beads. Additional flow
experiments were performed at moderate shear flow. The number of B6 beads was compared to
first, the number of B6scr1 beads and second, the number of B6scr2 beads. The mean numbers
of adhered beads on single cells are shown in Fig. 6.3 A. Similar amounts of all three bead types
(B6, B6scr1 and B6scr2) were determined. Beads with the second scrambled peptide (B6scr2) even
showed slightly increased attachment. The factor distributions of the number of targeted compared
to control beads are depcited in Fig. 6.3 B. Both distributions are similar and show a maximum
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around 1. This implies that the affinities of beads with either of the scrambled peptides are almost
equal. Thus, the amino acid sequence of the peptides does not play a role in the binding process
to HuH7 cells. There are two possibilities: all peptides, B6, B6scr1 and B6scr2, are ligands of the
TfR and bind specifically to the receptor, or they bind non-specifically to HuH7 cells due to other
attraction forces such as electrostatic interactions.
Figure 6.3: Effect of the scrambled amino acid sequence. Adhesion of beads with B6 ligand (dye 1) and
with B6 scrambled peptide (dye 2) on HuH7 cells after 40 min of moderate shear flow (263 s−1). (A) The mean
number of beads with B6 ligand (black column) and scrambled B6 peptide (B6scr1, light grey column; B6scr2,
dark grey column, second sequence) on single cells is shown. n = 122-123. (B) The factor distributions of B6
beads compared to control beads with scrambled peptide (B6scr1, light gray) or a second scrambled peptide
(B6scr2, dark gray) are depicted.
6.1.2.2 Uptake
Beads coated with the peptide B6 are designed to enter the target cells via the TfR. The endocytosis
of the Tf-TfR complex and its recycling is a fast process in the range of 10-20 min [146, 147]. Thus, a
high accumulation of nanoparticles within the cytosol is expected entering the cells via this route.
The receptor-mediated uptake of Tf is clathrin-dependent. Despite the fact that clathrin-coated
pits have a diameter of 100 nm, it has been shown that Tf-coated nanoparticles (> 500 nm) can be
internalized by clathrin-coated vesicles [350]. If the TfR targeted B6 beads are internalized by the
same route, an enhanced uptake efficiency is expected compared to the control beads.
The cellular uptake of nanoparticles can be assessed by various methods. With confocal microscopy,
it is possible to estimate if a particle is inside the cell, within the cell membrane region or outside
the cell thanks to the resolution in z. In this case the membrane of the cell has to be stained
and a two channel image has to be acquired. Another method to determine if the particles are
internalized is to use a quencher of the fluorescence (eg. trypan blue) of the particles. After the
treatment only the particles that are internalized are still fluorescent. Co-localization of particles
with endosomal markers is another procedure that gives information about the particles’ uptake.
Furthermore, the active transport of internalized particles can be recorded by visualization of the
particles’ movement. This method is a very clear and easy discrimination of particles inside the
cytoplasm and was used to show the uptake of the model nanoparticles. Therefore, TfR targeted
beads (A200-PEG5-B6) and control beads (A200-PEG5-B6scr1/B6mod/OH) labeled with ATTO 488
were incubated with target cells (DU145) for 6 h. Movies were recorded by spinning disk microscopy
where the movement of the beads was observed in one plane for approximately 1 min. In Fig. 6.4,
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the fluorescence of the beads at the beginning of the measurement is shown (left) and the respective
time projections (right). Transmission light images were used to mark the nuclei (dotted lines) and
the cell membrane (dashed line). Clearly, more B6 and B6scr1 beads than B6mod and OH beads
were internalized. Movement of actively transported beads can be observed in the time projections
as directional lines. Many B6 and B6scr beads show such motion whereas less movement of B6mod
and hydroxylated beads was observed. These control beads resided mainly in the perinuclear
reagion. A difference in the uptake behavior of B6 and B6scr beads was not detected. These results
confirm the findings of another uptake experiment where the beads were incubated with HuH7
cells for 2 h under static conditions (see chapter 4.3). In conclusion, B6 and B6scr show faster, but
similar uptake into target cells whereas the control beads with less surface charge are internalized
less efficient.
Figure 6.4: Uptake of TfR targeted B6 and control beads into DU145 cells. ATTO 488 labeled B6 beads or Cy5
labeled control beads (with scarmbled peptide B6scr, with modified peptide B6mod or hydroxylated) were
incubated on DU145 cells for 6 h in 8 well chambers, the fluorophores were excited by 488 nm and 639 nm
lasers and the fluorescence of one plane of several cells was measured with spinning disk microscopy for
65.37 s at 7.65 s−1. The first image of the time series is shown on the left, a time projection is depicted on the
right where a dashed line displays the cell borders and the dotted lines illustrate the region of the nucleus.
Moving beads on the cell membrane, during membrane penetration and diffusive motion within the cell can
be recognized as small lines, whereas larger lines indicate active transport of beads within the cell. Scale bar
= 10µm.
6.1.2.3 Colocalization with free ligand in endosomal compartments
As mentioned before, the receptor-mediated uptake of Tf is clathrin-dependent. Therefore, Tf
can be used as marker of clathrin-dependent endocytosis. This means, that beads entering the
cells via the same route should be in the same endosomal compartments as free Tf molecules. A
high degree of co-localization within target cells was expected for labeled Tf and TfR targeted B6
beads. Attention was paid that the concentration of labeled Tf was low. Thus, we could exclude
that free Tf competed for binding with the B6 beads. In the experiment, Alexa647 labeled Tf was
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Figure 6.5: Localization of TfR targeted B6 or control beads and free transferrin on single HuH7 cells. HuH7
cells were preincubated with Tf-Alexa647 (3.3µg/mL) for 45 min, ATTO 488-labeled beads were incubated for
1.5 h and the cells were fixated with PFA afterwards. The fluorophores were excited alternatingly with 488 nm
and 639 nm lasers and cell stacks were recorded by spinning disk microscopy. In the first row the fluorescence
of Tf-Alexa647 in one plane of single cells is shown, in the second row the fluorescence of A200-PEG5-x beads
(x = B6, B6scr, B6mod or hydroxylated), in the third row a merged image is displayed where colocalizing
spots are encircled. In the last row a z-projection over the whole cell is depicted. Predominantly there is no
colocalization of Tf and the beads indicating different uptake pathways. Scale bar = 10µm.
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preincubated for 45 min and coincubated with B6 or control beads for 1.5h with HuH7 cells under
static conditions. The cells were fixed and the fluorescence of Tf and the beads was investigated on
single cells by spinning disk microscopy. In Fig. 6.5, representative images of the fluorescence of
Tf (magenta), of the beads (A200-PEG5-B6/B6scr/B6mod/OH, green) and merged images of HuH7
cells are shown. A plan in the middle of the cells was chosen. The round, non-fluorescent areas
can be assigned to the regions of the nuclei. Co-localizing fluorescent spots of Tf and beads are
encircled. Additionally, z-projections of the cells are depicted. Transferrin was observed in the
perinuclear region of the cells. Beads of all types were mainly located on the cell membrane. Few
beads were internalized and few co-localizing spots of Tf with all kind of beads were found on
all cells. By qualitative analysis, most overlapping fluorescence with the fluorescence of Tf was
observed for B6 beads. No significant difference could be detected by comparison with the control
beads. When incubating labeled Tf with the cells for a longer period of time (6 h), no fluorescence
of the protein could be detected. Presumably, the Tf was recycled back into the cell medium during
this time. Overall, a distinct conclusion cannot be drawn form these findings. A clathrin-dependent
uptake of B6 beads cannot be excluded, but is very unlikely.
6.1.2.4 Colocalization with TfR-GFP
In addition to localize the TfR targeted B6 beads in clathrin-coated endosoms, we visualized
them directly on cells overexpressing fluorescent receptor. Therefore, HeLa cells were transfected
transiently with TfR-GFP and incubated with Cy5 labeled beads for 30 min and 2 h, respectively.
As a control, Tf labeled with Alexa633 was incubated with the cells. Fluorescence image stacks
over single cells were recorded by spinning disk microscopy with alternating excitation at 488 nm
and 639 nm. In Fig. 6.6, representative fluorescence images of TfR and B6 beads or Tf are shown
in a central cell plane. In addition, a merged image is displayed. The GFP labeled receptors were
located throughout the whole cell except the nuclear region. High accumulations of TfR were
found close to the nucleus and at pointed cell borders. The beads were not internalized after 30 min
and partially after 2 h. Few beads showed co-localization with the receptors. In contrary, high
amounts of free Tf was observed on the fluorescent receptors especially at the accumulation sites.
This proves the association of Tf with the TfR. In the first place, these results suggest that no or only
very few TfR targeted beads bind specifically to the receptors. However, the endogenous receptors
are not labeled. Moreover, the fluorescence of the GFP labeled receptor is not resolved for single
receptors. This means that there is still the possibility of specific binding which cannot be detected
by this experiment.
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Figure 6.6: Colocalization with GFP labeled TfR. GFP-TfR transfected HeLa cells (1st row) were incubated
with Cy5 labeled TfR targeted B6 beads for 0.5 and 2 h or with Alexa633 labeled transferrin (2nd row) for 0.5
and 2.5 h and the fluorescence was imaged alternatingly by excitation with 488 nm and 639 nm lasers with
spinning disk microscopy. Representative images of one plane of single cells are shown. In the third row
merged images are represented where co-localization can only clearly be detected for Tf and GFP-TfR. Scale
bar = 10µm.
6.1.2.5 Competition with free ligand
Before, it was shown that free Tf binds to GFP-labeled TfR, but mainly does not co-localize with
B6 beads on target cells. The amount of free Tf was very low to avoid competition of the natural
ligand for binding to the TfR. On contrary to these studies, we intended to block the surface TfRs
on the target cells in an additional experiment. Two effects were expected: first, that binding of TfR
targeted beads is reduced by free Tf and second, that beads which bind specifically to the TfR on
target cells show less binding compared to control beads which bind non-specifically.
HuH7 cells were pretreated with non-labeled holo-Tf for 45 min. Afterwards, model beads were
coincubated with an excess of holo-transferrin (5 mg/mL) with the HuH7 cells for 1 h. As a control,
model beads were incubated with HuH7 cells without Tf treatment. The fluorescence of all beads on
single cells was measured by spinning disk microscopy and the integrated density was calculated.
The determined mean values are depicted in Fig. 6.7. Beads with the peptide B6 and the two
scrambled versions (B6scr1 and B6scr2) bound in similar high amounts to the cells whereas the
adhesion of beads with reduced surface charge (B6mod and hydroxylated) was very low. This
result is consistent with the flow experiments. Treatment with free transferrin reduced the binding
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Figure 6.7: Competition with free transferrin. Adhesion of functionalized polystyrene beads (B6, B6 scram-
bled, B6 scrambled 2, B6 modified and hydroxylated) on TfR overexpressing HuH7 cells after 1 h of incubation
in cell medium without transferrin (Tf(-), black column) and with free transferrin (Tf(+), 5 mg/mL, 45 min
preincubation, white column). The mean values of the fluorescence integrated density (IntDens) of all beads
on a single cell are shown. n=20.
of B6, B6scr1 and B6scr2 to the same low degree, but did barely influence the binding of beads with
modified peptide or hydroxyl surface groups. There are two possible explanations: first, all beads
bind non-specifically to the HuH7 cells, but the highly positively charged are partially repulsed
by the negatively charged transferrin molecules bound on TfRs at the cell surface. As second
alternative, some of the beads with B6 or scrambled peptide bound to the TfR, but probably not at
the Tf binding site. Nonetheless, the main fraction of the beads seem to adhere in a non-specific
manner to alternative surface molecules. Thus, we assume that the binding of beads equipped with
the peptide B6 on HuH7 cells is essentially not based on specific receptor-ligand interactions.
6.1.2.6 Binding to non-target endothelial cells
As described in the previous chapters, we found many indications that model nanoparticles
equipped with the peptide ligand B6 do not bind specifically to target cells. The specificity to
the receptor is the main benefit of targeting ligands. Nevertheless, the targeting approach should
not involve considerable drawbacks such as enhancing undesired adhesion to non-target cells. In
other words, therapeutic nanoparticles should bind to diseased cells with target receptor overex-
pression, but not to healthy cells.
Hence, we tested the adhesion of the B6 beads to noncancerous endothelial HMEC-1 cells. As
described before, we performed flow experiments where the binding of TfR targeted B6 beads
is compared to the adhesion of hydroxylated control beads. A suspension of both bead types
with different fluorescent labels was perfused over a cell monolayer for 40 min at a low flow rate.
After fixation of the cells, the samples were imaged by widefield microscopy. Finally, the number
of fluorescent maxima was counted on single cells. In Fig. 6.8 A, representative images of the
fluorescence of B6 and hydroxylated beads are shown on single cells. To compare the adhesion
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Figure 6.8: Binding to target epithelial cancer cells and non-target endothelial cells under shear conditions.
Adhesion of beads with ligand (B6, dye 1) and hydroxylated control beads (OH, dye 2) on epithelial HuH7 and
DU145 cells and endothelial HMEC-1 cells after 40 min under low shear conditions (26 s−1). (A) Representative
images of receptor targeted beads (with ligand B6; green) and control beads (hydroxylated; magenta) bound
on single cells. The plasma membrane and the nucleus are depicted by white lines. Scale bar = 10µm. (B)
The mean numbers of beads, TfR targeted B6 beads (black columns) and hydroxylated control beads (white
columns) on single cells are shown. ***p<0.0001, **p≤0.001; n = 40-121.
of the beads on the human microvascular endothelial cells (HMEC-1) with the binding on tumor
cells, i.e. on hepatocellular carcinoma (HuH7) and prostate cancer (DU145) cells, the mean values
of adhered beads on these cell lines are plotted in Fig. 6.8 B. The number of B6 beads on single
endothelial cells (ca. 80) decreased significantly compared to the number on HuH7 target cells
(ca. 250) , but was in a similar range as the number on DU145 target cells (ca. 65). This result
implies that the affinity to HuH7 cells is higher, whereas the attraction to DU145 and HMEC-1
cells is almost equal. The lower binding to the endothelial cells is reasonable as they possess less
surface TfR than HuH7 cells (see Appendix 5). The lower affinity to DU145 cells might result
from a different composition of cell surface molecules and different cell surface charge. Thus, less
unspecific interaction of the beads with the cell surface occur. Interestingly, almost no hydroxylated
control beads bound to the HMEC-1 cells. This result suggests that HMEC-1 cells have a different
membrane composition than the epithelial cancer cell lines. In addition, endothelial cells are very
sensitive to shear forces. They can adapt to flow conditions by changing the morphology to a
smooth surface [326] and rearrangement of actin [299]. Concluding, the number of bound B6 beads
was still high on the non-target cells. Thus, nanoparticles equipped with the peptide B6 would
probably also bind to other cells and tissues within the body.
6.2 Cellular adhesion of c-Met targeted cMBP2 beads
The peptide cMBP2 (KSLSRHDHIHHHK) which was found to bind the HGFR/c-Met [313] was
investigated as a second potential ligand for receptor targeting. As described before for studies of
B6, the peptide cMBP2 was linked to PEGylated polystyrene beads. Beads with hydroxy surface
groups (OH) were used as control beads to analyze the electrostatic influences on cellular binding
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of the beads. Additionally, a scrambled peptide (cMBP2scr, HHSIHRLHHKSDK) was coupled to
the beads which is composed of the same amino acids, but in a different order. The obtained beads
possessed similar surface charge compared to the cMBP2 beads and served as specificity control.
The binding studies were performed on HuH7 cells which have been tested positive for c-Met
surface receptors by immunostaining analyzed by flow cytometry and fluorescence imaging (see
Appendix 5 and 4). Interestingly, the images revealed bright fluorescent spots on the cell surfaces
indicating that c-Met is clustered on the cell membrane. Furthermore, cells at different passage
numbers were immunostained. Higher amounts of c-Met were observed at higher numbers of
passaging (see Appendix 4).
Flow experiments with internal control allowed for assessing the potential of the cMBP2 peptide
to be used as a targeting ligand. We analyzed the effect of this peptide in the same way as for
the peptide B6. To apprise the binding capacity to non-targeting cells, we additionally tested the
adhesion behavior also on endothelial HMEC-1 cells.
6.2.1 Qualification of cMBP2 as a targeting ligand
In order to assess the potential of the cMBP2 peptide to serve as a suitable targeting ligand, flow
experiments were performed as described before. The adhesion of cMBP2 equipped beads was
compared to the adhesion of control beads on c-Met expressing HuH7 target cells. Representative
images of beads with ligand (green) and control beads (magenta) on single cells are illustrated in
Fig. 6.9 A for each type of experiment. Predominantly, the beads were homogeneously distributed
throughout the whole cell surface and did not attach to the bottom of the channel. The adjacent
bars in Fig. 6.9 B show the mean number of beads with cMBP2 compared to the mean number
of hydroxylated control beads per cell at low and moderate shear flow. Beads with cMBP2 ligand
showed 4-5 times higher attachment to HuH7 cells than the neutrally charged, hydroxylated beads
(electrostatic control) at low and moderate shear flow. The factor of the number of targeted divided
by the number of control beads on single cells was calculated and depicted in a histogram (Fig. 6.9
C). The frequency of the factors corresponds to the number of single cells for which the respective
factor was determined. The factor distributions shown in Fig. 6.9 C were similar for both flow
velocities and ranged from factors of 2 until 20. Despite the high heterogeneity, all factors were
above 1 indicating that the binding of beads with ligand was preferred on every cell. Experiments
with the scrambled peptide (cMBP2scr) control beads (specificity control) resulted in similar average
numbers of attached beads on the cells as the hydroxylated beads with lower surface charge (Fig.
6.9 D). The factor distribution at the low shear rate resembled the distribution at the moderate
shear rate (Fig. 6.9 E). Thus, by comparing the binding of both control bead types, the adhesion is
similar resulting in the assumption that the sequence of the cMBP2 peptide is crucial for binding to
the c-Met expressing HuH7 cells. We expected to reduce cellular binding by increasing the shear
force as observed by Sarfati et al. [303] for non-targeted particles and by Mennesson et al. [351]
for polyplexes. On the contrary, cMBP2 beads showed enhanced binding at increased shear flow.
A higher amount of adhered beads can be explained by the fact that the bead suspension passed
the cells 10 times more often at moderate flow (forth and back flow) than at low flow (flow in one
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Figure 6.9: Effect of the ligand cMBP2 on cellular binding. Adhesion of beads with ligand (cMBP2, dye 1) and
control beads (dye 2) on HuH7 cells after 40 min under low (26 s−1) and moderate (263 s−1) shear conditions. (A)
Representative images of receptor targeted beads (with ligand: cMBP2; green) and control beads (hydroxylated
or with scrambled peptide; magenta) on single cells after low shear flow. The plasma membrane and the
nucleus are depicted by white lines. Scale bar = 10µm. (B) The mean numbers of c-Met targeted cMBP2 beads
(black column) and hydroxylated control beads (white column) on single cells after low (left) and moderate
(right) shear flow are shown. ***p<0.0001; n =42-83. (C) The factor distributions of cMBP2 beads compared
to hydroxylated control beads after low (black) and moderate (white) shear flow are depicted. (D) The mean
numbers of c-Met targeted cMBP2 beads (black column) and control beads with scrambled peptide cMBP2scr
(grey column) on single cells after low (left) and moderate (right) shear flow are shown. ***p<0.0001, **p≤0.001;
n =80-81. (E) The factor distributions of cMBP2 beads compared to control beads with scrambled peptide
cMBP2scr after low (black) and moderate (grey) shear flow are depicted.
direction), enhancing the probability for cell contacts. However, one should mention that changing
the flow rate by the 10fold does not seem to dramatically change the factor distribution of the beads
but only induces slight changes in bound bead numbers per cell. Thus, we consider that the results
of the flow experiments are reasonable and independent in the regime of shear ranges we used.
6.2.2 Binding to endothelial cells
The adhesion of cMBP2 beads was also tested on microvascular endothelial cells (HMEC-1). Flow
cytometry tests revealed that c-Met is exposed on the cell surface of HMEC-1 cells to the same
extend as on HuH7 cells (see Appendix 5). However, with immunostaining and imaging by flu-
orescence microscopy different receptor levels were observed. While most HuH7 cells showed
fluorescence of immunostained c-Met on their plasma membrane, some of the HMEC-1 cells did
not show any fluorescence. Patel et al. [352] reported c-Met expression by HMEC-1 by western blot
analysis. They found high levels of the β-subunit and low levels of the α-subunit. Our images from
the immunostaining were obtained by using a primary antibody against c-Met with the antigen
located at the first 100 amino acids (N-terminal). This region corresponds to a part of the α-subunit.
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Figure 6.10: Binding of beads with cMBP2 ligand to non-targeted endothelial cells under shear conditions
compared to the binding on HGFR/c-Met targeted epithelial cancer cells. Adhesion of HGFR/c-Met targeted
cMBP2 beads (black column) compared to hydroxylated control beads (white column) on HuH7 target cells or
endothelial HMEC-1 cells after 40 min of low (26 s−1) shear flow. The mean numbers of bound beads on single
cells are depicted. ***p<0.0001; n = 83-127.
Thus, a possible explanation of our finding could be the lack of matured c-Met (heterodimer) on
the surface of some HMEC-1 cells, also taking into account that the number of passage was very
low (3 passages). Eventually, the divers expression level of c-Met at the HMEC-1 surfaces suggest
that the number of cMBP2 beads bound to single cells should vary highly on HMEC-1 cells.
Flow experiments with internal control were performed as described before. The mean numbers of
cMBP2 (black) and hydroxylated (white) beads on single HuH7 and HMEC-1 cells are depicted in
Fig. 6.10. Clearly, the binding of cMBP2 beads is significantly reduced on HMEC-1 cells. Only 3-4
beads adhered per HMEC-1 cell compared to around 80 per HuH7 cell. Almost no hydroxylated
control bead bound to the HMEC-1 cell surfaces. This finding confirms the results obtained
when comparing the adhesion of B6 beads to hydroxylated control beads on HMEC-1 cells. As
expected, the number of cMBP2 beads on single cells varied (from 0 to 29). Nevertheless, this result
can be interpreted by different levels of c-Met on single cells, but also might display biological
heterogeneity. Likewise, the numbers of cMBP2 beads counted on HuH7 cells was within a broad
range (18 to 169).
6.3 Summary and conclusion
In summary, we assessed the potential of peptide ligands to be a suitable targeting moiety. There-
fore, cellular binding studies under flow conditions were performed. The binding of model
nanoparticles (latex beads) equipped with targeting peptide was compared to the binding of in-
ternal control beads. The model beads were passed over a target cell monolayer for 40 min. First,
beads with ligand were compared to hydroxylated beads. The receptor targeted beads exhibited
a higher positive surface charge than the control beads which were considered as an electrostatic
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control. A specificity control was performed by comparting beads with ligand to beads with a
scrambled peptide, both exhibiting the same surface charge, but a different order of amino acids.
The number of attached beads on single cells was counted and the ratio between the numbers of
receptor targeted and control beads was calculated to yield factors. For a positive effect of the ligand
on cellular binding, factors above 1 were expected. Especially factors above 2 were considered as
significant. Factor mean values between 4-5 were obtained for the c-Met/HGFR targeting peptide
cMBP2 for both controls at low and moderate shear flow. However, comparing B6 beads to beads
equipped with a scrambled B6 peptide (B6scr1 or B6scr2), both bead types competed for binding
to HuH7 cells and adhered with a ratio of about 1. Beads with either of the peptides B6, B6scr1
and B6scr2 have a highly positive surface charge (zeta potential = 24-30 mV) in contrast to the
much lower surface charge of beads with B6mod peptide (zeta potential = -8 mV). Comparing the
adhesion of B6 beads to the B6mod beads, mean factors between 4-6 were obtained. Considering
the results of both types of control beads leads to the assumption that electrostatic interactions
predominated during binding of B6 beads to HuH7 cells. Our findings revealed that beads with the
peptide cMBP2 bind to target cells only when the amino acid sequence is in the correct order whereas
beads with the peptide B6 bind also with similar affinity containing a different order of amino acids.
As all three peptides, B6, B6scr1 and B6scr2 showed similar effects on cellular binding of model
beads, we assume that they have similar affinity to the target cells. Either all of them bind non-
specific or all of them target the TfR in a similar manner. Xia et al. [309] found certain peptide motifs
by phage display binding to the TfR. These short peptide motifs are "AKxxK/Rx", "KxKxPK/R" and
"KxK". The peptide B6 which is composed of only 9 amino acids, but also the scrambled versions
contain some of the motifs: the partial motif "KxPK" is included in the peptide B6scr1 and the
motif "KxK" in the peptide B6scr2, the peptide B6 contains additionally all motifs. Thus, each of
the scrambled peptides might represent another targeting ligand.
Increased shear flow did not significantly influence the factor distributions on single cells, but the
total number of beads bound per cell. The total amount of attached B6 beads decreased whereas the
number of cMBP2 beads increased. This can be explained by two facts occurring at enhanced shear
flow: the number of beads passing the cell monolayer is increased as the suspension is perfused
back and forth several times instead of passing once at low shear flow. Thus, more beads with
high affinity bind. On the other hand, the number of bound beads with lower affinity decreases
due to the enhanced shear force. Thus, less non-specifically binding beads are flushed away. Con-
cluding, our findings suggest that beads with the targeting ligand cMBP2 have a higher affinity to
the HuH7 cell surface whereas at least some of the B6 beads bind with lower affinity or non-specific.
The binding of model beads was investigated also on a non-targeted cell line, i.e. human microvas-
cular endothelial cells (HMEC-1). The results revealed that beads with and without ligand bound
in reduced amounts. The number of cMBP2 beads was around 3 per HMEC-1 cell whereas the
number of B6 beads was around 80 per cell. Almost no hydroxylated control beads bound to the
cells. Concerning the c-Met targeted beads, this was an interesting finding as the amount of c-Met
on the cell surface detected by flow cytometry was in the same range for HuH7 and HMEC-1 cells.
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Thus, similar amounts of bound cMBP2 beads were expected. We checked the receptor levels under
both, static and flow conditions, but did not detect significant differences (see Appendix Fig.6). It
should be noted that the statistics of the flow cytometry data were low as it was very difficult to
extract the immunostained living cells from the flow channels. As the cMBP2 beads attached in
significant differing numbers to two cell lines (HuH7 and HMEC-1), we assume that the cell lines
have different surface characteristics under the experimental conditions. The possibility that new
c-Met receptors are recruited to the HuH7 cell surface is very unlikely within the short time of
the experiment (40 min). Furthermore, the findings of Kos et al. [166] show that the short peptide
ligand does not induce signal transduction. More likely explanations are the following arguments:
endothelial cells adapt to shear conditions [353] for instance by smoothening of the cell surface
[326] and are deformed by the shear strain [354]. This would explain why less beads bound to
the endothelial cells. Moreover, the cell surfaces of cancer cells exhibit a different composition of
surface molecules such as integral proteins [355] like receptors and ion channels. In addition, the
glycosylation pattern thereof can be very different in cancer cells compared to noncancerous cells
[118, 356, 357]. This means that the binding sites of the beads are surrounded by different molecules
which enable better or worse attachment. The number of bound beads varied also significantly
on two different cell lines. Not only the TfR targeted B6 beads adhered in higher numbers to
hepatocellular carcinoma (HuH7) than prostate cancer cells (DU145), but also the hydroxylated
control beads. An elaborate method to verify unspecific binding on target cells would be using a
cell line which does not express the target receptor. As the TfR is ubiquitously expressed [342], a
comparison of cell lines with different receptor levels is considered as reasonable. Furthermore, TfR
expression could be knocked down by gene silencing, but suitable controls would be very difficult
for measuring single cells by fluorescence microscopy. All in all, the low amount of cMBP2 beads
bound to endothelial cells is favorable whereas the high amount of TfR targeted B6 beads on the
endothelial HMEC-1 cells is not favorable for the targeting approach. As assumed before, the B6
beads are presumably attached by unspecific interactions such as electrostatics. This means that
the beads would also bind to non-target tissues in vivo which would be undesirable.
To support our hypothesis of the unspecific binding of B6 beads, some additional experiments
were performed. As first approach, we investigated the uptake of the beads. The cellular inter-
nalization should be faster for receptor-meditated processes. We found similar uptake time ranges
and efficiencies for both, B6 and B6scr beads. These findings suggest that both bead types were
internalized by the same mechanisms. Incubation of the beads with free ligand revealed almost no
co-localization of internalized B6 and B6scr beads with labeled Tf in a central plane of single cells
after 1 h. This suggests that no or only few beads were internalized by receptor-mediated endo-
cytosis. While high co-localization of free labeled Tf with TfR-GFP was observed, B6 beads were
mainly not detected at the accumulation sites of the tagged TfR close to the nuclei. Thus, the labeled
Tf attached clearly to the TfR whereas the B6 beads mainly did not. It has to be mentioned that also
endogenous receptors were expressed in the cells during the experiment, but nevertheless a higher
degree of co-localization was expected in case of a specific attachment and uptake mechanism via
the TfR. Furthermore, experiments were performed where TfR targeted beads should compete for
binding with free ligand. However, the binding of B6 and B6scr1/2 beads was only little affected by
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a high amount of free Tf in the medium. There was no effect for B6mod and hydroxylated beads.
The latter two types of control beads bound to a much lower extend so that a small effect could
also disappear. There are two possible explanations of these findings. First, the B6 beads bound
nonspecifically and the Tf on the TfR blocked binding sites on the cell surfaces (e.g. sterically) or
second, only some of the B6 and B6scr beads bound "specifically" to the TfRs and they bind mainly
due to other effects such as electrostatic interactions. This second argument is supported by the
results of Xia et al.[309] which have shown that free Tf reduces B6 peptide binding. This means
that the coupling on the model beads diminished the targeting potential of B6. Furthermore, there
is the possibility that the small peptides do not bind at the same site as the Tf. Another aspect
which should be considered to interpret the findings correctly is the fact that the number of ligands
per bead also might play a role. Uptake experiments of Tf coated polystyrene particles by Tsuji et
al.[350] revealed a dependency of the uptake efficiency on the number of ligands and the number
of TfR expressed in the target cell line.
In conclusion, our binding studies under flow conditions show that the peptide cMBP2 is a potential
targeting molecule for c-Met whereas we do not recommend the peptide B6 for TfR targeting due
to its presumably unspecific binding characteristics.
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experiments for screening of polyplex
adhesion to different surfaces
Binding studies of model nanoparticles under flow conditions to assess the potential of peptide
ligands were described in the previous chapter. Can we also quantify the binding capacity of actual
therapeutic nanodevices? This is a challenging task because it is not always possible to synthesize
delivery systems which are exactly reproducible. They may vary concerning their size, defined
PEGylation, surface coating, amount of ligands and effective number of particles. For example,
some delivery systems such as polyplexes are formed by condensation, and different numbers of
polyplexes can be obtained for different approaches due to experimental deviations (e.g. pipetting
and mixing of very small volumes). As a result, polyplexes containing higher or lower amounts of
polymer and nucleic acids can affect the total number of formed particles. Thus, it is not reasonable
to compare the adhesion of different types of polyplexes by performing individual experiments.
Instead, in order to quantify the binding capacity of actual therapeutic nanodevices, the binding of
polyplexes of the same type and preparation should be compared on different surfaces in parallel.
This approach enables to study specific and non-specific interactions of the nanocarriers to various
relevant biological surfaces.
After intravenous administration of therapeutic delivery systems, these nanoferries come into con-
tact with blood, blood components and vessel walls. Then they enter the interstitial space through
fenestrations of leaky tumor tissue and encounter components of the stroma like extracellular
matrix or fibroblasts before they reach their actual target, the tumor cells. By performing animal
experiments, the potential of therapeutics is assessed regarding its suitability for clinical studies.
The accumulation of therapeutics at the diseased target site, but also in different organs is moni-
tored to analyze specificity and toxicity. Here, we present an in vitro approach to test the binding of
nanocarriers to different surfaces of relevance. More specifically, materials were used to which the
delivery systems could potentially bind in vivo or which reveal information about surface proper-
ties, such as attraction or repulsion of nanocarriers by surface charge and hydrophobicity.
This chapter deals with the extension of our flow system from an one-channel system with internal
control to a four-channels-in-parallel platform (Fig. 7.1). With this setup the adhesion of non-viral
gene vectors on different surfaces was investigated as a proof of principle. These gene delivery
systems, polyplexes, were formed by condensation of polymers with nucleic acids. Both, poly-
mers and nucleic acids (plasmid DNA and labeled siRNA) were kindly provided by the group of
Prof. Ernst Wagner (LMU Munich, especially by Dr. Christian Dohmen and Dr. Ulrich Lächelt).
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Figure 7.1: Scheme of two flow systems with four parallel channels. Two different polyplex suspensions
in two separate reservoirs (bottom) can simultaneously be passed over four different surfaces in the flow
channels (middle), for example two different surface coatings (left) and two different cell lines (right) via a
syringe pump.
Flow experiments with siRNA polyplexes and LPEI polyplexes as well as channel characterization
experiments were performed by the bachelor student Sebastian Siegl under my guidance. This
chapter gives insights into the possibilities provided by the extension of the flow system. Fur-
thermore, it shows how the adhesion of therapeutic nanoparticles can be studied in a quantitative
manner, and how the flow experiments can be used as a selection tool for suitable drug delivery
systems.
7.1 Development of a four-channel flow system
First studies on the interaction of nanocarriers with their biological environment are commonly
performed in cell culture assays [292]. To gain more detailed insights, animal experiments are
performed, mainly using mouse models. They exemplify the complex reality of multicellular or-
ganisms and biological heterogeneity and enable the analysis of biodistribution, accumulation sites
and clearance of the delivery systems. However, in the past few years, the gap between simple
cell culture and in vivo experiments is narrowing with the development of a variety of in vitro
models, including 3D cell cultures, tissue engineering and microfluidics [358]. Despite the lower
physiological relevance, such models permit control of experimental variables and quantitative
evaluation. In this context, we developed a simple microfluidic system designed to investigate the
specific and non-specific interaction of nano-therapeutics. Reduced gravitational sedimentation
and homogeneous particle concentration were provided by the microfluidic approach and a hy-
drodynamic microenvironment was introduced. In addition, with this flow setup it is possible to
simulate shear forces of vascular blood flow. On this basis, non-specific attachment to endothelial
cells or targeting thereof can be investigated.
In the following, the design of our expanded flow setup and the implementation of different surface
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coatings are described. In Fig. 7.1, the scheme of a parallelized flow setup is illustrated. From one
reservoir filled with a homogeneous particle suspension, particles are floated over four surfaces in
parallel channels on two different slides by the force of a syringe pump. In the channels of one
slide, cells are seeded (for example target and control cells). In the channels on the other slide,
the hydrophobic surface is coated, e.g. with blood components, extracellular matrix or interstitial
space components. Two or more four-channel systems can be installed for parallel experiments.
Parallelization of the flow channels allows for the simultaneous observation of particle adhesion,
hence comparing their affinity towards multiple surfaces.
Interesting cell coatings include target cells which overexpress specific receptors, but also endothe-
lial cells which intravenously administered delivery systems certainly encounter. Furthermore,
different surface coatings like artificial extracellular matrix or single components thereof, as well as
serum were deposited in the channels. While the cell monolayers were seeded according to stan-
dard protocols, the individual surface coatings were established for the flow experiments regarding
their appearance, layer thickness and autofluorescence characteristics.
An artificial gel, containing human extracellular matrix (ECM) components including collagens,
laminin, fibronectin, tenascin, elastin and a number of proteoglycans and glycosaminoglycans, was
diluted in cell culture medium on ice and further in cold buffer to prepare mixtures of different
densities. The gel was incubated at room temperature which induced polymerization. The network
formation was observed by transmission light widefield microscopy and the images are displayed
in Fig. 7.2 A. A dense mesh was obtained for high concentrations of ECM gel mixture, while
small holes could be observed at higher dilutions. To ensure that particles were not trapped in
the network structure during flow experiments, model nanoparticles were passed over different
dilutions of ECM gel under low shear conditions (see Fig. 7.2 B). Therefore, Cy5-labeled PEGy-
lated polystyrene beads with a terminal hydroxyl group were floated over 1:20, 1:50 and 1:100
dilutions of ECM gel. The particles’ fluorescence was monitored by widefield microscopy with a
short exposure time (50 ms) and a movie was recorded for 16 s. Time projections are depicted in
pseudo-color displaying the intensity range from 0-6000 pixel values. Particles interacting with the
ECM gel moved slower as they were retained and appeared on more frames of the movie. Thus,
in the time projections, they had higher intensity values (red) whereas fast moving particles were
dimmer (blue) and appeared as straight line. At higher concentration of ECM gel (1:20 dilution),
the particles were observed as bright spots caused by interaction with the matrix components. At
higher concentration of the gel (1:100), the particles appeared as long lines resulting from lower
interaction with the surface coating. ECM gel with diluted 1:50 was chosen for further experiments
because it provided a low retention of the particles.
To clearly distinguish the particles from the coating, the autofluorescence was analyzed. ECM gel,
poly-L-lysine and collagen did not show significant autofluorescence when excited with a 633 nm
laser at the respective laser power used for the experiments. On the contrary, pseudo-color images
of the autofluorescence of fetal bovine serum (FBS) in flow channels are illustrated in Fig. 7.2 C. The
fluorescence varied with concentration and excitation. Higher autofluorescence correlated with
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Figure 7.2: Characterization of surface coatings for flow channels. (A) Transmission light images of ECM
gel coated on hydrophobic flow channels at different dilutions (1:10-1:100). At higher concentration, the
matrix shows a higher density surface coverage. (B) Non-adhesive model beads (Cy5-labeled A200-PEG5-
OH beads) were floated over ECM layers (diluted 1:20, 1:50 and 1:100) under shear conditions (17.6 s−1) to
investigate the flow profile. Movies of beads passing the surface were recorded (exposure time: 50 ms) for 16 s.
Time-projections are depicted as pseudo-color images with pixel intensities between 0-6000 (blue-red). (C)
Autofluorescent background of flow channels coated with FBS was recorded depending on FBS concentration
and laser power. Pseudo-color images of single field of views (63.7x63.7µm2) are depicted for different FBS
dilutions (1:2-1:100) and excitation power (10-100 % AOTF). The autofluorescence was in a reasonable range
only at low concentration and low excitation power. (D) A hydrophobic flow channel was coated with collagen
A which was stained with ATTO 488. A fluorescence image after excitation with 488 nm is displayed. Scale
bars = 5µm.
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lower dilution of the serum and higher excitation power. For flow experiments, FBS concentrations
were chosen with low autofluorescence, such that polyplexes could still be discriminated properly
from the background. Furthermore, the FBS-coated surface was colored with Bradford reagent
after flow application to confirm that it was not washed away during the experiment. Successful
collagen coating was verified by incubation of the coated channel with ATTO 488 dye overnight.
After several washing steps, the stained collagen fibers were observed with widefield microscopy
and a representative image is displayed in Fig. 7.2 D. The image shows loose collagen fibers.
The viability of cells within the flow channels was monitored by transmission light widefield
microscopy. All together, we expanded our flow setup to a four-channel-in-parallel system designed
to compare the different affinities of gene vectors on cell lines and surface coatings.
7.2 Selection of suitable polyplexes
For adhesion experiments, non-viral gene delivery systems were used which are self-assembled
nanostructures consisting of polymers and nucleic acids. Three different types were considered for
the analysis. They varied in the polymer type and nucleic acid composition: polyplexes with (lin-
ear) polyethylene imine ((L)PEI), which is a standard transfection agent [64, 359], and polyplexes
with succinoyl tetraethylene pentamine building blocks (STP), which have been developed for nu-
cleic acid complexation in the past few years [360–363] contained either plasmid DNA or siRNA,
respectively. All polyplexes were shielded with polyethylene glycol (PEG) for improvement of
the biocompatibility and different targeting ligands were coupled to the individual polymers. The
polyplexes with siRNA have been designed and successfully tested for gene silencing on folate
receptor (FR) expressing cells [324]. Using LPEI as carrier polymer for pDNA, polyplexes have
been effectively applied for gene transfer on epidermal growth factor receptor (EGFR) express-
ing target cells when equipped with the short synthetic peptide GE11 [364]. Sequence-defined
STP-polymers have been developed for nucleic acid delivery [361] and demonstrated enhanced
transfection efficiency equipped with either the peptide B6 or c(RGDfK) in a ligand-dependent
manner in combination with endosomolytic agents [365]. All together, the selected polyplexes
have been successfully applied for gene delivery and hence chosen for studies of their specific and
non-specific binding behavior to relevant surfaces.
For quantification purposes some requirements have to be met, not only with respect to the detec-
tion system, but also concerning the particle properties. In order to quantify the adhesion of labeled
polyplexes on different surfaces, it is necessary that they can be detected on each of the surfaces
with similar quality. This means in particular that they should be bright enough to be visualized
even on the surface with the highest background fluorescence.
The fluorescence characteristics of the siRNA polyplexes were investigated by widefield mi-
croscopy. Freshly prepared FA-PEG-STP polyplexes were diluted in water and spin coated on
cover glass. In Fig. 7.3 A, the fluorescence of Cy5-labeled siRNA FA-PEG-STP polyplexes is de-
picted at the beginning of the laser excitation (t = 0 s) and after 66 s. Three fluorescent spots are
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Figure 7.3: Blinking and bleaching of small siRNA polyplexes. Cy5-labled FA-PEG24-STP siRNA polyplexes
were diluted 1:40 in water and spin coated on cover glass. A movie was recorded with widefield microscopy
exciting with a 633 nm laser (1.5 mW) for 66 s. (A) The fluorescence images of the first (t = 0 s) frame and after
66 s are shown. Scale bar = 5µm. (B) The fluorescence intensity profiles of three polyplexes selected in A
are displayed. The first polyplex shows one blinking and two bleaching steps (light grey arrows), the second
polyplex shows one bleaching step (dark gray arrow) and the third polyplex shows two bleaching steps (black
arrows).
encircled corresponding to three formed polyplexes. The fluorescence intensities of these poly-
plexes over the excitation time range are displayed in Fig. 7.3 B. Blinking and bleaching events are
indicated by arrows. One polyplex (light gray) showed blinking after 30 s, a steep bleaching step
after 35 s and a smaller bleaching step after almost 40 s. Being able to observe single bleaching steps
points to the fact that only very few fluorophores are attached on the siRNA of the polyplex. The
fluorescence of a second polyplex (dark gray) bleached completely in one step. This step was in the
same range of magnitude as the small bleaching step of the first polyplex. This finding assumes that
only one dye was bound to the polyplex. The third encircled polyplex (black) showed two small
distinct bleaching steps. Again, these steps were in the same range as the small bleaching steps.
Therefore, the latter polyplexes were labeled with approximately 2-3 dyes. Summarizing these
results, and taking into account that each siRNA molecule was labeled with only one fluorophore,
the resulting conclusion is that only few dyes were attached to single polyplexes.
When excited with UV/Vis light, cells auto-fluoresce in the blue and green range of visible light.
The fluorescence arises from endogenous fluorophores such as aromatic amino acids in proteins,
flavins, NAD(P)H and collagen [366]. Thus, the detectability of the siRNA polyplexes on cells and
surface coatings was tested. Freshly prepared siRNA polyplexes (FA-PEG-STP and Ala-PEG-STP)
were passed over KB cells, HMEC-1 cells, extracellular matrix (ECM) gel and fetal bovine serum
(FBS) coating in parallel flow channels for one hour. Fluorescence images of the Cy5-labeled poly-
plexes on the cells and surface coatings are depicted in Fig. 7.4. The folate receptor (FR) targeted
polyplexes were mainly found on KB cells and only a few attached to the ECM gel. Only a very
low amount of non-targeted polyplexes adhered to KB cells and almost none of them on the en-
dothelial cells and the surface coatings. Single polyplexes could not be spotted. They appeared
mainly aggregated or clustered. This implies that detection with particle counting is not possible.
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Figure 7.4: Small siRNA polyplexes on different surfaces. Cy5-labeled FA-PEG24-STP (upper row) and Ala-
PEG24-STP (lower row) siRNA polyplexes were floated simultaneously over KB cells, HMEC-1 cells, an ECM
layer and a FBS layer in parallel flow channels for 1 h under low shear conditions (4.4 s−1). After fixation of
the cells, the fluorescence was measured with widefield microscopy by excitation at 633 nm. Representative
fluorescence images of single field of views (63.7x63.7µm2) are depcited. Scale bars = 10µm.
A fluorescence intensity based approach should be used which in turn would correspond to a bulk
measurement because determination of the mean fluorescence intensity of single polyplexes would
be a very vague and presumably incorrect estimation. Hence, these polyplexes were not suitable for
detection with widefield microscopy. In addition, measurements with confocal microscopy could
not exclude that some of these small polyplexes would not be detected due to the autofluorescence
of the cells and surface coatings.
In a next step, we investigated polyplexes with a higher number of labeling dyes to ensure proper de-
tectability. Larger polyplexes are formed by condensation of a polymer with plasmid DNA (pDNA).
Two kinds of polymers were used: linear polyethylene imine (LPEI) and succinoyl tetraethylene
pentamine (STP). Single plasmids were labeled with around 50 or more fluorophores. Much
brighter polyplexes were obtained compared to siRNA polyplexes, even by mixing with unlabeled
copies of pDNA. In the upper row of Fig. 7.5, the fluorescence of pDNA polyplexes spin coated on
cover glass is illustrated. The LPEI polyplexes appeared as fluorescent spots. The cRGD-PEG-LPEI
polyplexes resulted in bigger polyplexes arising from condensation of a higher number of plasmids
(and polymer) than GE11-PEG-LPEI and Cys-PEG-LPEI polyplexes. The size distribution of STP
polyplexes (cRGD/GE11/Ala-PEG-STP) was broad as illustrated in the lower row of Fig. 7.5. Thus,
both types of pDNA polyplexes were bright enough and did not bleach significantly during laser
illumination. Single fluorescence maxima could be detected.
The uptake capability of the selected polyplexes into HuH7 cells was monitored to test their func-
tionality. For both types of polyplexes, two ligands were chosen. The cRGD peptide is selectively
recognized by αVβ3 and α5β1 integrins [367] and GE11 is bound by the epidermal growth factor
receptor (EGFR) [368]. Successful targeting involves faster uptake of polyplexes with ligand com-
pared to polyplexes without ligand by receptor-mediated endocytosis. HuH7 cells express both
receptors, EGFR in high [369] and αVβ3 integrins in low [370] amounts. Freshly prepared polyplexes
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Figure 7.5: Fluorescence of pDNA polyplexes. Cy5-labeled pDNA polyplexes were diluted 1:50 in HBG
buffer and coated on coverglass. The fluorescence was measured with widefield microscopy by excitation
with a 633 nm laser. The images of the following poyplexes are depcited: cRGD-PEG2-LPEI, GE11-PEG2-LPEI,
Cys-PEG2-LPEI, cRGD-PEG2-STP, GE11-PEG2-STP and Ala-PEG2-STP. Scale bars = 5µm.
Figure 7.6: Association of pDNA polyplexes with HuH7 cells. Cy5-labeled pDNA polyplexes
(cRGD/GE11/Cys-PEG2-LPEI or cRGD/GE11/Ala-PEG2-STP) were incubated with HuH7 cells for 1.5 h un-
der static conditions. The cell membranes were stained with WGA-Alexa488 (green) and the nuclei with DAPI
(blue). The fluorescence was recorded using spinning disk microscopy by excitation at 405 nm (DAPI), 488 nm
(Alexa488) and 639 nm (Cy5). Images of polyplexes (magenta) in one central plane of several cells are shown.
Orthogonal views are displayed on top (xz) and on the right (yz). Scale bars = 10µm.
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were incubated with HuH7 cells for 1.5 h under static conditions. The cell membranes were stained
with WGA-488 (green), the nuclei with DAPI (blue) and the polyplexes on the cells were imaged
by spinning disk microscopy. In Fig. 7.6, the fluorescence of Cy5-labeled polyplexes (magenta)
is depicted in a representative the HuH7 cells. Orthogonal views of the xz-plane (on top) and of
the yz-plane (left) are additionally shown. As can be observed, the cRGD- and GE11 polyplexes
of both polymer types clearly accumulated on and within the cells. Only few control polyplexes
bound to the cells. In flow experiments lasting 1 h, internalization of a low number of polyplexes is
expected according to the previous findings. As a consequence, the merge of their fluorescence in
endosomes is considered as negligible and thus the detection of fluorescence maxima is reasonable.
Certainly, we were aware of the fact that some polyplexes aggregated, but polyplexes of the same
polymer type showed similar aggregation tendencies.
7.3 Differential binding of polyplexes to multiple surfaces
We intended to provide an in vitro experiment suitable to pre-select delivery devices by testing their
adhesion to biologically relevant surfaces under shear conditions. With our parallelized channel
approach, not only the binding efficiency is examined, but also the unspecific adhesion to essential
surfaces. Typically, polyplexes in cell medium were passed over four different parallelized surfaces
for 1 h under very low shear conditions. After fixation, the fluorescence of adhered polyplexes,
labeled with Cy5, was measured in each flow channel and the mean numbers were plotted in
a diagram. To compare the binding capacities of different polyplexes, relative values calculated
by normalization to the maximum number of bound polyplexes in every experiment were used.
Binding profiles were obtained, for example: 100 % on cell line 1, x % on cell line 2, y % on surface
coating 1, z % on surface coating 2. By evaluation of the binding profiles, one can to estimate
potential binding sites of the delivery systems and the ratio of affinities to them.
In the following it is described as a proof of principle how polyplexes of different compositions
bind to various surfaces in the channels of the parallelized flow setup. The experiments are not
restricted to the parameters we used and can be performed with modified settings to answer
further research questions. Herein, we investigated the binding profiles of LPEI and STP pDNA
polyplexes to selected cell lines and surface coatings. We picked three examples: in a first approach,
the binding profiles of receptor-targeted polyplexes were compared to those of polyplexes without
ligand (section 7.3.1); in a second experiment, different surface combinations were tested (section
7.3.2) and as third exemplification, the effect of different polymer types forming the polyplexes and
the influence of serum content are shown (section 7.3.3).
7.3.1 Receptor targeting
Binding profiles of EGFR-targeted GE11 and control polyplexes were recorded to approximate the
effect of the targeting ligand on binding. As described before, a four-channel-in-parallel flow ex-
periment was performed. EGFR-targeted GE11-PEG2-LPEI polyplexes and Cys-PEG2-LEPI poly-
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Figure 7.7: Binding profiles of EGFR targeted and control polyplexes on four different surfaces. Adhesion
of Cy5-labeled polyplexes with ligand (GE11-PEG2-LPEI) and without (Cys-PEG2-LPEI) were perfused over
four different surfaces (HuH7 target cells, HMEC-1 cells, ECM and FBS) in parallel for 1 h at very low shear
conditions (4.4 s−1). The fluorescence was recorded by widefield microscopy exciting with a 633 nm laser,
adjusting the focus over single cells or on the surface, respectively. (A) Representative fluorescence images of
the polyplexes per field of view. Scale bars = 5µm. (B) The mean number of polyplexes per field of view are
shown (right scale) and normalized to the maximum number of bound polyplexes in one channel (left scale).
n = 40 (field of views/channel).
plexes were passed over hepatocellular carcinoma cells (HuH7), microvascular endothelial cells
(HMEC-1), extracellular matrix (ECM) gel and fetal bovine serum (FBS) coating in four parallel
flow channels. In Fig. 7.7 A, representative images of the two types of polyplexes on the different
surfaces are shown. The mean numbers of adhered polyplexes are depicted in the diagram in Fig.
7.7 B (left scale) and are normalized to the maximum amount of bound polyplexes (right scale). In
particular, the maximum number of adhered GE11-PEG2-LPEI polyplexes was 38 on HuH7 cell,
thus this value was set to 100 %. Accordingly, values for polyplexes bound to the other surfaces
were determined with respect to this maximum value. For the GE11-PEG2-LPEI polyplexes fol-
lowing binding profile was obtained: 100 % on HuH7 cells, 40 % on HMEC-1, 5 % on ECM, 5 % on
FBS. This profile can be interpreted by a high attraction of the polyplexes to EGFR overexpressing
HuH7 cells, lower attraction to HMEC-1 cell which also express EGFR [371] and only low unspecific
attraction to ECM and FBS. For the control polyplexes (Cys-PEG2-LPEI) a similar binding profile
was determined with slightly lower binding affinities to HMEC-1 cells, but higher numbers on
matrix gel. These findings indicate that the targeting ligand GE11 did not have an effect on binding
to the target cells as higher numbers were expected on the HuH7 cells for the receptor-targeted
polyplexes. Hence, the carrier polymer LPEI with its positive charges contributed mainly to the
affinity of the polyplexes to the negatively charged cell surfaces.
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Figure 7.8: Binding profiles of EGFR-targeted polyplexes with different combination of surfaces. Cy5-
labeled GE11-PEG-STP polyplexes were perfused over four different surfaces in parallel for 1 h at very low
shear conditions (4.4 s−1). The fluorescence of the polyplexes was recorded by widefield microscopy excited
by a 633 nm laser. The number of polyplexes was counted per field of view (63.7x63.7µm2) based on the
intensity maxima. (A) Representative fluorescence images per field of view are shown on HuH7 cells, HMEC-
1 cells, ECM and collagen (Experiment 1) or on HuH7 cells, HMEC-1 cells, Poly-L-lysine and FBS (Experiment
2). Scale bars = 5µm. (B) The mean numbers of polyplexes per field of view are illustrated (right scale)
and normalized to the maximum number of bound polyplexes in one channel (left scale). n = 32 (field of
views/channel).
7.3.2 Binding profile on different surfaces
In a second approach, binding profiles with different combinations of surface coatings were investi-
gated. The same cell lines were used in both experiments, while the surface coatings were changed.
As described before, EGFR-targeted GE11-PEG-STP polyplexes were passed through four different
flow channels with HuH7 cells, HMEC-1 cells and different surface coatings for 1 h under very low
shear conditions. In Fig. 7.8 A, representative images of the Cy5-labeled polyplexes on the cells
and coatings are displayed for experiment 1 and 2. The mean values and normalized values with
respect to the maximum number of bound polyplexes are shown in Fig. 7.8 B. In experiment 1,
the following binding profile was obtained: 100 % on HuH7 cells, 50 % on HMEC-1, 5 % on ECM
and 15 % on collagen. This distribution resembles the binding profile described in the previous
section (see 7.3.1) for GE11-PEG2-LPEI polyplexes with the difference that collagen was coated in
one channel instead of FBS. In experiment 2, similar numbers of GE11-PEG-STP polyplexes were
counted on HuH7 cells (ca. 120-130) as in experiment 1, whereas the number of polyplexes on
HMEC-1 cells was lower (instead of 50 %, ca. 20 % compared to HuH7). This observation could
be explained by biological or experimental variance, but could also result from different polyplex
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aggregation in the two separate experiments. Moreover, it can be observed in the images that
polyplexes also attach non-specifically to the channel bottom, especially in the case of HMEC-1
cells. Hence, another reason could be that more polyplexes bound to the channel bottom in the
second experiment. To exclude such causes, a cell layer confluence of 100 % will be used in further
experiments.
The binding profile of experiment 2 differed strongly. The maximum number of polyplexes was
counted on poly-L-lysine coating. This polyamino acid is positively charged at physiological pH
and used to promote attachment of cells or proteins to surfaces by electrostatic interactions. The
GE11-PEG-STP polyplexes contain polymer with neutral building blocks (STP) and posses a low,
slightly positive zeta potential [365]. Thus, electrostatic attraction would mainly involve the nega-
tively charged phosphate backbone of the pDNA. This explanation would include a disassembly
of the polyplexes at least to some extent. Interestingly, the fluorescent spots detected on poly-L-
lysine were more uniform and smaller than those observed on cells. Hence, the polyplexes were
more aggregated on the cells. This would support the afore mentioned hypothesis that polyplexes
aggregate in cell medium and bound to cells in an aggregated state. Another explanation would
be that the polyplexes mainly aggregate on the cell either after or during cellular binding, or in
endosomes.
7.3.3 Effect of polymer type and serum content on polyplex binding
In a third approach, the binding profiles of two types of polyplexes composed of two different
polymer types were compared. In contrast to the previous experiments, FBS was not coated on the
bottom of the channel, but its content in the fluid medium was increased to study the influence of
the formation of a protein corona around the nanoparticles. This is relevant as blood contains much
higher levels of serum than the 10 % usually used in cell culture experiments. Salvati et al. showed
that transferrin-coated nanoparticles lost their targeting capability when serum biomolecules ad-
sorbed on their surface [372]. The buffer was supplemented with 55 % FBS. In our demonstrations
we adapted this parameter and supplemented the cell medium with 55 % FBS to show the interac-
tion in presence of high serum content.
The binding experiments under flow conditions were conducted with integrin-targeted cRGD-
PEG2-LPEI and cRGD-PEG2-STP polyplexes, first in cell medium with low serum (10 % FBS) and
then with high serum (55 % FBS) content. In Fig. 7.9 A, representative images of polyplexes are
illustrated. The mean values of bound polyplexes are displayed in Fig. 7.9 B on the left scale and
normalized to the number of maximum bound polyplexes on the right scale. The integrin-targeted
LPEI polyplexes showed maximal adhesion on collagen and bound in similarly high amounts to
HuH7 and HMEC-1 cells, and they basically did not show attachment on ECM gel. As expected,
the number of polyplexes on HMEC-1 cells was increased as this cell line expresses a manifold of
integrins [373]. The high affinity of the LPEI polyplexes presumably originates from the nature of
the polymer carrier, as STP polyplexes showed almost no unspecific binding to the scleroprotein.
Comparing the binding profiles of the LPEI polyplexes of low and high serum content, it is obvious
that the binding profile did not change significantly. Fewer polyplexes were counted on the cells.
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However, the number of polyplexes in solution was expected to be similar. Thus, a meaningful
conclusion was not possible. In the case of the STP polyplexes, the same effect of overall reduced
polyplex binding was observed with increased serum content. Here, the binding profile changed,
and the percentage of polyplexes bound to endothelial cells doubled, whereas it almost vanished
on ECM gel. For further conclusions, additional experiments and more statistics are required to
reliably elucidate the binding behavior of these polyplexes.
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Figure 7.9: Influence of the polymer type and the serum content on the binding profiles of integrin targeted
polyplexes. Cy5-labeled cRGD-PEG2-LPEI and cRGD-PEG-STP polyplexes were passed over four different
surfaces (HuH7 cells, HMEC-1 cells, ECM and collagen) in parallel for 1 h at low shear conditions (4.4 s−1). The
fluorescence of the polyplexes was recorded by widefield microscopy excited by a 633 nm laser. The number of
polyplexes was counted per field of view (63.7x63.7µm2) based on the intensity maxima. (A) Representative
fluorescence images of the polyplexes are shown. The cell medium during the experiment was supplemented
either with 10 % FBS (upper row) or with 55 % FBS (lower row). Scale bars = 5µm. (B) The mean numbers
of LPEI (left) and STP (right) polyplexes on different surfaces per field of view are shown (right scale) and
normalized to the maximum number of bound polyplexes in one channel (left scale). The cell medium during
the experiment was supplemented with 10 % FBS (upper diagrams) and with 55 % FBS (lower diagrams). n =
32 (field of views/channel).
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7.4 summary and conclusion
In summary, we expanded our flow system (described in chapter 5) to a four-channel-in-parallel
setup to perform binding studies of actual therapeutic nanoparticles. In particular, a solution
with nanoparticles was passed through four parallel flow channels containing different cell mono-
layers and surface coatings. In principle, these surfaces were either targets of the polyplexes or
surfaces which they would encounter in vivo. They included epithelial hepatocellular carcinoma
cells, microvascular endothelial cells, extracellular matrix gel, fetal bovine serum and collagen. As
therapeutic nanoparticles polyplexes were chosen, i.e. non-viral gene delivery particles formed by
condensation of nucleic acids with cationic polymers. More specifically, pDNA polyplexes were
selected as they provided the requirements for quantitative analysis, such as good detectability
and stability in cell medium. The described binding experiments of these polyplexes on different
surfaces were performed as a proof of concept. The assessed binding profiles revealed some inter-
esting conclusions about polyplex binding. Similar amounts of LPEI polyplexes with and without
the peptide ligand GE11 (targeted to the EGFR) were observed on all surfaces. This implies that
the binding was primary mediated by the carrier polymer. High amounts of LPEI polyplexes with
the peptide ligand cRGD were found on the scleroprotein collagen indicating high affinity to it.
Another observation was that the binding of polyplexes varied most on HMEC-1 cells suggesting
high sensitivity of this cell line to already little ambient or experimental changes. As discussed in
literature [374], serum molecules in cell media influence the binding of nanoparticles. The binding
of polyplexes of both types of polymers, LPEI and STP, was significantly reduced at increased
serum content (from 10 to 55 %) in the cell medium. The STP polyplexes showed barely unspecific
binding to extracellular matrix gel and collagen at high serum content. This is highly favorable for
in vivo applications.
In addition to these findings, it is important to point out that the flow setup with parallel channels
is not restricted to the investigations shown herein. Many variations can be implemented including
the change of cell lines and surface coatings, the tuning of flow generating very low until high shear
forces. Furthermore, different particle types can be analyzed and additional soluble components
introduced. The variables ultimately depend on the research question.
In the following, some examples of applications will be elucidated. The flow provides many op-
portunities to either determine the magnitude of particle affinity to respective surfaces or mimic
the shear forces of blood flow. The latter can hence provide useful information of specific and
unspecific binding to endothelial cells. Thus, aspects of the toxicity of certain nanocarriers can
be obtained or the (tumor) vasculature can be targeted [375]. Active targeting strategies to can-
cer endothelium can be pursued by coupling targeting ligands to therapeutic nanoparticles which
address overexpressed receptors like various integrins [192] or vascular endothelial growth factor
receptors (VEGFR) [376]. A further application of the flow system with parallelized channels could
be the testing of binding to different components of the extracellular matrix, thus determining
the main interactions with this gel. By blocking surface receptors with free ligand or antibodies,
targeting studies could be performed. This is especially practicable for cheap ligands like folic acid
93
7 Proof of principle: Development of flow experiments for screening of polyplex adhesion to different surfaces
as high amounts of it are needed to saturate the cell medium in the whole flow system. To explore
the effect of a ligand on the binding of the particles, the adhesion to cell lines with and without
targeting receptor could be simultaneously observed. In this case, it would be important to test the
receptor status on the cell lines by western blot or flow cytometry. The variation of perfusion time
could disclose binding kinetics of the nanoparticles.
Additionally, the parallelization of flow channels allows for screening multiple surfaces. An inter-
nal standard could be incorporated in the flow experiments. For example, LPEI polyplexes without
PEG shielding could be used as a particle type with maximum affinity and PEGylated model beads
as particles with minimal binding affinity. Moreover, a surface coating could be used as an internal
standard of the system to which the particles have high affinity. Based on our preliminary findings,
collagen could serve as control surface for LPEI polyplexes and poly-L-lyisine for STP polyplexes.
In conclusion, the flow setup with parallel channels offers many possibilities to answer a multitude
of research questions.
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8.1 Materials
DMEM/F-12, DMEM (low glucose, GlutaMAX and pyruvate), MCDB-131, RPMI 164 (with glu-
tamine) and CO2-independent medium, GlutaMAXTM, HEPES buffer, human epidermal growth
factor (hEGF), fetal bovine serum (FBS), phosphate buffered saline (PBS), transferrin (Tf) -Alexa
Fluor®647 conjugate, WGA-Alexa Fluor®488 conjugate, DAPI and aliphatic amine latex beads
(71.8µEq NH2/g, 2 % w/v, 0.2µm) were purchased from Life Technologies AG (Carlsbad, CA, USA).
Hydrocortisone, anhydrous dimethylsulfoxide (DMSO), ethylenediaminetetraacetic acid (EDTA),
2-mercaptoethanol, dithiothreitol (DTT), citric acid monohydrate, 4-(2-hydroxyethly)- 1-piperazine
ethanesulfonic acid (HEPES), ultra filtrated water, poly-L-lysine, MaxGel ECM and human apo-
Tf were obtained from Sigma-Aldrich Corp. (St. Louis, MO, USA). Sterile ibiTreat µ − Slides,
8-well and sterile ibiTreat µ − Slides I0.4 Luer and VI0.4 Luer were purchased from ibidi GmbH
(Martinsried, Germany), para-formaldehyde (PFA) from Science Services GmbH (Munich, Ger-
many), ATTO 488-NHS from ATTO-TEC GmbH (Siegen, Germany), Cy5-NHS from GE Healthcare
(Freiburg, Germany), ortho-pyridyldisulfide-polyethylene glycol-N-hydroxysuccinimide (OPSS-
PEG(5 kDa)-NHS) from Rapp Polymere GmbH (Tübingen, Germany), X-tremeGENE 9 DNA trans-
fection reagent from F.Hoffmann-La Roche AG (Basel, Swiss), collagen A from Merck KGaA
(Darmstadt, Germany) and iron(III) chloride from Grüssing GmbH (Filsum, Germany). Cy5 la-
bel IT was purchased from Mirus Bio LLC (Madison, WI, USA) and Secure-Seal Imaging spac-
ers (φÂ 9 mmx0.12 mm) from Grace Bio-labs, Inc. (Bend, OR, USA). The plasmid pCMVLuc
from plasmidfactory GmbH& Co. KG (Bielefeld, Germany) was kindly provided by the group
of Prof. Ernst Wagner (LMU Munich). The plasmid pBa.TfR.GFP (Addgene 45060) was re-
ceived from Gary Banker (Oregon Health & Science University). Peptide-cysteine derivatives
were kindly provided by Dr. Ulrich Lächelt and Stephan Morys. B6-cysteine (B6-Cys, CGHKAKG-
PRK), cMBP2-cysteine (cMBP2-Cys, KSLSRHDHIHHHK(C)) were synthesized under standard
Fmoc chemistry conditions using an ABI 431A peptide synthesizer (Applied Biosystems, Foster
City, CA, USA). B6scr1-Cys (CAGKHGKRPK), B6mod-Cys (CGHGAGGPGG) and cMBP2scr-Cys
(HHSIHRLHHKSDK(C)) were synthesized under standard Fmoc chemistry conditions using a Syro
Wave peptide synthesizer (Biotage AB, Uppsala, Sweden). The site-specific coupling of cysteine
at the ε-amine of the C-terminal lysine of cMBP2 and cMBP2scr was achieved with orthogonally
protected Fmoc-Lys(ivDde)-OH. Peptide identity was verified by MALDI-TOF (Matrix-assisted
laser desorption/ionization- time-of-flight) mass spectrometry, carried out using an Autoflex II
mass spectrometer (Bruker Daltonics, Bremen, Germany) and a 2,5-dihydroxybenzoic acid (DHB)
matrix. Folic acid-cysteine (FA-Cys) and PEGylated constructs (FA-PEG2-Cys and FA-PEG24-Cys),
transferrin-iminothiolane [Tf(it)] and transferrin-pyridyldithiol propionate [Tf(pdp)] were kindly
provided by Dr. Ulrich Lächelt. The transferrin constructs were loaded with iron(III) (1.25µL/mg
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Tf; 1 Eq Fe3+/mg Tf) by incubation with iron(III) buffer (1 mM FeCl36˙H2 O; 200 mM citric acid
monohydrate, pH 7.8, sterile-filtered) for 30 min at room temperature.
8.2 Particle synthesis, preparation and characterization
8.2.1 Polystyrene beads
Synthesis, DLS and zeta potential
Functionalized and labeled model beads, A110/200-(dye)-PEG5-(ligand/modification) were pre-
pared according to the following procedure. Aliphatic amine latex beads (100µL; 0.155µmol NH2,
mean diameter: 0.11µm; or 0.158µmol NH2, mean diameter: 0.2µm) were centrifuged at 13 400 rpm
(Microcentrifuge 5417R, Eppendorf AG, Hamburg, Germany) for 15 min and the supernatant was
removed. The beads were resuspended in PBS (0.1 mL), shortly sonicated (Sonorex RK31, Bandelin
electronic GmbH & Co. KG, Berlin, Germany), and ATTO 488-NHS (7.4µL, 12.6 nmol) or Cy5-
NHS (9.4µL, 7.9 nmol) dissolved in anhydrous DMSO, was added. The suspension was shaken
at 1000 rpm (Thermomixer comfort, Eppendorf) protected from light at room temperature for 2 h.
Then, the reaction mixture was centrifuged for 20 min, the supernatant removed, the beads washed
with PBS (3 x 0.5 mL) and resuspended in PBS (0.1 mL). To the labeled beads A110/200-(dye)
(100µL, 0.155 or 0.158µmol NH2) OPSS-PEG (2 or 5 kDa)-NHS (78µL, 1.55 or 1.58µmol), dissolved
in anhydrous DMSO, and PBS (80µL) were added. The reaction mixture was shaken (1000 rpm) at
room temperature for 2 h. The suspension was washed as described above and the beads finally
resuspended in PBS (200µL) with EDTA (2.5 mM) to prevent oxidation. An assay with DTT was
performed to estimate the yield of PEG-OPSS on the beads. The procedure which was used to esti-
mate the coupling efficiency of OPSS-PEG(2 or 5 kDa)-NHS to the amine latex beads was previously
described in literature [377, 378]. In brief, to a suspension of PEGylated A110/200-(dye)-PEG2/5-
OPSS beads (10µL) in PBS (9.2µL) containing EDTA (2.5 mM), DTT (0.8µL, 1 M) was added and
the reaction mixture was shaken at 500 rpm for 1 h at room temperature. The disulfide bridge
within the OPSS residue was reduced to yield 2-thiopyridone (2-TP), which was released into the
supernatant after centrifuging at 13 400 rpm for 15 min. The absorption at 343 nm A343 of 2-TP was
measured five times (Nanodrop ND-1000, PEQLAB Biotechnology GmbH, Erlangen, Germany)
and the molar concentration of 2-TP was calculated by using its molar extinction coefficient ε343 =
8.08 x 103 M−1cm−1. The obtained concentration corresponds to the concentration of PEG-OPSS on
the latex beads in the assay. For coupling with Tf(pdp), the beads were pretreated with DTT (at an
excess of 100 Eq over PEG-OPSS, 10 mM) for 2 h at room temperature to provide a free thiol group.
To a suspension of A110/200-(dye)-PEG2/5-OPSS (100µL), peptide ligand (B6-Cys, cMBP2-Cys),
modified peptide (B6scr1/2-Cys, B6mod-Cys, cMBP2scr-Cys), folate ligand (FA-Cys, FA-PEG2-Cys
or FA-PEG24-Cys), natural ligand [Tf(it) or Tf(pdp)] or 2-mercaptoethanol (HS-CH2CH2-OH) (each
at an excess of 20 Eq over PEG-OPSS) and PBS were added to a total volume of 200µL. The re-
action mixture was shaken at 1000 rpm at 23 °C for 2 h. Then, the suspension was centrifuged for
20 min, the beads were washed with PBS (3x400µL) and resuspended in PBS (50µL). The average
hydrodynamic diameter of the functionalized beads (1.5µL) was measured in water (800µL, 1 mM
NaCl, pH 6.8 and 7.4) as a triplicate in 10 sub-runs of 10 s in a folded capillary cell (DTS1061) by
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dynamic light scattering (DLS, Zetasizer Nano ZS, Malvern Instruments Ltd., Worcestershire, UK).
The employed settings were an equilibrating time of 0 min, a temperature of 25 °C, a refractive
index of 1.330, a dispersant dielectric constant of 78.5 and a viscosity of 0.8872 mPa · s. The Z-
average and the polydispersity index (PdI) were determined by fitting of single exponentials to the
correlation function. The same samples were used to determine the zeta potentials as triplicates in
10-30 sub-runs of 10 s at 25 °C. Data was analyzed by the Smoluchowski equation.
Fluorescence characterization on cover glass
For comparison experiments of different PEG linkers, beads (A110/200-PEG2/5-B6/OH) labeled with
Cy5 or ATTO 488 were shortly vortexed, diluted 1:300 in PBS buffer, sonicated for 15 min, pipetted
on a cover glass (5µL) and coated by a spin coater 1001 (Convac GmbH, Vaihingen, Germany)
at 2000 rpm. To compare different preparation methods including dilution and sonication, beads
(A200-PEG2-OH/PEG24-FA) were sonicated for 10 min, diluted (1:10 or 1:100) and again sonicated
(for 0, 5 or 15 min), pipetted on cover glass (5µL) and spin coated at 2000 rpm. Snap shots of the
beads’ fluorescence were recorded by widefield microscopy focusing on the surface of the cover
glass.
External controls
Two external controls were performed as schematically depicted in Fig. 8.1. In both control
experiments, the remnant of the mixture (5µL) of beads with ligand (dye 1) and control beads (dye
2) which was used for the flow experiments was investigated. In the first test, the mixture (5µL)
was pipetted on a cover glass and spin coated at 3000 rpm.
Figure 8.1: External control. Schematic drawing of two different external control experiments. For one
external control, a mixture of beads with ligand and control beads was spin coated; for the other, the mixture
was pipetted into an image spacer chamber.
In the second test, the mixture (9µL) was pipetted into a imaging spacer chamber (9 mm diameter,
0.12 mm height) on a cover slide which was pre-coated with collagen A (10 % solution, 10µL) for
30 min. The chamber was sealed by another cover glass. In both experiments, snapshots of the
beads’ fluorescence were recorded of multiple field of views (63.7x63.7µm2). The fluorescent max-
ima were counted and the mean values ± standard error (SE) calculated. By dividing the number
of beads with ligand by the number of control beads per field of view, the correction factor was
obtained.
Integrated fluorescence Density (IntDens)
To obtain the integrated fluorescence density (IntDens) of single beads, ATTO 488 labeled A200-
PEG5-B6/B6scr/B6mod/cMBP2/cMBP2scr/OH beads were diluted in PBS buffer (1:100), sonicated
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for 15 min and added to CO2-independend medium supplemented with 10 % FBS in chamber slides.
The fluorescence was measured by spinning disk microscopy.
Light absorption
The absorption of polystyrene beads (2µL, 1:200 dilution in PBS buffer) was measured at 225-231 nm
(Nanodrop ND-1000, PEQLAB Biotechnology GmbH, Erlangen, Germany) as quintuplicates. To
calculate the concentration of amino groups in the suspension, a calibration curve was used.
Therefore, serial dilution of unmodified beads was prepared and the absorption measured (see
Appendix 1).
8.2.2 Polyplexes
Polyplexes are formed by condensation of nucleic acids with polymers. Cy5 labeled siRNA and
polymer for siRNA polyplexes, and polymers and plasmid DNA for pDNA polyplexes were kindly
provided by the group of Prof. Ernst Wagner (LMU Munich).
Labeling of plasmid DNA
Plasmid DNA (pCMVLuc, encoding for luciferase under control of the promotor CMV, 6400 bp,
4550 kDa) was labeled with Cy5 by covalent alkylation of reactive heteroatoms of the pDNA with
the labeling reagent of the Label IT µArray, Cy5 Labeling kit (Mirus Bio LLC, MAdison, WI, USA)
using the manufacturer’s protocol. The Cy5-labeled pCMVLuc was purified by precipitation with
sodium acetate (0.14 M, pH 5.2) in absolute ethanol at -20 °C overnight. After centrifugation at
maximum speed with a microcentrifuge at 4 °C, the pellet was washed with cold ethanol (70 %, 3x),
dried and resuspended in ultra filtrated sterile water to yield Cy5 labeled pCMVLuc (40µg/mL).
The concentrations of the label and the pDNA were determined with Nanodrop ND-1000 (PEQLAB
Biotechnology GmbH, Erlangen, Germany).
8.2.2.1 siRNA polyplexes
Polymers and siRNA were kindly provided by Dr. Christian Dohmen (group of Prof. Ernst
Wagner, LMU Munich). The oligomers were synthesized by standard peptide synthesis strategy
using Fmoc-protection and solid phase support [67]. The sequence-defined polymers consist of
2x4 succinoyl tetraethylene pentamine (STP) building blocks, polyethylene glycol (PEG) with a
defined length of 24 units ethylene glycol as shielding, and folic acid for receptor targeting or
alanine as control. The identity was verified by MALDI-MS (matrix-assisted laser desorption/ion-
ization mass spectrometry) and the purity was analyzed by RP-HPLC (reversed phase high per-
formance/pressure liquid chromatography). The obtained oligomers are FA-PEG24-K-(STP4-C)2 (
referred as FA-PEG-STP, 4076 g/mol, 25 amines) and Ala-PEG24-K-(STP4-C)2 (referred as Ala-PEG-
STP). The siRNA was provided according to Dohmen et al. [324], and it is a siRNA against the
house keeping gene AHA1, each molecule was labeled with one Cy5 dye (siANA1, sense sequence:
Hexynyl-C6-ss-C6-5’-GGAuGAAGuGGAGAuuAGudTsdT-3’; antisense sequence: (Cy5-NH-C6-5’-
ACuAAUCUCcACUUcAUCCdTsdT-3’; 21 bp, 13500 Da).
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The siRNA polyplexes (20µg/mL siRNA) were freshly prepared for each experiment. Stock so-
lutions of polymer and nucleic acid were mixed in HEPES buffered glucose (HBG buffer, 20 mM
HEPES, pH 7.1, 5 % w/v glucose) with a molar ratio of polymer nitrogens to siRNA phosphates,
N/P = 16. After incubation for 30 min at room temperature the formed polyplexes were used for
experiments.
8.2.2.2 LPEI-pDNA polyplexes
Receptor targeted (cRGD-PEG2-LPEI22 and GE11-PEG2-LPEI22) and control (Cys-PEG2-LPEI22)
polymers were synthesized by members of the group of Prof. Ernst Wagner (LMU Munich) by a
standard peptide synthesis strategy using Fmoc-protection and solid phase support according to
the literature [364, 379]. They consist of linear polyethylene imine (LPEI, 22 kDa), a PEG linker
(2 kDa) and cRGD or GE11 for targeting or cysteine as a control. The cRGD peptide (H-βA-
C1DC2RGDC3FC4-NH2, C1C4/C2C3-bicyclo, 955 Da) was obtained form IRIS Biotech (Marktred-
witz, Germany) and GE11 (CYHWYGYTPQNVI) from Biosyntan (Berlin, Germany).
The pDNA LPEI-polyplexes (20µg/mL pDNA) were freshly prepared for each experiment. Stock
solutions of polymer and nucleic acid (20-40 % Cy5 labeled mixed with non-labeled pCMVLuc)
were mixed in HBG buffer with a molar ratio of polymer nitrogens to pDNA phosphates, N/P = 6
and incubated for 30 min at room temperature to form LPEI-polyplexes.
8.2.2.3 STP-pDNA polyplexes
Polymers (c(RGDfK)-PEG24-K[Stp4-C]2, GE11-PEG24-K[Stp4-C]2 and A-PEG24-K[Stp4-C]2) were
kindly provided by Dr. Ulrich Lächelt (group of Prof. Ernst Wagner, LMU Munich). The oligomers
were synthesized by standard peptide synthesis strategy using Fmoc-protection and solid phase
support according to the literature [361]. They consist of succinoyl tetraethylene pentamine (STP)
building blocks, PEG spacer (24 units ethylene glycol) and targeting ligands (cRGD or GE11) or
alanine as a control. The polymers were purified by size exclusion chromatography.
The pDNA STP-polyplexes (20µg/mL pDNA) were freshly prepared for each experiment. Stock
solutions of polymer and nucleic acid (20-40 % Cy5 labeled mixed with non-labeled pCMVLuc)
were mixed in HBG buffer with a molar ratio of polymer nitrogens to pDNA phosphates, N/P = 12
on ice and incubated for 45 min at room temperature to form STP-polyplexes.
8.2.2.4 Polyplexes on cover glass
To investigate the fluorescence intensity of Cy5 labeled siRNA polyplexes, freshly prepared poly-
plexes (FA-PEG-STP) were diluted in water (1:40) and coated on cover glass at 3000 rpm. Movies
(200 frames) of the polyplexes’ fluorescence were recorded with widefield microscopy.
LPEI- and STP-polyplexes (20µg/mL pDNA, 5µL) labeled with Cy5 were diluted in HBG buffer
(1:50) prior to coating on cover glass. The fluorescence was observed with widefield microscopy.
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8.3 Cell culture
Human hepatocellular carcinoma cells (HuH7) were cultivated in DMEM/F-12, human cervical
cancer cells (HeLa) in DMEM (low glucose), human prostate cancer cells (DU145) in RPMI 1640
(with glutamine), human nasopharyngeal epidermoid carcinoma cells (KB) in RPMI 1640 (without
folic acid) and human dermal microvascular endothelial cells (HMEC-1) in MCDB-131 medium
supplemented with 1 % Glutamax, 10 ng/mL hEGF and 1µg/mL hydrocortisone. All media were
prepared with addition of 10 % FBS. Cells were cultivated at 37 °C in a 5 % CO2 containing, humid-
ified atmosphere. For static experiments, cells were seeded into sterile ibiTreat µ − Slides, 8-well
with a cell density of 2x104 (1x104) per well and incubated for 24 or48 h prior to the measurement.
For live cell-imaging and experiments under static conditions, the medium was replaced by CO2-
independent medium supplemented with 10 % FBS prior to imaging. For experiments under flow
conditions, cells were seeded into sterile ibiTreat µ − Slide I0.4 Luer or VI0.4 Luer flow chambers
with a cell density of 4-4.5x105 per channel and incubated for 48 or 72 h. Before measuring, the
medium was removed and replaced by CO2-independent medium supplemented with 10 % FBS.
Fixed cells were obtained by rinsing the cells twice with PBS, treatment with 4 % of PFA for 15 min
followed by two final washing steps with PBS.
8.4 Cell experiments under static conditions
Experiments under static conditions were performed with cells cultivated in ibiTreat µ − Slides,
8-well chambers.
8.4.1 Uptake
8.4.1.1 Uptake of functionalized polystyrene beads
Two types of uptake experiments of functionalized polystyrene beads were performed. In the first
one, Cy5 labeled latex beads (A200-PEG5-B6/B6scr1/B6scr2/B6mod/cMBP2/cMBP2scr/OH) were
sonicated for 10 min, diluted in PBS buffer (1:25), again sonicated for 15 min. The beads (10µL)
were added to HuH7 cells in 8-well chambers (300µL) and incubated for 2 h. After fixation,
z-stacks of the labeled beads on the cells and of the cell membrane stained with WGA-Alexa
Fluor488 (3.3µg/mL for 2 min) were acquired with spinning disk microscopy. For the second
uptake experiment, latex beads (ATTO 488 labeled A200-PEG5-B6 and Cy5 labeled A200-PEG5-
B6scr/B6mod/OH) were incubated with DU145 cells for 6 h in presence of free Tf (1.25 mg/mL).
Movies (500 frames) of the labeled beads in plane of the cells were recorded by live-cell imaging
with spinning disk microscopy.
8.4.1.2 Uptake of polyplexes
Freshly prepared polyplexes (3µL, see Section 8.2.2) were incubated with HuH7 cells in DMEM/F12
at 37 °C under 5% CO2 atmosphere for 1.5 h. The cells were fixated afterwards. Next, cell membranes
were stained with WGA-Alexa Fluor488 ( 3.3µg/mL for 2 min) and nuclei with DAPI (300µL,
300 nM for 5 min). Uptake was measured with spinning disk microscopy.
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8.4.2 Folate receptor targeting
To target the folic acid receptor, Cy5 labeled A200-PEG5-FA/PEG2-FA/PEG24-FA were sonicated for
5 min, diluted in PBS buffer (1:25) and again sonicated for 15 min. The particle suspensions (10µL)
were separately incubated with KB cells for 45 min at 37 °C and 5 % CO2 atmosphere in folic acid
free medium supplemented with 10 % FBS. After fixation with PFA, cell membranes were stained
with WGA-Alexa Fluor488 (3.3µg/mL for 2 min) and the cells were measured with spinning disk
microscopy.
8.4.3 Competition with free ligand
Competitive adhesion experiments of A200-PEG5 beads with free Tf were performed on HuH7
cells. The concentration of the different bead suspensions was adjusted according to light absorption
measurements at 230 nm. Cy5 labeled A200-PEG5-B6/B6scr1/B6scr2/B6mod/OH beads (49µM NH2,
1.5 x 1011 beads/mL) were incubated with HuH7 cells for 1 h at 37 °C in a 5 % CO2 atmosphere with
and without preincubation of holo-Tf (5 mg/mL) for 45 min. The cells were washed with PBS
buffer (3x 300µL) and fixated with PFA. Cell membranes were stained with WGA-Alexa Fluor488
(3.3µg/mL for 2 min) and the integrated fluorescence density (IntDens) of the beads was measured
with spinning disk microscopy.
8.4.4 Co-incubation with labeled, free ligand
The localization of TfR targeted and control beads in relation to free ligand was tested. HuH7 cells
were preincubated with Tf-Alexa Fluor647 (3.3µg/mL) for 45 min. Next, ATTO 488 labeled A200-
PEG5-B6/B6scr/B6mod/OH beads (0.2µL, sonicated for 5 min) were added and the cells incubated
for another 1.5 h. Afterwards, the cells were washed with PBS buffer (3x 300µL) and fixated with
PFA. The beads and the Tf were imaged with spinning disk fluorescence microscopy.
8.4.5 TfR-GFP co-localization
For co-localization experiments of TfR and B6 beads or free Tf, HeLa cells were transfected with
pBa.TfR.GFP (44 ng/µL, 9.5µL with transfection reagent Xtreme GENE9 according to standard
procedure) which was expressed in E.coli Top10 and purified with a QIAprep Spin Miniprep Kit
(Quiagen N. V., Venlo, Netherlands). Sonicated, Cy5 labeled B6 beads or Alexa Fluor633 labeled Tf
(3.3µg/mL) were incubated on the GFP-TfR expressing HeLa cells in CO2-independent medium
for 0.5 and 2/2.5 h and their localization was analyzed by live-cell imaging.
8.5 Flow experiments
8.5.1 Experimental setup
Flow experiments were performed using a custom-built flow setup consisting of three main parts:
a reservoir (15 mL falcon tube), a flow chamber (sterile ibiTreat µ − Slide I0.4 or VI0.4) and a syringe
pump (KDS Legato 210P Infuse/Withdraw Programmable, KD Scientific Inc., Hollison, MA, USA),
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all connected by flexible tubing (inner diameter: 1.6 mm; Tygon®). The reservoir was warmed
in a heat bath to keep the temperature constant at 37 °C and the particle suspension was stirred
to maintain a constant concentration within the whole volume. The flexible tubing, syringe and
flow chambers were pre-filled with cell medium and assembled in such a way that no air bubbles
were contained within the flow system. For experiments with parallel flow channels, the tubings
were connected by Y-pieces. In Table 8.1, the typical parameter settings of the flow experiments are
displayed if not otherwise stated.
Table 8.1: Parameter settings for flow experiments. Parameters of the flow channels, syringe, pump settings,
volumes of fluid and duration of the experiments are listed.
Parameter One channel (µ-slide I0.4 ) Four channels (µ-slide VI0.4)
Channel dimensions 50x5x0.4 mm 17x3.8x0.4 mm
Channel volume 100µL 30µL
Syringe volume 10 mL 10 mL
Syringe diameter 15.8 mm 15.8 mm
Target volume 8 mL 6 mL
Flow rate 0.2 and 2 mL/min 0.1 mL/min
Pump mode withdraw and withdraw/infuse withdraw
Reservoir filling 9 mL 7 mL
Total fluid volume 13 mL 11 mL
Duration 40 min 60 min
8.5.2 Shear rate and shear stress
During flow experiments, shear stress is exerted on the cells on the channel bottom which refers to
the force per cross-section area deforming the cells. Depending on the flow rate (φ) which is set at
the syringe pump, the shear stress (τ) and the shear rate (γ) vary. Both parameters were calculated
according to the technical report by ibidi GmbH [380]. They are based on the dynamical viscosity
of water at 22 (η = 0.01 dyn · s/cm2).
Shear stress:
γ = A · φ[dyn
cm2
] (8.5.1)
where A is a factor depending on the respective chamber slide (A = 1.316 for µ − Slide I0.4 Luer and
A = 1.761 for µ − Slide VI0.4 Luer).
Shear rate:
γ = B · φ[s−1] (8.5.2)
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where B is a factor depending on the respective chamber slide (B = 131.6 for µ − Slide I0.4 Luer and
B = µ − Slide VI0.4 Luer).
In the flow experiments with internal control, the shear stress was 0.263 dyn/cm2 or 2.632 dyn/cm2
and the shear rate was 26.3 s−1 or 263.2 s−1 at a low (0.2 mL/min) or a moderate (2 mL/min) flow rate,
respectively. For flow experiments screening different surfaces, the shear stress was 0.044 dyn/cm2
and the shear rate 4.4 s−1 at a very low flow rate (0.1 mL/min).
8.5.3 Cellular adhesion with internal control
Stock solutions of beads with ligand as well as control beads were sonicated for 10 min. The bead
solutions (2µL) were diluted in PBS buffer (800µL) and sonicated again for 15 min. These dilutions
of beads with ligand (dye 1, ca. 1010 /mL, 750µL) and control beads (dye 2, ca. 1010 /mL, 750µL)
were added to the reservoir filled with CO2-independent medium (7.5 mL) and magnetically stirred
for 3 min to provide a homogenized suspension. The reservoir was surrounded by a warming bath
to maintain a constant temperature (T = 37 °C). A continuous flow of particle suspension from the
reservoir through the flow channel into the syringe (10 mL, Terumo®) was generated at a low flow
rate of 200µL/min (shear rate = 26.3 s−1) and back and forth at a moderate flow rate of 2 mL/min
(shear rate = 263.2 s−1) by the syringe pump. The flow channel containing the cell monolayer at
which the beads could bind during the experiment was mounted on a warming stage (T = 37 °C).
After 40 min of flow, the flow channel was rinsed with warm PBS buffer at the same flow rate to
remove unbound beads from the chamber. Afterwards, the cells were fixed. Experiments were
performed as duplicates or triplicates.
8.5.4 Adhesion kinetics
To measure cellular adhesion kinetics, ATTO 488 labeled A110-PEG5-B6 and Cy5 labeled A110-
PEG5-OH beads were sonicated for 10 min, diluted (1:300) in PBS buffer, again sonicated for 15 min
and added to the reservoir (750µL each) of the flow system. The cellular adhesion of the beads was
observed by live-cell imaging. Thereafter, snapshots of single cells were taken with transmission
light and movies (50 frames, 272 ms exposure time) of the same field of view were recorded by
fluorescence widefield microscopy.
8.5.5 Characterization of different surfaces
Different methods were used to characterize the coatings within the flow channels (ibidiµ − Slide VI0.4):
MaxGel ECM was diluted 1:10 in DMEM/F12 according to the manufacturer’s protocol and further
diluted in PBS (final ratios: 1:20, 1:50, 1:100). The formed network structure was air-dried and
observed with transmission light widefield microscopy. Additionally, Cy5 labeled model beads
(A200-PEG5-OH, 500µL), sonicated and diluted (1:300) were passed over the ECM structures (1:20,
1:50 and 1:100 dilutions) at low shear flow (shear rate = 4.4 s−1) [? ]. Movies (200 frames) of the
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beads’ movement were recorded by widefield microscopy.
The autofluorescence of different dilutions of FBS was investigated by exposing the coated channel
bottom to different laser intensities (10-100 % AOTF) and recording snapshots with widefield mi-
croscopy.
To image the collagen fibers within the flow channels, coated chambers (10 % collagen A, 2 h) were
incubated with ATTO 488 overnight at 37 °C at 5 % CO2 atmosphere. After washing with PBS
buffer, the fluorescence of the fibers was measured with widefield microscopy.
8.5.6 Parallel adhesion experiments on different surfaces
One slide of flow channels (ibiTreated µ − Slide VI0.4) was coated with cells (HuH7 and HMEC-1)
and another one (hydrophobic µ − Slide VI0.4) with different coatings (FBS, ECM, poly-L-lysine or
collagen). FBS was diluted in water (1:5), poly-L-lysine (0.01 % solution) or collagen A (10 % solu-
tion) was pipetted into the channel, incubated for 2 h and dried on air. MaxGel ECM was diluted in
water (1:50), pipetted into the channels on ice and incubated at 37 °C and 5 % CO2 atmosphere for 2 h.
Polyplexes were freshly prepared as described above (see Section 8.2.2). They were added (10µL,
20µgDNA/mL) to the reservoir filled with CO2-independent medium (6 mL), stirred for 3 min and
a low flow rate (100µL/min) was applied for 1 h using the syringe pump. The polyplex suspension
was passed over the four surfaces in parallel through branched tubing. After the experiment, the
channels were washed with PBS buffer and fixed with PFA.
8.6 Fluorescence microscopy
The fluorophores used in this work are listed in Table.
Table 8.2: Fluorescent dyes. The absorption (λabs) and emission (λ f l) maxima, and the applied excitation
wavelength (λexc) of fluorophores used in this work are listed below.
Fluorescent dye λabs [nm] λ f l [nm] λexc [nm]
Alexa Fluor 488 495 519 488
Alexa Fluor 633 632 647 633
Alexa Fluor 647 650 668 633/639
ATTO 488 501 523 488
Cy5 649 670 633/639
DAPI 358 461 405
FITC 493 528 488
GFP 488 509 488
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Figure 8.2: Widefield fluorescence microscope setup. Four different lasers (488 nm, 532 nm, 561 nm and
633 nm) are directed onto an AOTF. The selected wavelengths are passed through a multimode fiber and
focused on the back focal plane of an objective illuminating the sample. Emitted fluorescent light is separated
from the excitation beam by a dichroic mirror and split into two ranges of wavelengths. After passing
appropriate emission filters, the fluorescent light is detected by two separated EMCCD cameras.
8.6.1 Widefield microscope
Particle characterization and cancer cell targeting experiments were imaged with a custom-built
widefield fluorescence microscope based on a Nikon Eclipse Ti microscope corpus (Nikon Corp.,
Chiyoda, Tokyo, Japan). ATTO 488 and Cy5 dyes were excited alternately with 488 nm (Sapphire,
Coherent Inc., Santa Clara, CA, USA) and 633 nm (gas laser, Nec Corp., Minato, Tokyo, Japan)
laser lights, using a Plan Apo TIRF 60x, 1.45 NA oil immersion objective (Nikon). The fluorescence
light was collected in epifluorescent mode, splitted into two beams by a dichroic mirror (565 DCXR,
Chroma Technology Corp., Bellows Falls, VT, USA), passed through emission filters (GFP 526/50 and
Cy5 720/149, Semrock Inc., Lake Forest, IL, USA) and directed onto two electron multiplying charge
coupled devices (EMCCD, DU-897 iXon+, Andor Technology Ldt., Belfast, UK). The individual
settings for each experiment are listed in Table 8.3. The laser light output was chosen such that an
optimized signal-to-noise ratio and minimal autofluorescence were obtained. The camera gain was
set to 300. Movies (25 or 50 frames) of single cells (ca. 40/flow channel) were recorded capturing the
fluorescence of all particles on the cell within the field of view. To locate cell membranes and nuclei,
transmission light images were recorded. Fluorescence of particles on cover glass was captured
with one snapshot. Bleaching and blinking of siRNA polyplexes and beads passing ECM were
observed by recording movies (200 frames). The images were visualized by applying the software
Andor IQ.
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Table 8.3: Widefield microscope settings.
Experiment (section) Lasers
[nm]
Dyes AOTF
[%]
Exposure
time [ms]
Frame rate
[Hz]
Fluorescence of beads ( 8.2.1) 488/633 ATTO 488/
Cy5
20/10 300 3.01
External control I ( 8.2.1) 488/633 ATTO 488/
Cy5
30/20 272/300 3.29/3.03
External control II ( 8.2.1) 488/633 ATTO 488/
Cy5
20/15 272/300 3.29/3.03
Internal control ( 8.5.3) 488/633 ATTO 488/
Cy5
20/15 272/300 3.29/3.03
Adhesion kinetics ( 8.5.4) 488/633 ATTO 488/
Cy5
30/20 272/300 3.29/3.03
siRNA pp ( 8.2.2) 633 Cy5 100 300 3.03
Surfaces screening ( 8.5.6) 633 Cy5 20 300 3.03
pp on cover glass ( 8.2.2) 633 Cy5 20 300 3.03
ECM, flow ( 8.5.5) 633 Cy5 20 50 12.45
FBS autofluorescence ( 8.5.5) 633 Cy5 10-100 300 3.03
collagen A ( 8.5.5) 488 ATTO 488 30 273 3.30
8.6.2 Spinning disk microscope
Confocal imaging was performed with a spinning disk microscope (Zeiss Cell Observer SD) con-
taining a Yokogawa spinning disk unit CSU-X1. The fluorophores were excited by 405 nm, 488 nm
and 639 nm laser light, passing through a quad-edge dichroic beamsplitter (FF410/504/582/669-
Di01-25x36, Semrock) and a Plan apochromat 63x or 100x, 1.40 NA oil immersion objective (Zeiss,
Oberkochen, Germany). The emitted light was collected in epifluorescent mode, split at a dichroic
mirror (560 nm or 660 nm, Semrock, Rochester, NY, USA), passed through emission filters (525/50
and 690/60, Semrock) and directed onto two separate EMCCD cameras (PhotometricsEvolve). The
fluorescence was measured by recording z-stacks (∆z = 200 nm). All excitation wavelength were
alternated in one plane before the next plane was measured. The excitation power was adjusted
individually for every experiment (405 nm laser: 72µW, 488 nm laser: 168-416µW and 639 nm
laser: 27-309µW), such that the signal was clearly detected and low autofluorescence recorded.
The camera gain was set to 800. The settings for the different experiments are listed in Table 8.4.
The images were visualized by applying the software ZEN, blue edition (Zeiss).
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Figure 8.3: Spinning disk microscope setup. Four lasers (405 nm, 488 nm, 561 nm and 639 nm) are directed on
an AOTF and are coupled into an optical fiber. In the spinning disk unit, the light is directed onto microlenses
which focus it onto pinholes on a second disk from where it is directed into the objective illuminating the
sample. Emitted fluorescent light is collected by the objective, guided back through the pinholes to a dichroic
mirror separating it from the excitation light. The fluorescence is split by a second dichroic mirror into two
ranges of wavelengths, passed through appropriate filters and recorded by two separated EMCCD cameras.
The illustration was kindly provided by Dr. Veronika Weiß.
Table 8.4: Spinning disk microscope settings.
Experiment (section) Lasers
[nm]
Dyes AOTF
[%]
Exposure
time [ms]
Objective
IntDens of beads ( 8.2.1) 488 ATTO 488 20 200 100x
Uptake of beads I (8.4.1.1) 488/639 Alexa488/
Cy5
25/10 100 63x
Uptake of beads II (8.4.1.1) 488/639 ATTO 488/
Cy5
50 100 63x
FR targeting (8.4.2) 488/639 Alexa488/
Cy5
25/10 100 63x
Competition of Tf (8.4.3) 488/639 Alexa488/
Cy5
25/10 100 100x
Co-localization of Tf (8.4.4) 488/639 ATTO 488/
Alexa647
10/100 100 100x
TfR-GFP (8.4.5) 488/639 GFP/ Cy5 25/20 100 100x
Uptake of polyplexes (8.4.1.2) 405/488/
639
DAPI/
Alexa488/
Cy5
20/25/40 200 63x
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8.7 Qualitative data analysis
8.7.1 Image visualization
Images for qualitative analysis were edited with Fiji [381]. The background was subtracted (rolling
ball alogrithm r = 0.3 or 0.5 pixels) and a convolution Gaussian filter was applied (r = 1.0 pixel).
The contrast and brightness of the fluorescence images were adjusted to obtain optimal visibility
of labeled components.
8.7.2 Localization of particles on cover glass or cells
In order to localize particles on cells, two different procedures were used. With widefield mi-
croscopy, transmission light images were recorded from which the cell membrane and the areas of
the nuclei were transferred to the fluorescence images. For confocal cell images obtained by spin-
ning disk microscopy, the cell membranes (and the nuclei) were stained and the particles localized
by merging the images of each fluorescence channels for every recorded plane.
Co-localization of ATTO 488 labeled B6/B6scr/B6mod/OH beads with Alexa Fluor647 labeled Tf was
studied by merging the images of both fluorescence channels (green and red) of recorded z-stacks.
In one central plane of the cell, co-localization was observed when the maximum fluorescence in
both channels overlaid accurately.
To analyze the co-localization of GFP-TfR and Cy5-B6 beads/Alexa Fluor633-Tf, one central plane
of single cells was displayed for each fluorescence channel and the merged image was evaluated
qualitatively. Co-localization was obtained at the fluorescence maxima overlaying in both channels.
Bleaching and blinking of the fluorescence of siRNA polyplexes was analyzed by creating a time
profile of single polyplexes. Using Fiji [381], single fluorescent spots (polyplexes) were encircled in
movies of 200 frames, and the intensity/time profile was plotted.
The flow profile of model beads over ECM was evaluated by creating time projections of recorded
movies (16 s) with Fiji. The obtained images were pseudo-color coded.
The autofluorescence of FBS dilutions within flow channels was depicted by coloring the recorded
snapshots with pseudo-colors. Low autofluorescence was indicated by low intensity values (blue)
and high background fluorescence by high intensity values (red).
8.8 Quantitative data analysis
8.8.1 Particle counting
Recorded movies of single cells were projected to one image using Fiji. The intensity maxima
were selected and automatically counted with a Fiji macro (see Appendix 10). The accuracy of
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this procedure was verified by manual counting of particles in parallel evaluations. The mean
numbers of adhered beads per cell were calculated and presented as mean±standard error (SE), n
= 79-140. To compare two groups, the unpaired student’s t-test was performed. The results were
considered as highly significantly different when p<0.0001. Transmission light images of the cells
were recorded in differential interference contrast (DIC) mode. The regions of nucleus and plasma
membrane were thus transferred to overlay images created with Fiji.
8.8.2 Particle in Cell 3D
The fluorescence integrated density (IntDens) of particles was obtained by using the ImageJ based
macro Particle_in_Cell-3D described by Torrano et al. [276]. Several routines can be chosen. The
IntDens of single particles was obtained by using the calibration routine 4. In brief, stacks of labeled
particles on cover glass or on a chamber bottom were analyzed by integrating the fluorescence of
each particle in every z-plane. The fluorescence of single particles can be plotted in a histogram,
fitted and the maximum can be selected as mean IntDens of a particle type. The IntDens of particles
on single cells was determined by the semi-/quantification routine 2 and 3. In brief, stacks of cells
obtained by alternating excitation of Cy5 labeled nanoparticles and cell membrane stained with
WGA-Alexa Fluor488 were split into separate channels. The macro creates a mask of the cell in every
plane and background subtraction as well as an intensity threshold for the particle fluorescence
have to be set. The macro measures the fluorescence intensity (IntDens) of each object (particle or
agglomerate). Furthermore, the cell is reconstructed in 3D, and detected particles are alighned to
three different regions: intracellular, enlarged membrane region and extracellular. Additionally, a
color-coded image of the cell is displayed.
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List of abbreviations
abbreviation explanation
AAV adeno-associated virus
Ala alanine
AOTF acousto-optical tunable filter
Arf6 ADP-ribosylation factor 6
ATP adensoine triphosphate
BPEI branched PEI
CAF cancer-associated fibroblast
Cbl Casitas B-lineage lymphoma
CD cyclodextrin
CDC42 cell devision control 42
cMBP2 c-Met binding peptide 2
CME clathrin-mediated endocytosis
cRGD cyclic RGD
Cys cysteine
DAPI 4’,6-diamidino-2-phenylindole
DHB 2,5-dihydroxybenzoic acid
DIC differential interference contrast
DLS dynamic light scattering
DMEM dulbecco’s modified eagle’s medium
DMSO dimethyl sulfoxide
DNA deoxyribonucleic acid
DTT dithiothreitol
DU145 human prostate cancer cell line
ECM extracellular matrix
EDTA ethylenediaminetetraacetic acid
EGF(R) epidermal growth factor (receptor)
(EM)CCD (electron multiplying) charge coupled device
EPR enhanced permeability and retention effect
Eq equivalents
ER endoplasmic reticulum
ERC endocytic recycling compartment
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abbreviation explanation
FA folic acid
FBS fetal bovine serum
Fc fragment, crystallizable
FGF fibroblast growth factor
FITC fluorescein isothiocyanate
Fmoc fluorenylmethyloxycarbonyl
FR folate receptor
FRAP fluorescence recovery after photobleaching
FRET Förster resonance energy transfer
GFP green fluorescent protein
GPCR G-protein coupled recpeptor
GPI gylcosyl phosphatidyl-inositol
GTP guanosine triphosphate
HBG HEPES buffered glucose
hEGF human EGF
HeLa human cervix adenocarcinoma cell line
HEPES 4-(2-hydroxyethly)-1-piperazineethanesulfonic acid
HGF(R) hepatocyte growth factor (receptor)
HIV human immunodeficiency virus
HMEC-1 human microvascular endothelial cell line
HPLC high performance/pressure liquid chromatography
HuH7 human hepato cellular carcinoma cell line
IFP interstitial fluid pressure
IgG/M immunoglobulin G/M
IntDens integrated fluorescence density
IPT Ig-like, plexins, transcription factors
it iminothiolane
ivDde Nε-1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl
KB human nasopharyngeal epidermoid carcinoma cell line
LDL low density lipoprotein
LPEI linear PEI
LSM laser scanning microscopy
LV lentivirus
Lys lysine
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MALDI matrix-assisted laser desorption/ionization
MCDB-131 (Molecular, Cellular, and Developmental Biology): cell culture medium
miRNA micro RNA
mod modified
MPS mononuclear phagocytic system
MTOC microtubule-organizin center
MSC mesenchymal stem cell
MVB multivesicular bodies
NA numerical aperture
NAD(P) nicotinamideadenine dinucleotide (phosphate)
NHS N-hydroxysuccinimide
NLS nuclear localization sequence
NSOM near-field scanning optical microscopy
OH hydroxyl
OPSS ortho-pyridyldisulfide
PAA polyacrylic acid
PALM photo-activated localization microscopy
(D)PBS (Dulbecco’s) phosphate buffered saline
PCFT proton-coupled folate transporter
PCI photochemical internalization
PDGF platelet-derived growth factor
PDI polydispersity index
pDNA plasmid DNA
pdp pyridyldithiol propionate
PEG polyethylene glycol
PEI polyethyleneimine
PEO polyethylene oxide
PFA para-formaldehyde
PI particle intensity
PLL poly-L-lysine
PSF point spread function
PSI plexin, semaphorin, integrin
PTP1B protein-tyrosine phosphatase 1B
RFC reduced folate carrier
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abbreviation explanation
RGD (cyclic) arginine-glycine-aspartic acid
RhoA Ras homolog gene family, member A
RNA ribonucleic acid
ROI region of interest
ROS reactive oxygen species
RPMI 1640 (Roswell Park MEmorial Insitiute): cell culture medium
scr scrambled
SD spinning disk
SE standard error
SF scatter factor
SH Src homology
SIM structured illumination microscopy
siRNA small interfering ribonucleic acid
STED stimulated emission depletion
STORM stochastical optical reconstruction microscopy
STP succinoyl tetraethylene pentamine
Tf(R) transferrin (receptor)
TGFα transformation factor α
THF tetrahydrofolate
TIRF(M) total internal reflection fluorescence (microscopy)
TOF time-of-flight
2-TP 2-thiopyridone
Tyr tyrosine
UV/Vis ultraviolet-visible
VEGF(R) vascular endothelial growth factor
vWF von Willebrand factor
WGA wheat germ agglutinin
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1 Absorption calibration
Figure 1: Calibration graph of the absorption of A200 polystyrene beads at 230 nm. The absorption is linearly
proportional to the concentration of amino groups on the surface of the beads.
To calibrate the absorption of the latex beads at 230 nm, different concentrations of unmodified beads
were measured as quintuplicate and fitted linearly. The attenuation coefficient ε* was calculated
using the equation of the regression slope:
ε∗ =
a
l
=
94740 M−1
0.1 cm
= 947400 M−1cm−1 (1.1)
where a is derived from the fitting curve and l is the length of the light pathway of the spectropho-
tometer.
2 PEGylation
The amount of PEGylated amino groups of the polystyrene beads was estimated by performing
a small assay (DTT assay, see Chapter 8.2.1). For all batches, the degree of PEGylation was in
the range of 5-10 % of the amino groups of the beads. According to the manufacturer’s data, the
surface area of a bead was calculated to equal 1.2566 ·10−13 m2. This corresponds to an area of
65.74 Å2/NH2 group or 1.52 NH2 groups/nm2. If 5-10 % of the amino groups are PEGylated, the
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distance D between the amino groups attached to a PEG molecule is 4.57-9.14 nm or the density of
PEG molecules 0.08-0.15 PEG/nm2.
To evaluate the conformation of the PEG chains on the surface of the beads, the Flory radius rf was
determined [382]:
rF = a ·N 35 = 0.35 nm · (5000/44) 35 = 5.989 nm (2.1)
where a is the monomer size which is 0.35 nm for ethylene gylcol and N is the number of monomer
units which is 5000/44≈ 114 for a 5 kDa PEG spacer.
The classification of the PEG chain conformation is defined in the literature. [283, 383, 384] If the
distance D between the PEG chains is greater than the Flory radius rf , the PEG chains are coiled
into a "mushroom"-like conformation whereas if D is smaller than rf , the PEG chains arrange into
a "brush"-like structure.
For a PEGylation degree of 5 % with D = 9.14 nm a "mushroom"-like conformation is obtained, for
10 % PEGylation with D = 4.57 nm a "brush"-like conformation is expected.
3 Quantification of nanoparticles with fluorescence
microscopy
The quantification of nanoparticles was performed by measuring the fluorescence of labeled par-
ticles by widefield or confocal microscopy and two different evaluation methods. One analysis
involved the counting of intensity maxima with the program ImageJ, the other was based on
integrating the fluorescence intensity. In Fig. 2, both methods were compared.
144
3 Quantification of nanoparticles with fluorescence microscopy
Figure 2: Particle analysis by counting fluorescent maxima and fluorescence integrated density (IntDens)
based evaluation. In the first column, z-projections of fluorescence stacks of A200-PEG5-x (x = the peptide
B6, B6scr, B6mod, cMBP2, cMBP2scr or hydroxylated) beads in CO2 independent medium and 10 % FBS are
shown. In the second column, the fluorescent maxima are selected by yellow crosses and counted as single
beads. Scale bar = 5 µm. In the third column, the distribution of the IntDens of objects (corresponding to
one or more beads) analyzed by Particle_i_Cell-3D. [276] are shown. The Nnumber of particles per object is
depicted in the last column.
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Table 1: External control II. Beads (A200-ATTO 488-PEG5-B6) with ligand and control beads (A200-Cy5-PEG5-
OH/B6scr1/B6mod) from flow experiment preparations (1:400) were mixed 1:1 and pipetted into small imaging
spacer chambers (9 mm diameter, 0.12 mm thickness) on a coverglass coated with collagen A. The beads were
imaged with widefield microscopy, counted and the mean value obtained per field of view (63.7x63.7 µm2) is
shown. n = 40-51. The ratio was calculated and is displayed in the last column.
B6 (ATTO 488) control (Cy5) Ratio
B6 : OH 58.4 ± 3.6 72.7 ± 16.8 0.87 ± 0.14
B6 : B6scr1 65.4 ± 9.5 41.6 ± 9.0 1.7 ± 0.40
B6 : B6mod 38.0 ± 14.9 37.9 ± 7.9 0.97 ± 0.36
4 External control
As the numbers of beads per cell were counted in our experiments, we assessed the initial numbers
of beads added to the experiment in external control measurements. A suspension of beads with
ligand (B6 beads) and control beads (Oh, B6scr1 or B6mod) as used in the flow experiments was
pipetted into a imaging spacer chamber which was coated with collagen A. The chamber was closed
by a second cover glass and the particles were imaged by widefield microscopy. In Table 1, the
numbers of B6 beads compared to the number of control beads counted per field of view is shown.
The ratio of both particle types is displayed in the last column. They ranged from 0.87 to 1.7. Thus,
the factors of receptor targeted beads compared to control beads per single cell could be altered
between 0.87 and 1.7. As we did not included these control factors into the resulting factors, only
factors above 2 were considered to show a clear effect of the ligand.
5 Second scrambled peptide
Flow experiments were performed with a second scrambled peptide. In Fig. 3, the mean values of
the number of B6scr2 beads on HuH7 cells compared to the number of hydroxylated beads and the
factor distribution are shown.
Figure 3: Effect of the scrambled peptide B6scr2 on binding to HuH7 cells. Adhesion of beads with scrambled
peptide (B6scr2, labeled with Cy5) and hydroxylated control beads (labeled with ATTO 488) on HuH7 cells
after 40 min under moderate (263 s−1) shear conditions. (A) The mean numbers of B6scr2 (black column) and
hydroxylated control beads (white column) on single cells are shown. n = 121. (B) The factor distribution of
B6scr2 beads compared to hydroxylated control beads is depicted.
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6 Immunostaining of surface receptors
Immunostaining and visualization by fluorescence microscopy
The presence of HGF receptors (c-Met) and transferrin receptors (TfR) on HuH7 cells was qualita-
tively assessed by immunostaining and visualization by fluorescence microscopy. Fixed cells were
incubated with blocking buffer (10 % FBS in PBS) for 30 min, washed (4x, 5 min) and incubated
with monoclonal rabbit anti-human c-Met primary antibody (3.9µg/mL) or monoclonal mouse
anti-human TfR primary antibody (10µg/mL) for 50 min at room temperature. After washing with
PBS (4x, 5 min), the treated cells and untreated cells for control were incubated with polyclonal
donkey anti-rabbit Alexa647 secondary antibody (10µg/mL) or monoclonal goat anti-mouse FITC
secondary antibody (10µg/mL), respectively. Finally, the cells were washed again with PBS (4x,
5 min). Images of the cells were obtained by spinning disk microscopy. The recorded z-stacks of
single cells were transformed into z-projections with maximum intensity using Fiji imaging soft-
ware and are displayed in Fig. 4. The images of the immunostained receptors and the respective
IgG control images are illustrated with the same contrast settings.
Figure 4: Immunostaining of HGFR/c-Met and TfR on HuH7 and HMEC-1 cells and visualization by
fluorescence microscopy. HuH7 and HMEC-1 cells cultivated under static conditions were immunostained
with monoclonal rabbit anti-human HGFR/c-Met and monoclonal mouse anti-human TfR. Surface receptor
expression status was detected by using Alexa647 labeled donkey anti-rabbit and FITC labeled goat anti-mouse
secondary antibodies. The fluorescence was imaged excitation with 639 nm and 488 nm lasers respectively by
spinning disk microscopy. Representative z-projections of stacks over cells are shown. Scale bar = 10 µm.
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Immunostaining and flow cytometry analysis
The levels of HGF receptor (c-Met) and transferrin receptor (TfR) on HuH7 cells were determined
by immunostaining and flow cytometry analysis. For each experiment, 300 000 cells in 100µL
blocking buffer (10 % FBS in PBS) were incubated with monoclonal mouse anti-human HGFR/c-met
antibody, monoclonal mouse anti-human TfR or IgG control for mouse primary antibodies (1:100
dilution) for 1 h on ice and afterwards washed twice with blocking buffer. The cells were incubated
with Alexa488- labeled goat anti-mouse (1:400 dilution) and FITC- labeled goat anti-mouse (1:100
dilution) secondary antibodies, respectively for 1 h on ice, washed twice and resuspended in 1 mL
blocking buffer. After counterstaining with DAPI (1µg/mL) the cells were analyzed on a CyanTM
ADP flow Cytometer (Dako, Hamburg, Germany) using SummitTM acquisition software (Summit,
Jamesville, NY, USA). The fluorophores were excited at 405 nm (DAPI) and 488 nm (Alexa488,
FITC) and detected with a 450/50 nm bandpass filter and a 530/40 nm bandpass filter, respectively.
In Fig. 5 and 6, the geometric mean fluorescence intensity (gMFI) of the plotted cell population is
displayed.
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Figure 5: TfR and HGFR/c-Met receptor levels on HuH7 and HMEC-1 cells. HuH7 and HMEC-1 cells,
cultivated under static conditions, were immunostained with monoclonal mouse anti-human HGFR/c-Met,
anti-human TfR and IgG control. Surface receptor expression levels were detected by using Alexa488 and
FITC labeled goat anti-mouse secondary antibodies and flow cytometry. The geometric mean values of the
surface receptor levels on the different cell lines are depicted on the right and the different receptors on the
same cell line at the bottom row.
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Figure 6: TfR and HGFR/c-Met receptor levels on HuH7 and HMEC-1 cells cultivated under static and
flow conditions. HuH7 and HMEC-1 cells were cultivated under static conditions, seeded into flow channels
and either remained under static conditions (static) or low shear flow (26 s−1) was applied for 40 min (flow).
The cells were immunostained with monoclonal mouse anti-human HGFR/c-Met, anti-human TfR and IgG
control. Surface receptor expression levels were detected by using FITC labeled goat anti-mouse secondary
antibody and flow cytometry. The geometric mean values of the different receptor levels on the two cell lines
are depicted at the bottom.
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Figure 7: Binding of TfR targeted B6 beads compared to control beads without shear flow. Adhesion of
beads with ligand (B6, dye 1) and control beads (dye 2) on HuH7 cells after 40 min incubation within a flow
channel, but no shear flow (0 s−1). (A) The mean numbers of B6 beads (black columns) and control beads (withe:
hydroxylated, light gray: with scrambled peptide B6scr1 and dark gray column: modified peptide B6mod) on
single cells are shown. n = 81-126. The factor distributions of B6 beads compared to (B) hydroxylated control
beads, (C) with scrambled peptide B6scr1 or (D) with modified peptide B6mod are depicted.
7 Experiments with B6 beads in flow channels under static
conditions
Experiments studying the adhesion of B6 beads with internal control were performed under static
conditions with the same bead concentration as under flow conditions and within flow channels.
Model beads with the ligand B6 were mixed separately with differently labeled control beads: with
hydroxylated beads (OH), with scrambled peptide (B6scr1) and with modified peptide (B6mod).
The mixture was incubated with target HuH7 cells within flow channels for 40 min. After washing
and fixation, the samples were imaged by widefield microscopy. In Fig. 7 A, the mean numbers
of B6 beads (black) were compared to hydroxylated (white), B6scr1 (light gray) and B6mod (dark
gray). In general, the total number of beads per cell was much smaller (between 25-35) compared
to the numbers counted on cells exposed to shear flow (between 150-300). This result can be ex-
plained by the higher number of beads passing the cell surfaces under flow conditions. Diffusion
and sedimentation are the main process by which particles appraoch the cell surfaces in static
experiments. On average, around 20 B6 beads bound per cell in each experiment. The number of
control beads differed strongly. While only a quarter of hydroxylated beads bound compared to
the TfR targeted beads, the number of scrambled and modified peptide beads was similar to the
number of B6 beads. Thus, both control peptides showed a similar affinity to the target cells as
the ligand B6. By dividing the number of B6 beads by the number of control beads on single cells,
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factors were calculated. The distributions of the factors are shown in Figures 7 B-D. The factor
distribution of B6 compared to hydroxylated beads is conform with the distribution under flow
conditions. Interestingly, the ratios of B6 to B6mod beads on single cells is close to 1 and assimilates
the distribution of B6 to B6scr1. This means that the B6mod peptide has a higher affinity to the
HuH7 cells under static conditions despite the lack of basic amino acids. Whether this increased
attraction is due to specific receptor-ligand recognition or due to non-specific interactions cannot
be concluded from the experiment.
Discussion:
It was found that replacing the basic amino acids within the peptide chain of B6 by glycines revealed
that beads with either B6 or B6mod bound similarly under static conditions.This finding leads to the
assumption that the initial binding step could be driven thermodynamically. It has to be mentioned
that the experiments under static and flow conditions cannot be compared reasonably even tough
they were conducted in the same flow channels with the same particle concentration, because the
number of beads passing the cell surfaces is drastically increased under flow conditions. This fact
implies that a multi-fold volume passes the cells, depending on the flow rate. The growth area of
the cells in the channels is 2.5 fold higher than in the well chambers and thus the cell densities vary
between 40.000 cells/cm2 in a well and 360.000 cells/cm2 in a channel. In addition, the number of
bound beads was relatively low in the flow channels of the static experiment. Thus, the statistics
are low and the binding could have been unspecific. Comparing the flow experiments to static
experiments in well chambers is even more critical as the height of the medium in the channels is
much lower than in the well chambers (0.4 mm compared to 3 mm). Moreover, the bead concentra-
tion was lower in flow experiments, up to the factor of 6.4 (1:48000 dilution compared to 1:750 for
uptake experiments and 1:2000 for Tf competition).
8 Reproduction of experiments with cMBP2 beads
The experiments described in Chapter 6.2.1 were reproduced with another batch of HuH7 cells and
the results are displayed in Fig. 8.
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Figure 8: Reproduction of cMBP2 binding studies under flow conditions. The graphs show the experiments
from Fig. 6.9 reproduced with another batch of HuH7 cells: Adhesion of beads with ligand (cMBP2, dye 1) and
control beads (dye 2) on HuH7 cells after 40 min under low (26 s−1) and moderate (263 s−1) shear conditions.
(A) The mean numbers of c-Met targeted cMBP2 beads (black column) and hydroxylated control beads (white
column) on single cells after low (left) and moderate (right) shear flow are shown. n =124-160. (C) The factor
distributions of cMBP2 beads compared to hydroxylated control beads after low (black) and moderate (white)
shear flow are depicted. (D) The mean numbers of c-Met targeted cMBP2 beads (black column) and control
beads with scrambled peptide cMBP2scr (grey column) on single cells after low (left) and moderate (right)
shear flow are shown. n =120-121. (E) The factor distributions of cMBP2 beads compared to control beads
with scrambled peptide cMBP2scr after low (black) and moderate (grey) shear flow are depicted.
9 Surface functionality of polystyrene beads
The beads used as model nanoparticles (see Chapter 4, 5 and 6) were commercially available
polystyrene beads (Aliphatic Amine latex, 2 % w/v 0.2µm) with surface amino groups. The manu-
facturer’s data claim a diameter of 0.20 ± 0.05µm, a density of 1.055 g/cm3 for polystyrene at 20 ◦C
and an amine content of 71.8µEq/g. Subsequent, some parameters of interest were calculated by
using the information above.
The volume of one bead Vbead is:
Vbead =
4
3
· r3 · pi = 4.189 · 10−21 m3 = 4.189 · 10−12 µL (9.1)
where r is the radius of the bead. The volume of all beads in 1 mL suspension is:
V =
m
ρ
=
0, 022g
1, 055 g/cm3
= 0, 02085 mL (9.2)
where m is the mass of the solids (beads) and ρ is the density of the beads. Thus, the concentration
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c of the beads is:
c =
V
Vbeads(200 nm)
= 4.978 · 1012 beads/mL (9.3)
The amine concentration c(NH2) is:
c(NH2) =
0, 022 g · 71, 8 µmol/g
1 mL
= 1, 5796 µmol/mL (9.4)
Thus, the amine content of one bead nbead(NH2) is:
nbead(NH2) =
1, 5796 µmol/mL
4.978 · 1012 beads/mL = 3.173 · 10
−19 mol/bead (9.5)
The number of amino groups per bead nbead(NH2) is:
nbead(NH2) = 3.173 · 10−19 mol/bead · 6, 022 · 1023 mol−1 = 191088 NH2/bead (9.6)
This means that beads labeled with 5 % Cy5 contain a maximum of 9554 dyes and labeled with
8 % ATTO488 contain a maximum of 15287 dyes, respectively. Furthermore, emanating from a
PEGylation degree of 5-10 %, the maximum modification of one bead is in the range between 9554
- 19109 ligands/bead.
10 Macro for particle counting
To count fluorescent spots on cells a macro for Fiji (open source) was used. In principle, the fluo-
rescent maxima of the labeled particles were counted. The macro is displayed below. The options
"Subtract Background", "Gaussian Blur" and "Find maxima" were adjusted according to the signal
to noise of the fluorescence images.
run ( " Close All " ) ;
d i r1 = g et D ir ec t or y ( " S e l e c t a n a n o p a r t i c l e image " ) ;
d i r2 = g et D ir ec t or y ( " Choose Des t ina t ion Direc tory1 : Z−P r o j e c t i o n s " ) ;
d i r3 = g et D ir ec t or y ( " Choose Des t ina t ion Direc tory2 : Resul t s " ) ;
/ / / / / / / / / / / / / / / / / / / / / / / / / / / / / / /
l i s t = g e t F i l e L i s t ( d i r1 ) ;
setBatchMode ( t rue ) ;
f o r ( i =0; i < l i s t . length ; i ++) {
showProgress ( i +1 , l i s t . length ) ;
open ( dir1+ l i s t [ i ] ) ;
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rename ( " z−P r o j e c t i o n "+ l i s t [ i ] ) ;
run ( " Z P r o j e c t . . . " , " s t a r t =1 stop =100 p r o j e c t i o n =[Max I n t e n s i t y ] " ) ;
saveAs ( " t i f f " , d i r2 +"z−pro_ " + l i s t [ i ] ) ;
c l o s e ( ) ;
}
run ( " Close All " ) ;
l i s t = g e t F i l e L i s t ( d i r2 ) ;
setBatchMode ( t rue ) ;
f o r ( i =0; i < l i s t . length ; i ++) {
showProgress ( i +1 , l i s t . length ) ;
open ( dir2+ l i s t [ i ] ) ;
rename ( " z−P r o j e c t i o n "+ l i s t [ i ] ) ;
run ( " S ubt rac t Background . . . " , " r o l l i n g = 5 0 " ) ;
run ( " Gaussian Blur . . . " , " sigma = 1 . 0 " ) ;
run ( " Find Maxima . . . " , " noise =80 output =[ Point S e l e c t i o n ] exclude " ) ;
run ( " Create Mask " ) ;
saveAs ( " t i f f " , d i r3 +"Mask_ " + l i s t [ i ] ) ;
run ( " Analyze P a r t i c l e s . . . " , " s i z e=1− I n f i n i t y c i r c u l a r i t y =0.00−1.00
show=Nothing display c l e a r add " ) ;
roiManager ( " Show All with l a b e l s " ) ;
roiManager ( " Show All " ) ;
n = nResul ts ;
p r i n t ( n ) ;
saveAs ( " Resul t s " , d i r3 +" Resul t s " + l i s t [ i ] ) ;
}
selectWindow ( " Log " ) ;
saveAs ( " t e x t " , d i r3 + " LogFi le . t x t " ) ;
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